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Summary 
 
The picornavirus family is composed of small, non-enveloped viruses which contain a 
single stranded RNA genome of positive polarity. The genome is translated into one large 
polyprotein which is then processed into the mature viral proteins by virally encoded 
proteinases. In human rhinoviruses and enteroviruses, two chymotrypsin-like proteinases, 
3Cpro and 2Apro carry out these cleavages. 2Apro executes the first cleavage on the 
polyprotein, cleaving itself from the VP1 capsid protein. 2Apro also cleaves several cellular 
proteins, amongst which is the eukaryotic initiation factor (eIF) 4G. eIF4G is a scaffolding 
protein that brings together the cellular capped mRNA and the ribosomes. Thus, the 
cleavage of this factor leads to the shut off of the cellular translation, as the mRNA is no 
longer able to reach the ribosome. The viruses can use this reduced translation machinery 
as they do not need the cap-dependent initiation mechanism to bind the ribosome and 
synthesize their proteins.  
There are more than 100 serotypes of rhinoviruses divided in two genetic groups, A 
and B. However, the level of sequence identity between the groups A and B is quite variable. 
For example, there is only 40% amino acid identity between the 2Apro of HRV2 (group A) and 
HRV14 (group B). Nevertheless, these two proteinases cleave their respective polyproteins 
at practically the same rate. In contrast, HRV2 2Apro completes the cleavage of eIF4G 
isoforms I and II at similar times whereas HRV14 2Apro cleaves first eIF4GI and eIF4GII later. 
In order to understand and identify the residues responsible for the differences in properties 
of these proteinases, we decided to perform site directed mutagenesis experiments. We 
found that HRV14 2Apro cannot cleave the eIF4GI cleavage sequence in the polyprotein, due 
to the presence of the arginine residue at P1. The mutations A104C or A104S in HRV14 
2Apro restored cleavage when arginine was present at P1, although not to wild-type levels.  
 The crystal structure of HRV2 2Apro helped to identify the residues involved in HRV2 
2Apro specificity. However, the low level of amino acid identity between HRV2 2Apro and 
HRV14 2Apro limited the use of this crystal structure for HRV14 2Apro. Therefore, we purified 
HRV14 2Apro with the objective of solving its crystal structure. We were able to obtain highly 
purified protein at suitable concentrations for crystallization trials. However, the purified 
protein appeared to be incorrectly folded. Optimization of the expression and purification 
methods are needed. 
We also wanted to identify new cellular binding partners of 2Apro. To this end, we used 
a proteomics approach in which cellular proteins complexed with 2Apro were purified and 
identified by mass spectroscopy. Although we identified some known and some putative 
binding partners, none of the previously undetected proteins were bound or cleaved by 2Apro. 
Optimization is needed in order to lower the amount of false positives and increase the 
sensitivity for bona fide partners. 
 To know more about the interaction of viral proteinases with eIF4G, we purified a 
domain of eIF4GII containing the cleavage sites for HRV2 2Apro and the leader proteinase of 
foot and mouth disease virus and the binding site for eIF4E (cap binding protein). The 
ultimate aim was to determine the crystal and nuclear magnetic resonance structures of this 
fragment. The protein was successfully expressed in E. coli and labelled with 15N. However, 
in both cases, the protein was incorrectly folded. Experiments with the eIF4GII complexed 
with eIF4E need to be done, as there is evidence that eIF4E induces a conformational 
change in eIF4G which leads to a defined structure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Zusammenfassung 
 
Die Familie der Picornaviridae besteht aus unbehüllten Viren mit einer 
einzelsträngigen, linearen RNA mit positiver Polarität als Genom. Dieses wird in ein großes 
Polyprotein translatiert und von viralen Proteinasen prozessiert. So entstehen die reifen 
Proteine. In humanen Rhino- und Enteroviren sind zwei Chymotrypsin-ähnliche Proteasen 
für die Prozessierung verantwortlich: 3Cpro and 2Apro. 2Apro führt den ersten Schnitt am 
Polyprotein aus, indem es sich selbst vom VP1 Kapsidprotein schneidet. Weiters ist sie für 
die Spaltung diverser zellulärer Proteine verantwortlich, darunter auch der eukaryotische 
Initiationsfaktor (eIF) 4G. Dieser bringt die zelluläre gecappte mRNA und die Ribosomen 
zusammen. Eine Spaltung dieses Faktors führt also zu einer Inhibierung der RNA und 
Proteinsynthese der Wirtszelle. Die virale Translation bleibt davon unbeeinflusst, da sie 
durch Verwendung einer IRES (internal ribosomal cleavage site) cap-unabhängig ist. 
Es gibt mehr als 100 Serotypen von Rhinoviren die in 2 Gruppen eingeteilt werden: A 
und B. Das Ausmaß der Übereinstimmung dieser beiden Gruppen ist variabel. Zum Beispiel 
stimmt die Aminosäuresequenz der 2Apro von HRV2 (Gruppe A) und HRV14 (Gruppe B) nur 
zu 40 % überein. Dennoch schneiden diese beiden Proteinasen ihr jeweiliges Polyprotein im 
selben Ausmaß. Im Gegensatz dazu, ist die Spaltung des eIF4G unterschiedlich. HRV2 2Apro 
spaltet die Isoformen eIF4GI and II gleichzeitig, während die HRV14 2Apro zuerst eIF4GI und 
erst danach eIF4GII schneidet. Um diese unterschiedlichen Eigenschaften zu verstehen und 
die verantwortlichen Reste zu identifizieren verwendeten wir ortspezifische Mutagenese. 
HRV14 2Apro kann die eIF4GI Sequenz im Polyprotein nicht schneiden, wegen eines Arginin 
Restes an der P1 Position. Die Mutationen A104C und A104S in der HRV14 2Apro 
ermöglichten ein Spaltung  von eIF4GI in Anwesenheit eines Arginins in P1 Position, 
wenngleich nicht auf Wildtyp-Niveau. 
Die Kristallstruktur von HRV2 2Apro half jene Reste zu identifizieren, die in die 
Spezifität der  HRV2 2Apro involviert sind. Durch die geringe Sequenzübereinstimmung 
zwischen den Proteasen der beiden Gruppen kann diese Kristallstruktur aber nur bedingt für 
die HRV 14 2Apro angewendet werden. Daher purifizierten wir HRV14 2Apro mit dem Ziel, ihre 
Kristallstruktur zu bestimmen. Wir konnten hoch reines Protein in für die Kristallisation 
geeigneter Konzentration herstellen. Da das Protein aber falsch gefaltet zu sein scheint, ist 
eine Optimierung der Expression und Purifikation nötig. 
Weiters wollten wir neue zelluläre Bindungspartner der HRV 2Apro identifizieren. Dafür 
wurde die HRV 2Apro mit zelluläre Proteinen komplexiert, purifiziert und mittel 
Massenspektroskopie identifiziert. Obwohl wir einige bereits bekannte und einige vermutliche 
Bindungspartner identifizierten, wurde keines der zuvor undetektierten Proteine von der HRV 
2Apro gebunden oder geschnitten. Daher ist eine Optimierung notwendig, um falsch positive 
Ergebnisse zu minimieren und die Sensitivität für bona fide Partner zu erhöhen. 
Um mehr über die Interaktion von viralen Proteasen mit eIF4G zu erfahren, 
purifizierten wir jene Domaine of eIF4GII die die Spaltungstellen der HRV2 2Apro, der 
Leaderproteinase des Maul- und Klauensäuchevirus und die Bindungsstelle für eIF4E (cap 
bindendes Protein) enthält.  
Das Ziel war, sowohl die Kristall- also auch die NMR (Nukleare Magnetresonanz) Struktur 
dieses Fragmentes zu erhalten. Das Protein wurde erfolgreich in E.coli exprimiert und mit 15N 
markiert. Allerdings war das Protein in beiden  Fällen inkorrekt gefaltet. Da es Anzeichen 
gibt, dass eIF4E eine Konformationsänderung im eIF4E induziert müssen Experimente mit 
eIF4GII im Komplex mit eIF4E durchgeführt werden. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of abbreviations 
 
All the abbreviations for amino acids are presented on table 22 in the appendix C. 
μCi – microcurie 
µl – microlitre 
µM - micromolar 
4EBP – 4E Binding Protein 
aa – amino-acid 
AP – Alkaline Phosphatase 
APS - Ammonium persulfate 
ATCC - American Type Culture Collection 
ATP - Adenosine 5'-triphosphate 
AUG – starting codon for methionine 
BCIP - 5-Bromo-4-chloro-3-indolyl phosphate 
°C – degrees centigrade 
CaBP – Calmodulin Binding Protein 
CAR – Coxsackie and Adenovirus Receptor 
CBP – Cap Binding Protein 
CD - Cluster of Differentiation 
CIP - Calf Intestine Phosphatase 
CITE – Cap Independent Translation Enhancer 
CREB - cAMP Response Element-Binding 
Cryo-EM – cryo Electron Microscopy 
CTE – C-Terminal Extension 
CV – Coxsackievirus 
DAF – Decay Accelerating Factor 
DMEM - Dulbecco’s Modified Eagle Medium 
DMSO - Dimethyl sulfoxide 
DNA - Deoxyribonucleic acid 
DNase - Deoxyribonuclease 
dNTP – deoxynucleotide triphosphate 
DTT - Dithiothreitol 
ECACC - European Collection of Cell Cultures 
ECL - Enhanced chemiluminescence 
EDTA - Ethylenediaminetetraacetic 
eIF – eukaryotic Initiation Factor 
EMCV – Encephalomyocarditis Virus 
ER – Endoplasmic Reticulum 
Fc - fragment crystallizable 
FCS - Foetal Calf Serum 
FMDV – Foot and Mouth Disease Virus 
FPLC - Fast Protein Liquid Chromatography 
g - gram 
GST - Glutathione S-transferase 
GTP - Guanosine-5'-triphosphate 
HAV – Hepatitis A Virus 
HEK  cells - Human Embryonic Kidney cells 
HeLa cells - Henrietta Lacks' cells 
HEPES - 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HP – Heparan Sulphate 
HRP - Horseradish Peroxidase 
HRV – Human Rhinovirus 
ICAM – Intercellular Adhesion  Molecule 
Ig – Immunoglobulin 
IPTG - Isopropyl β-D-1-thiogalactopyranoside 
IRES – Internal Ribosomal Entry Site 
kb – kilobase 
kDa - kilodalton 
l - litre 
Lpro – Leader Proteinase 
Labpro – Leader Proteinase ab 
Lbpro – Leader Proteinase b 
LB – Luria Bertani 
LCB - Lysis Cell Buffer 
LDL – Low Density Lipoprotein 
LGB – Lower Gel Buffer 
M - Molar 
MAPK - Mitogen-activated protein kinase 
MEM - Modified Eagle Medium 
MFPL – Max F. Perutz Laboratories 
mg – milligram 
MHz - Megahertz 
ml – millilitre 
mm - millimetre 
mM – millimolar 
mmol - millimol 
Mnk1 - (MAPK)-interacting kinase 1 
MOI – Multiplicity Of Infection 
MOPS - 3-(N-morpholino)propanesulfonic Acid 
mRNA – messenger Ribonucleic Acid 
MS – Mass Spectroscopy 
NBT - Nitro blue tetrazolium 
NCBI  nr - National Center for Biotechnology Information – non redundant 
ng – nanogram 
nM – nanomolar 
nm – nanometre 
NMR - Nuclear Magnetic Resonance 
NPC – Nuclear Pore Complex 
NTP - Nucleotide triphosphate 
Oct1 - Octamer Transcription Factor 
PABP – PolyA Binding Protein 
pBS - PBluescript 
PBS - Phosphate Buffered Saline 
PBS-T – PBS-Tween 
PCR – Polymerase Chain Reaction 
Phe – Phenylalanine 
pmol - picomol 
pol – polymerase 
ppm – parts per million 
pro - proteinase 
PV – Poliovirus 
RNA - Ribonucleic Acid 
RNase- Ribonuclease 
rpm – rotations per minute 
RRL - Rabbit Reticulocyte Lysate 
SDS - Sodium Dodecyl Sulfate 
SDS-PAGE - SDS- Poly-Acrylamide Gel Electrophreis 
Sf9 - Spodoptera frugiperda cells 
SFM – Serum Free Medium 
S-MEM - Minimum Essential Medium Eagle Joklik Modification 
TAE - Tris-acetate-EDTA 
TAP - Tandem Affinity Purification 
TB – Terrific Broth 
TBP – TATA box Binding Protein 
TBq - Tera-becquerels 
TCA - Trichloroacetic Acid 
TE – Trypsin/EDTA 
TEB – Tris/EDTA Buffer 
TEMED - Tetramethylethylenediamine 
TEV - Tobacco Etch Virus 
TF – Transcription Factor 
tRNA – transfer Ribonucleic Acid 
U - Units 
UGB – Upper Gel Buffer 
UTR – Untranslated Region 
UV – Ultra Violet 
V - volts 
v - volume 
VP – Viral Protein 
VPg – Virion Protein genome 
w - weight 
zVAD.fmk - benzylloxycarbonyl-Val-Ala-Asp(OMe).fluoromethyl ketone 
zVAM.fmk - benzylloxycarbonyl-Val-Ala-Met.fluoromethyl ketone 
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1 Introduction 
 
1.1 Picornaviruses 
The family Picornaviridae is composed of 9 genera (table 1), all infecting vertebrates. 
Some are important human and animal pathogens, such as poliovirus (PV) or foot and mouth 
disease virus (FMDV).  
 
   Genus                                                    Members                                                       Serotypes 
   Enterovirus                                  Poliovirus, Coxsackievirus,                                              95  
                                                       Swine Vesicular Disease Virus    
   Rhinovirus                                   Common Cold Virus                                                        103 
   Cardiovirus                                  Encephalomyocarditis Virus,                                               5          
                                                       Theilers Murine Encephalomyelitis 
                                                       Virus, Mengovirus 
   Aphthovirus                                 Foot-And-Mouth Disease Virus                                           8 
                                                       Equine Rhinovirus A 
   Hepatovirus                                 Including Hepatitis A Virus                                                  3 
   Parechovirus                               Human Parechovirus                                                           4 
   Erbovirus                                     Equine Rhinovirus B                                                            2 
   Kobuvirus                                    Including Aichi Virus                                                            2 
   Teschovirus                                 Including Teschen Disease Virus                                       11 
 
Table 1: The Genera of the family of Picornaviruses (Fauquet and International Committee on 
Taxonomy of, 2005). 
 
 1.1.1  Human rhinoviruses 
 Human rhinoviruses (HRV) are the most frequent cause of the common cold, a mild 
infection of the upper respiratory tract, in humans. The primary sites of infection are the nose 
and throat (Arruda et al., 1997). However, infection of the lower respiratory tract does occur 
(Mosser et al., 2005; Papadopoulos et al., 2000). Rhinoviruses are also involved in 
exacerbation of asthma and pneumonia (Turner, 2007; Xatzipsalti et al., 2005). Furthermore, 
recent reports show a connection between rhinoviruses and severe respiratory-tract infection 
in children (Renwick et al., 2007). 
There are more than 100 serotypes of HRV which are divided in two genetic groups, 
A and B, according to sequence data on VP1 and VP4 (Laine et al., 2006; Savolainen et al., 
2002). However, recently, a new genotype of HRV, has been identified in patients presenting 
symptoms of influenza-like disease where no influenza viruses were detected (Lamson et al., 
2006). The complete genome of three of these new viruses has been sequenced and 
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revealed that they belong to a new species, HRV-C (Lau et al., 2007). The genome of HRV-
C viruses is relatively small compared with HRV-A and HRV-B. The polyprotein of HRV-C 
showed 51% amino acid identity with HRV-A and 48% with HRV-B. Phylogenetic analysis of 
HRV-C strains formed a distinct cluster from HRV-A and HRV-B (figure 1). Out of 26 HRV 
strains isolated from children with acute respiratory tract infection, 21 were found to belong to 
the HRV-C group (Lau et al., 2007).     
 
 
Figure 1: Phylogenetic tree of the VP4 region of 26 HRV strains collected from nasopharyngeal 
aspirates (Lau et al., 2007).  
 
A second classification system clusters these viruses according to the receptor used 
to enter the host cell. The major group, which comprises 90% of the serotypes, binds the 
intercellular adhesion molecule (ICAM) (Greve et al., 1989; Staunton et al., 1989) whereas 
the minor group utilizes the Low Density Lipoprotein (LDL) receptor (Hofer et al., 1994). 
Some serotypes can also use the heparan sulphate (HS) receptor as a second receptor 
(Khan et al., 2007). 
 
 1.1.2 Viral particle 
Picornaviruses are small, non-enveloped viruses with a single stranded RNA genome 
of positive polarity. The term picornavirus is derived from the small (pico) size of the viral 
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particle and their RNA genome. These viruses have a simple structure with a spherical 
shape of about 30 nm of diameter, arranged in an icosahedral symmetry. The X-ray 
structures of many picornaviruses are available and were crucial for understanding the viral 
capsid. Among these structures are PV1 (Hogle et al., 1985), HRV14 (Rossmann et al., 
1985), HRV16 (Oliveira et al., 1993), FMDV serotype O (Acharya et al., 1989) and 
coxsackievirus (CV) B3 (Muckelbauer et al., 1995).  
The viral capsid is composed of four structural proteins, VP (Viral Protein) 1, VP2, 
VP3 and VP4. The precursor of VP2 and VP4 is VP0, which is cleaved during the maturation 
of the viral particle. VP1, VP2 and VP3 share the same topology despite having different 
sequences. VP4 is located in the inner surface of the particle. The structure of the capsid 
proteins is a wedge-shaped, eight stranded, antiparallel β-barrel. One copy of each protein 
unites to form a protomer, the basic building block of the picornavirus capsid. 60 protomers 
form the viral capsid (figure 2). The shape similarity shared by the viral proteins facilitates 
their interaction with one another and their packing in the capsid. The interactions of the β-
barrel domains of adjacent proteins form a dense and rigid shell that surrounds the naked 
RNA genome (Flint, 2004).  
 
 
Figure 2: Structure of picornaviruses. A) Representation of the packing of VP1-VP2-VP3 structural 
units. 60 copies of each viral protein pack tightly forming the viral capsid. The protomer is highlighted 
in blue and forms two adjacent faces of an icosahedron. VP4 lies on the inner surface of the protein 
shell. (Flint, 2004)  B) Poliovirus particle determined from X-ray crystallographic data (Hogle et al., 
1985). 
 
 The functions of the viral capsid are protection of the genome from the surrounding 
environment, recognition of cell receptors and thus tissue tropism determination, 
                                                                                                                                            1. Introduction 
 4
determination of antigenicity and release of the RNA genome. Despite their similarity, 
picornaviral capsids vary in some physical properties. For example, cardioviruses, 
enteroviruses, hepatoviruses and parechoviruses are acid stable and remain infective at pH 
lower than 3. Other picornaviruses, such as rhinoviruses and aphthoviruses, are labile at pH 
lower than 6 (Fields et al., 2007). These differences influence the location at which the 
viruses replicate. For example, rhinoviruses replicate in the respiratory tract whereas 
enteroviruses are able to replicate in the alimentary tract. 
 Although many structures of picornaviruses have been solved, there is still no insight 
into why some genera have a high number of serotypes, such as human rhinoviruses, and 
others like polioviruses have just few serotypes. The antigenicity of the picornaviruses is 
determined by the loops that connect the β-strands and the N- and C- terminal sequences 
that stretch out from the β-barrel domain. These regions contain the main structural 
differences among VP1, VP2 and VP3 and the major neutralization antigenic sites of the 
virus. 
 
1.1.3 Picornaviral Genome 
 Picornaviral genomes are composed of a single stranded RNA molecule of positive 
polarity, with lengths of 7.1 kb (HRV) to 8.2 kb (FMDV). The viral genome is divided into 
three regions: the 5’ UTR (untranslated region) (0.6 to 1.2 kb), the coding region (6.5 to 7 kb) 
and the 3’ UTR (up to 0.1 kb) that contains a polyA tail of several dozen nucleotides (Agol, 
2002). Picornaviral RNA does not possess a 5’ cap structure; instead the RNA is covalently 
linked to the virion protein genome (VPg) (Flanegan et al., 1977; Lee et al., 1977) through a 
tyrosine residue.  
cis-Elements (RNA sequences that regulate the expression of genes located on that 
same strand) involved in replication and translation of viral RNA are mainly present in the 5’ 
UTR. However, some can be found within the coding region. One cis-element present in the 
5’ UTR is the Internal Ribosome Entry Site (IRES). The IRES is composed of discontinuous 
RNA segments which associate with each other acquiring a functional conformation 
(Witherell et al., 1995). This highly structured region of the genome serves as recognition site 
for the ribosome, ensuring the formation of a pre-initiation template/ribosome complex (Agol, 
2002). IRES sequences are formed by approximately 450 nucleotides and contain different 
sequence and secondary structure among the different picornavirus genera. There are three 
types of IRES in picornaviruses: type I in entero and rhinoviruses; type II in cardio, aphtho- 
and parechoviruses and type III in hepatoviruses (figure 3).  The classification of IRES was 
based on sequence comparisons and biochemical or enzymatic probing (Ehrenfeld and 
Teterina, 2002). 
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Figure 3: Schematic representation of the predicted stem-loop structures in the (A) poliovirus, 
(B) encephalomyocarditis virus, and (C) hepatitis A virus 5’ UTR of the viral RNAs (Ehrenfeld 
and Teterina, 2002).  
 
The 5’ UTR also contains an oligopyrimidine stretch and an AUG codon separated by 
about 20 nucleotides which was postulated as being a cis-acting element (Beck et al., 1983; 
Pilipenko et al., 1992). However, it is not clear whether the oligopyrimidine, AUG codon and 
the spacer function as a single template element or whether they are separated elements in 
which the spacer determines the position of the AUG codon relative to the IRES (Pilipenko et 
al., 1995). 
  Aphthoviruses and cardioviruses contain a polyC tract in their 5’ UTR, which varies in 
length within the several serotypes. In cardioviruses the longer length of the polyC sequence 
is associated with higher virulence (Fields et al., 2007). 
 The 3’ UTR is shorter than the 5’ UTR (47 nucleotides for HRV and up to 125 
nucleotides in encephalomyocarditis virus (EMCV)) (Fields et al., 2007). The 3’ end contains 
a pseudoknot which might be involved in the initiation of the synthesis of minus strand RNA 
(Jacobson et al., 1993). Furthermore, the removal of the polyA tract in PV produces non-
infectious RNA (Spector and Baltimore, 1974). However, it was shown recently that the 3’ 
non coding region is not required for HRV and PV infectivity (Brown et al., 2005). 
 The coding region is composed of a single open-reading frame which is translated as 
a single polyprotein. Processing of the polyprotein by viral proteinases gives the mature 
proteins (Fields et al., 2007) (see section 1.1.6) . 
 
1.1.4 Replication cycle  
Picornaviruses replicate in the cytoplasm of an infected cell. The replication cycle is 
divided in three steps: attachment and entry, decoding of genetic information and synthesis 
of new genomes and finally assembly and release of the particle. 
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A single replication cycle can take 5 to 10 hours, depending on the virus, 
temperature, host cell or pH. Figure 4 shows a schematic representation of the picornaviral 
replication cycle. 
 
 
Figure 4:  Overview of the picornavirus replication cycle.  After binding to the receptor (1) the 
virus releases its genome and the VPg (virion protein, genome linked) is removed from the viral RNA 
(2). The RNA is translated (3) into a polyprotein that is co-translationaly cleaved (4) into the the viral 
proteins. The RNA synthesis is carried out in vesicular membranes where (-) strand RNAs are 
synthesized by the RNA polymerase (5). The (-) strand RNAs are then used to produce more (+) stand 
RNAs (6). During early infection the newly synthesized (+) RNA is translated into viral proteins (7) 
while during late infection it is packed into the viral particles (8), which are finally released upon cell 
lysis (9) (Fields et al., 2007). 
 
Once the virus enters the cell its RNA needs to be translated as no cellular 
polymerase can copy it and no viral enzymes are carried within the viral capsid.   
 Instead of a 5’-terminal cap structure, picornaviruses have an IRES sequence (see 
section 1.1.3) which allows them to bind to the ribosomes and translate their genome. How 
the viruses take over the cellular translation machinery will be described in section 1.1.6. In 
EMCV the central domain of eukaryotic initiation factor (eIF) 4G (see section 1.2.1.1), 
containing the binding sites for eIF3 (binds directly to the ribosome) and eIF4A (an RNA 
helicase) remains and stimulates IRES mediated translation (Pestova et al., 2001). 
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Additionally, FMDV RNA translation is also stimulated by the appearance of proteolytic 
cleavage products of eIF4G (Ohlmann et al., 1995). An exception is hepatitis A virus (HAV) 
which requires intact eIF4G (Borman and Kean, 1997).  
Upon picornaviral infection, the intracellular membranes of the cell go through 
rearrangement. The endoplasmatic reticulum (ER) and Golgi apparatus are destroyed and 
double membrane vesicles fill the cytoplasm (Schlegel et al., 1996). Viral replication occurs 
on the surface of these membranes. About 50,000 copies of the viral positive-stranded 
genome are produced in the infected cell, through a negative-stranded intermediate (Fields 
et al., 2007). The genomic RNA serves as mRNA and as template for synthesis of the 
negative strand. These processes do not occur simultaneously (Barton et al., 1999).  
 The synthesis of the negative strand is performed by 3Dpol, a RNA dependent RNA 
polymerase encoded by the virus. Once 3Dpol and other essential proteins have been 
synthesized, the genomic RNA starts to be used as template for the negative-stranded 
intermediate. The 3Dpol together with 3AB, forms two dimensional lattices coating the 
membranes where the viruses replicate. These structures result in a increase of substrate 
affinity simply by reducing the collisions between reactants (Lyle et al., 2002). 
The shift between translation and replication is controlled by an RNA element at the 5’ 
end of the viral RNA genome, a cloverleaf structure of 64 nucleotides. 3CD (the polymerase 
precursor) binds to this structure, repressing viral translation and promoting negative 
stranded RNA synthesis (Gamarnik and Andino, 1998). 
 After release of the P1 region from the rest of the polyprotein, viral proteinases cleave 
the VP0-VP3 and VP3-VP1 bonds. Afterwards, one copy of VP0, VP3 and VP1 assemble 
forming an immature structural unit, the 5S protomer. Five protomers assemble to build a 
pentamer, which can self-assemble in vivo and in vitro into empty capsids. There are two 
models for the insertion of the viral RNA into the capsid. According to the first model, the 
RNA is inserted into the intact capsid after it is assembled (Jacobson and Baltimore, 1968). 
The second model states that the pentamers assemble with the RNA to form provirions 
(Nugent and Kirkegaard, 1995). 
 The final step of assembly is the cleavage of VP0 into VP2 and VP4 by an unknown 
proteinase activity. As the scissile bond is not accessible to viral or cellular proteinases, it 
was suggested that the cleavage can be autocatalytic. The process would involve the Ser10 
of VP2 and basic RNA groups that would serve as proton-abstracters as in a serine protease 
type mechanism (Arnold et al., 1987). However, experiments in which the Ser10 was deleted 
showed that this residue is not involved in the cleavage mechanism (Harber et al., 1991). 
Later it was shown that the His195 of VP2 is probably involved in the VP0 cleavage. His195 
may activate local bound water molecules that can initiate a nucleophilic attack at VP0 
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cleavage site (Hindiyeh et al., 1999). This cleavage results in an increase in particle stability 
and acquisition of infectivity (Lee et al., 1993). 
After assembly and maturation, viral particles are released by lysis except for HAV 
which is released without causing cytopathic effect. The cytopathic effect consists of 
condensation of chromatin, nuclear blebbing, proliferation of membranous vesicles, changes 
in membrane permeability, leakage of intracellular components and shrinking of the entire 
cell (Fields et al., 2007). 
 
1.1.5 Binding to the receptor and cell entry 
 Picornaviruses use different cell surface molecules as receptors (table 2).  
Virus Receptors 
Foot and mouth disesase virus Heparan sulphate, αvβ3, αvβ8 
Encephalomyocarditis virus VCAM-1, sialated glycophorin 
Polioviruses 1-3 PVR (CD155) 
Coxsackieviruses A ICAM-1, CD55, αvβ3, αvβ6 
Coxsackieviruses B CAR, CD55 (DAF) 
Echoviruses Α2β1-integrin, CD55 
Parechovirus 1 αvβ1, αvβ3 
Enteroviruses  CD55, sialic acid 
Hepatitis A virus HAVCR-1 
Major group rhinoviruses ICAM-1, heparan sulphate 
Minor group rhinoviruses LDL receptor family 
 
Table 2: Viruses and their receptors. Adapted from (Fields et al., 2007). 
 
PV, CV and HRV capsids have a five fold axis of symmetry, which is rounded by a 
deep depression, named the canyon. Many receptors, such as ICAM or CD55, bind to the 
canyon. Aphthoviruses and cardioviruses do not have these canyons (Fields et al., 2007).  
 
1.1.5.1 Poliovirus 
PV uses CD155, an adhesion molecule of the Ig (Immunoglobulin), superfamily. The 
Ig superfamily receptors have 2 to 5 Ig domains and the viral recognition site lies at the N-
terminal domain. This domain penetrates into the picornavirus canyon, causing instability in 
the capsid, thus facilitating the release of RNA. (Rossmann et al., 2002). Upon receptor 
binding, conformational changes occur leading to the formation of a pore through which the 
RNA can enter the cell (Bubeck et al., 2005). Two recent studies suggest that poliovirus 
enter different cells through different mechanisms (Bergelson, 2008). In the first study, the 
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results showed that in HeLa and HEK 293 cells, the uncoating occurs within clathrin- and 
caveolin-independent vesicles in the cell periphery and that it is more than a simple 
consequence from the interaction with the receptor. It requires energy, an intact cytoskeleton 
and activity of cellular tyrosine kinases (Brandenburg et al., 2007). The second study showed 
that in human brain microvascular endothelial cells, viral entry is caveolin and dynamin 
dependent. The internalization of the caveolar vesicles occurred in response to specific 
signals from specific ligands. Additionally, the ligation of the virus to the receptor triggered 
rearrangements of the actin cytoskeleton which were also required for the entry process 
(Coyne et al., 2007). 
 
1.1.5.2 Coxsackievirus 
CVA21 binds DAF (decay accelerating factor) and ICAM-I. CVB bind DAF on the 
apical surface of the cell, inducing rearrangements that allow the viruses to access to their 
actual receptor, CAR (coxsackie and adenovirus receptor), that is located in the tight 
junctions of the cell (Fields et al., 2007). 
 
1.1.5.3 Foot and mouth disease virus 
FMDV A12 uses integrin αvβ3 for attachment whereas the laboratorial strain FMDV O 
uses HS (Jackson et al., 1996; Neff et al., 1998). FMDV (and some HRVs) enter the cell by 
endocytosis and the uncoating process is induced by acidification of the endosome. In these 
cases, the binding to the receptor does not trigger conformational changes, it just secures 
the viral particle to the cell so it can enter via endocytic pathway. At pH 6.5, the viral capsid 
separates itself into pentamers and releases the RNA (van Vlijmen et al., 1998).  
 
 1.1.5.4 Human rhinovirus 
As mentioned in section 1.1.1, major group human rhinoviruses bind to ICAM-I and 
minor group human rhinoviruses bind to the LDL receptor family. Although the overall 
structures of HRV are similar, the binding to their respective receptors is highly specific 
(Kolatkar et al., 1999). For minor group HRVs, the receptor binding region, situated on the 
left side of the five fold axis, contains mainly basic residues. Among these residues  is a 
lysine that is conserved in the minor group and seems to play a central role on receptor 
recognition (Vlasak et al., 2003). The same region of major group HRVs contains mostly 
uncharged or acidic residues. The nature of the interaction of LDL family receptors was 
reported to be between acidic residues of the receptor and basic residues of ligands 
(Yamamoto et al., 1984). Figure 5A shows the surface potential of the HRV2 (minor group) 
pentamer. The area where the receptor binds was magnified (figure 5B) and compared to 
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other HRVs of minor and major groups. Blue shows a positive potential and red shows a 
negative one. A clear difference between groups can be observed (Vlasak et al., 2003). 
 
 
Figure 5: Surface potential of the receptor binding site of several HRVs. A) HRV2 pentamer. B) 
Magnification of the receptor binding sites of HRV2, HRV1A (minor group), HRV14 and HRV16 (major 
group). Blue areas show positive potential whereas red areas show negative potential. The conserved 
lysine of minor group viruses is marked by a bold circle in the surface of HRV2. Adapted from Vlasak 
et al., 2003. 
 
Major group HRVs bind to their receptor ICAM-1 via residues that are located in the 
canyon (Figure 6) (Kolatkar et al., 1999; Olson et al., 1993). This mode of binding prevents 
bulky neutralizing antibodies from accessing the receptor binding site (Rossmann et al., 
2000). The binding occurs through the distal amino-terminal of ICAM-1. The tip of the most 
distal domain of ICAM-1 presents a high level of shape and charge complementarity with the 
wall and floor of the canyon of HRV14 and HRV16 (Kolatkar et al., 1999). This 
complementarity is not observed in HRV2 (Rossmann et al., 2000). 
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Figure 6: Cryo-EM (cryo electron microscopy) image reconstruction of HRV14 complexed with 
a soluble fragment of ICAM-1 (Kolatkar et al., 1999). 
 
1.1.6 Polyprotein processing 
The polyprotein processing occurs co-translationally via intramolecular cleavages 
(primary cleavages) and intermolecular cleavages (secondary cleavages). All picornaviruses 
encode 3Cpro, which performs the primary cleavage between 2C and 3A (Fields et al., 2007). 
 The processing events vary among the different picornaviruses (figure 7). The single 
picornaviral open reading frame is translated into a long polyprotein which is processed by 
virally encoded proteinases. The picornaviral polyprotein is divided in three regions: P1, P2 
and P3. P1 contains the four capsid proteins VP1 to VP4; P2 and P3 regions contain the 
non-structural proteins. Cardioviruses and aphthoviruses contain an additional protein, 
named Leader, preceding the P1 region.  
 Hepato- and parechoviruses polyprotein processing is the simplest among 
picornaviruses. These viruses encode only one enzyme with proteolytic activity, 3Cpro. 3Cpro 
performs the second primary cleavage between 2A and 2B in the P2 region (Martin et al., 
1995) and all the secondary cleavages of the HAV polyprotein, showing an activity profile 
broader than that of 3Cpro of other picornaviruses (Schultheiss et al., 1994). The 2A protein of 
these viruses has no known function. 
 In aphthoviruses and cardioviruses, 2A is not active as a proteinase. This protein is 
released from the polyprotein through a mechanism in which the peptide bond between the 
last residue of 2A and the first residue of 2B is not formed (Ryan et al., 1999). In this 
mechanism, the nascent 2A interaction with the exit pore from the ribosome is altered. The 
orientation of the protein within the peptidyl-transferase center of the ribosome is changed, 
thus inhibithing the peptide bond formation and releasing the 2A (Ryan et al., 1999). The first 
encoded protein in aphtho- and cardioviruses is the Leader protein (L). In cardioviruses, the 
Leader protein has no proteolytic activity and the cleavage at its C-terminus is carried out by 
3Cpro. However, the leader protein of mengovirus has a role in the antiviral host cell 
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response, by interfering with the iron homeostasis and inducing NF-κB (Zoll et al., 2002). In 
contrast to cardioviruses, the aphthoviruses Leader protein is a proteinase (Lpro) (Guarne et 
al., 1998). It cleaves between its own C-terminus and the N-terminus of VP4. The secondary 
cleavages are performed by 3Cpro. 
 For entero- and rhinoviruses, the primary cleavage that separates the P1 and P2 
regions is carried out by 2Apro. The 3Cpro performs most of the secondary cleavages. In PV 
the 3Cpro precursor, 3CDpro, cleaves between VP0 and VP3 and between VP3 and VP1 (Jore 
et al., 1988; Ypma-Wong et al., 1988). Additionally, the 2Apro of PV and some HRV serotypes 
can cleave the precursor 3CD into the products 3C’ and 3D’ (Hanecak et al., 1982; McLean 
et al., 1976). However, the suppression of this cleavage site in PV does not affect viral 
replication.  
 
 
 
Figure 7: Primary cleavages of picornavirus polyprotein. Hepatoviruses possess the simplest 
cleavage pattern in wich 3Cpro performs all the primary cleavages. In cardioviruses and aphthoviruses 
2A releases itself from the 2B protein, although it is not a proteinase. 3Cpro separates 2A from the P1 
region. FMDV Lpro releases itself from the VP4 protein. In enteroviruses and rhinoviruses the 2Apro 
carries out the cleavage between P1 and P2 regions through autocleavage. Adapted from (Fields et 
al., 2007). 
 
After a first round of translation, picornaviral proteinases cleave the scaffolding 
protein eIF4G, whose function is to bring together ribosomes and capped mRNA (figure 8 
and section 1.2.1.1). The consequence of eIF4G cleavage is the host cell translation shut-off. 
The cellular capped mRNA is no longer able to bind to the ribosomes. Therefore the virus 
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takes over the cell translational machinery, through an IRES sequence present in its genome 
(section 1.1.3), to synthesize all the proteins necessary for replication and assembly. The 
cleavage of eIF4G by picornaviral proteinases will be described in detail in sections 1.1.8.1.4 
and 1.1.8.3.4. 
 
 
 
Figure 8: 5’ cap-dependent versus IRES-dependent translation initiation. Binding of eIF4E to the 
5’ cap positions the ribosome on the mRNA. After eIF4G cleavage the 5’ capped mRNA can no longer 
bind the ribosome. However, the IRES can bind the C-terminus of eIF4G which remains from the 
cleavage and therefore recruit the ribosome. 
 
1.1.7 Picornaviral non-structural proteins 
The P1 region contains the structural proteins described in section 1.1.2. P2 and P3 
contain the non-structural proteins. This section will not consider those viral proteins with 
proteinase activity; they will be described in more detail below. 
P2 contains the proteins 2A, 2B and 2C. As mentioned above, aphtho- and 
cardioviruses 2A do not have proteolytic function. However, EMCV 2A seems to be required 
for efficient translation of EMCV RNA in vivo to neutralize the competition from cellular 
mRNAs (Svitkin et al., 1998). 2B forms pores on the ER and Golgi membranes. Therefore, it 
decreases the Ca2+ concentration in these organelles and increases the levels of this ion in 
the cytoplasm. 2B is also involved in the anti-apoptotic response in polioviruses, perhaps due 
to its ability to disturb the intracellular Ca2+ homeostasis (van Kuppeveld et al., 2005). The 
precursor of 2B, 2BC, is responsible for the accumulation of the Golgi and ER derived 
vesicles, in the cytosol, where viral replication takes place (Bienz et al., 1994).  2C binds to 
membranes and RNA. In poliovirus, 2C binds to the 3’ end of the negative strand replication 
intermediate (Goodfellow et al., 2003) and it may have a role in viral encapsidation (Vance et 
al., 1997). 
The P3 region consists of four proteins, 3A to 3D. 3A appears to have a role in 
altering the ER-Golgi trafficking facilitating the evasion of the host immune system (Choe et 
al., 2005). 3B is the virion protein genome (VPg) which covalently binds to the 5’ end of the 
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viral RNA (Flanegan et al., 1977). This peptide is cleaved off the RNA upon entry in the cell 
and is not necessary for translation. However, VPg is found in nascent RNA chains, both 
positive and negative, (Pettersson et al., 1978) and acts as a primer for RNA synthesis (Paul 
et al., 1998). Finally, 3D is the RNA dependent RNA polymerase responsible for copying the 
RNA genome (section 1.1.4) (Crowder and Kirkegaard, 2004; Pata et al., 1995). 
 
1.1.8 Picornaviral Proteinases 
1.1.8.1  Leader proteinase (Lpro) 
Two in frame AUG codons that are situated 84 residues apart in the viral polyprotein 
originate two forms of the Leader proteinase (Lpro). When the protein synthesis starts at the 
first AUG codon Labpro is produced; when the synthesis starts at the second AUG codon Lbpro 
is formed (Clarke et al., 1985; Sangar et al., 1987). Both proteins are active and able to 
perform cleavage from the polyprotein in cis and in trans (Cao et al., 1995; Medina et al., 
1993). 
 
1.1.8.1.1 Properties 
Lpro is inhibited by general sulphydryl-specific reagents and E-64 (a general inhibitor 
of cysteine proteinases), implying that this proteinase activity follows a papain like 
mechanism (Burroughs et al., 1984; Kleina and Grubman, 1992). 
 
1.1.8.1.2 Structure 
The structure of Lbpro was solved by X-ray crystallography (Guarne et al., 1998). The 
proteinase has a papain-like folding with two domains: a α-helical domain (also called left 
domain) and a β-sheet domain (right domain). In contrast to papain, Lbpro has no prominent 
surface loops and contains a C-terminal extension (CTE). The CTE structure is very flexible. 
The active site is formed by the catalytic dyad Cys51 and the His148, at the interface 
between the two domains (figure 9). Asp163 keeps the active His148 in the correct 
orientation in respect to the Cys51. 
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Figure 9: The structure of FMDV Lbpro. α-helices and β-strands are coloured green and magenta, 
respectively. The CTE is presented in two possible conformations: ordered (orange) and disordered 
(blue). Two active site residues are shown as ball and stick models (Guarne et al., 1998). 
 
1.1.8.1.3 Specificity 
The cleavage sites of Lpro are presented in table 3. The structure showed that the 
most important interactions in the Lpro substrate-binding groove are with the residue at the P2 
position (Guarne et al., 1998) (the nomenclature Pn-P1-P1’-Pn’ is that of (Schechter and 
Berger, 1967)). The protein developed a pocket to anchor a hydrophobic residue at this P2 
position. This pocket accepts valine or leucine; however, it does not accept a phenylalanine 
(table 3).  
In contrast, the residues at P3, P1 and P1’ are more variable. This might be because 
P1 and P3 residues point away from the enzyme.  At the P1 site, a positively charged 
residue is well accepted as the Glu96 and Glu147 help to stabilize the positive charge and 
the side chains provide a hydrophobic environment for the lysine side chain (Guarne et al., 
1998). It is not clear why Lpro accepts glycine at P1 position in the eIF4G isoforms. 
Interestingly, the P1’ residue is the most variable among the substrates. (Guarne et al., 
1998). Although there is no structural information about the interaction of the substrate with 
the enzyme, comparisons with the papain structure can provide some information on the P1’ 
residue. These analysis show that the Asp164 could accommodate a positively charged 
residue at the P1’ site, as it happens for the cellular substrate, eIF4GI (Skern et al., 2002). 
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Substrate 
Cleavage sites 
           P    *   P’     
54321   1234 
Lbpro/VP4 QRKLK * GAGQ 
eIF4GI FANLG * RTTL 
eIF4GII LLNVG * SRRS 
eIF4GII not cleaved FADFG * RQTP 
 
Table 3: Lbpro cleavage sites on known substrates. eIF4GII is not cleaved at the analogous 
sequence to that recognized in eIF4GI (last lane).  
 
1.1.8.1.4 Interaction with cellular proteins 
Lpro has developed a high level of specificity. Therefore, the only substrates known in 
the cell are the two isoforms of eIF4G, whose cleavage leads to the host cell translation shut 
off. As shown in table 3, Lpro does not cleave eIF4GII at the analogous site of eIF4GI; instead 
the cleavage occurs at LNVG*SRRS (Gradi et al., 2004). 
 
 1.1.8.2  3C proteinase (3Cpro) 
 3Cpro was the first viral protein shown to have proteolytic activity through work done in 
EMCV  (Gorbalenya et al., 1979; Palmenberg et al., 1979; Svitkin et al., 1979) and PV  
(Hanecak et al., 1982; Hanecak et al., 1984).  
  
 1.1.8.2.1 Properties  
 3Cpro are inhibited by N-ethylmaleimide, iodocetamide and Hg2+ ions (Pelham, 1978), 
but not by E-64  (Orr et al., 1989). The mechanism of PV 3Cpro seems to be similar to the one 
of serine proteases; however, this mechanism does not involve a thiolate-imidazolium ion 
pair (Sarkany et al., 2001). 
 
 1.1.8.2.2 Structure 
 3Cpro is a single chain protein with homology to chymotrypsin-like serine proteases.  
The X-ray structure of 3C from HAV (Allaire et al., 1994; Bergmann et al., 1997), HRV14 
(Matthews et al., 1994), HRV2 (Matthews et al., 1999) and PV (Mosimann et al., 1997) are 
available. All these structures contain two topologically equivalent six-stranded β-barrels. A 
long, shallow groove for substrate binding is situated between the two domains. The catalytic 
triad is constituted by His40, Cys146 and Glu71 in HRV14, and His44, Cys172 and Asp84 in 
HAV (Gorbalenya et al., 1989; Kean et al., 1991). Figure 10 shows the structure of PV 3Cpro. 
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 A RNA binding site, constituted by basic residues is situated on the opposite side of 
the active site. Two phenylalanine residues seem to play a role in RNA binding (Matthews et 
al., 1994). The precursor of 3Cpro, 3CD interacts with the viral RNA and plays a role in 
translational control (Gamarnik and Andino, 1998; Gamarnik and Andino, 2000; Marcotte et 
al., 2007). 
 
 
Figure 10: The structure of PV 3Cpro. The β-barrels are indicated in blue (domain I) and in green 
(domain II). The individual four-stranded β-sheets are shown in dark-blue, cyan, and green (Mosimann 
et al., 1997). 
  
 1.1.8.2.3 Specificity 
 3Cpro usually cleaves between Gln*Gly. However, the cleavage sites vary among 
different genera. PV 3Cpro cleaves only between Gln*Gly whereas EMCV 3Cpro accepts 
Glu*Ser or Glu*Ala and FMDV 3Cpro recognizes Gln*Leu and Gln*Ile as well.  Nevertheless, 
these sequences are not sufficient for cleavage; the flanking residues are also important for 
specificity (Ypma-Wong et al., 1988). The residues at P4 and P2 sites are conserved in both 
HRVs and enteroviruses (an aliphatic residue at P4 and proline at P2).  Cardioviruses 
process substrates that contain proline at P2 and P2’ sites. In rhino- and enteroviruses sites 
P4, P1, P1’ and P2’ are sensitive to substitutions. HRV14 and PV have a preference for 
alanine at P4, glutamine at P1, glycine at P1’ and proline at P2’ (Cordingley et al., 1990; 
Long et al., 1989). EMCV accepts serine, cysteine, glycine and alanine at P1’ but not 
threonine, isoleucine or tyrosine (Parks et al., 1989). 
   
 1.1.8.2.4 Interaction with cellular proteins 
 PV 3Cpro cleaves the transcription factors TFIIIC (Clark et al., 1991), TFIID (Clark et 
al., 1993) Oct1 and CREB (Yalamanchili et al., 1997b; Yalamanchili et al., 1997c), and the 
microtubule-associated protein 4 (Joachims et al., 1995). FMDV 3Cpro cleaves histone protein 
                                                                                                                                            1. Introduction 
 18
3 (Tesar and Marquardt, 1990) and the initiation factors eIF4A and eIF4GI (Belsham et al., 
2000). However eIF4GI cleavage happens later than the cleavage by Lpro. 
All these cleavages affect host-cell transcription and translation. 
  
1.1.8.3  Entero- and rhinoviruses 2A proteinase (2Apro) 
In enteroviruses and rhinoviruses, 2Apro is responsible for the initial cleavage of the 
polyprotein, separating the structural proteins from the non structural ones. It cleaves 
between its own N-terminus and the C-terminus of VP1. 2Apro also cleave several cellular 
proteins. 
 
1.1.8.3.1 Properties 
 2Apro are inhibited by iodocetamide, N-ethylmaleinimide and Hg2+ ions, but not E-64. 
Chymostatin and elastatinal (serine proteinases inhibitors) are also efficient against 2Apro. 
However, leupeptin, another inhibitor of serine and cysteine proteinases, has no effect 
(Sommergruber et al., 1992). Recently, it was found that a methylated form of the caspase 
inhibitor benzylloxycarbonyl-Val-Ala-Asp(OMe).fluoromethyl ketone (zVAD.fmk) inhibits 2Apro 
(Deszcz et al., 2004). Based on structural analysis of zVAD.fmk and HRV2 2Apro, a new 
inhibitor derived from zVAD.fmk was synthesized. The new compound was named 
benzylloxycarbonyl-Val-Ala-Met.fluoromethyl ketone (zVAM.fmk). It inhibits specifically 2Apro 
but not caspases. Therefore, zVAM.fmk is a specific tool to study the roles of 2Apro during 
viral replication, as the proteinase can be inactivated at specific points of the infectious cycle 
(Deszcz et al., 2006). 
2Apro are also potential drug targets. Crowder and Kirkegaard (2005) showed that PV 
bearing 2Apro without enzymatic activity can function as dominant negative inhibitors of wild-
type growth. In experiments in which cells are co-infected with wild type PV and PV bearing 
mutations in the 2Apro sequence which make the proteinase inactive, the mutants suppress 
the growth of the wild type viruses (Crowder and Kirkegaard, 2005). There is evidence that 
the cleavage between VP1 and 2Apro is exclusively intramolecular (Toyoda et al., 1986). 
Therefore, the uncleaved VP1-2A can accumulate and co-assemble with wild type VP0 and 
VP3 forming non-functional capsids, preventing the growth of wild type viruses (Crowder and 
Kirkegaard, 2005). 
 
1.1.8.3.2 Structure 
 2Apro are cysteine proteinases with a chymotrypsin-like fold. The X-ray structure of 
HRV2 2Apro has been solved (Petersen et al., 1999). The NMR structure of CVB4 2Apro is 
also available (Baxter et al., 2006). 2Apro is composed of an N- and a C-terminal domain, 
connected by an interdomain loop. This proteinase shows unique characteristics, compared 
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to other chymotrypsin-like proteinases, the N-terminal domain is not a β-barrel, but a four 
stranded anti-parallel β-sheet (figure 11). The C-terminal domain is made of a β-barrel and 
contains a zinc ion that is tightly coordinated by Cys52, Cys54, Cys112 and His114. The zinc 
ion is essential for the maintenance of the structure and is thought to compensate the 
reduced size of the N-terminal domain. The zinc ion connects the interbarrel loop with the C-
terminal domain, therefore contributing to the stability of the protein (Petersen et al., 1999).  
 The active site of HRV2 2Apro is composed of a catalytic triad, His18, Asp35 and 
Cys106 and is topologically similar to the chymotrypsin-like serine proteinases. The histidine 
shows an unusual flexibility which is stabilized by the aspartate (Petersen et al., 1999). 
During the interaction with the substrate, chymotrypsin-like proteases develop a negative 
charge, which is stabilized by a structure named oxyanion hole. The stabilization is achieved 
by a network of hydrogen bridges, by anchoring the residues 102-108 to a hairpin loop 
formed by residues 62-65 (Petersen et al., 1999). 
 
 
Figure 11: The structure of HRV2 2Apro. Ribbon diagram of the overall structure of HRV2 2Apro.The 
residues composing the catalytic triad (His18, Asp35 and Cys106), the zinc ion (purple sphere) and 
the zinc binding site are shown (Petersen et al., 1999). 
 
 1.1.8.3.3 Specificity 
 The minimum length of a substrate for HRV2 2Apro is 9 amino acids, P8 to P1’ 
(Sommergruber et al., 1992). The residues at positions P2 and P1’ are of great importance 
for substrate recognition. P2 residue is able to form hydrogen bonds with Ser83 (in HRV2 
2Apro or the equivalent residue in other 2Apro) and seems to provide favourable binding 
energy. HRV2 2Apro accepts threonine, asparagine and serine at P2. At P1’ position, it only 
processes glycine as Leu19 blocks the access of bulkier residues. The P1 position is more 
flexible, accepting a variety of amino acids (methionine, leucine, tyrosine, phenylalanine, 
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threonine and arginine) (Skern et al., 1991; Sommergruber et al., 1992). Moreover, HRV2 
2Apro processes substrates with tyrosine and methionine at P1 site more efficiently than the 
wild type alanine (Sommergruber et al., 1992). The structure shows that the substrate 
binding site, S1, is narrow and deep and is mainly filled with the side chain of Cys101. This 
characteristics make it possible to accommodate long and flexible side chains, like 
methionine (Petersen et al., 1999). Additionally, the presence of Glu102 located at the 
bottom of the pocket provides a negative charge that can support the presence of lysine or 
arginine at the P1 site. 
 
 1.1.8.3.4 Interaction with cellular proteins 
 The best characterized cleavage of cellular proteins by 2Apro is the one of eIF4G, a 
cellular protein involved in the initiation of protein synthesis. The cleavage of both eIF4GI and 
II leads to the inhibition of host cell protein synthesis (Gradi et al., 1998b; Svitkin et al., 
1999). HRV and CV 2Apro were shown to cleave eIF4G directly (Lamphear et al., 1993; Liebig 
et al., 2002). There is evidence that PV1 2Apro also cleaves eIF4G directly (Ventoso et al., 
1998). However, there is also evidence that the cleavage of eIF4G by PV1 2Apro can occur 
indirectly, via activation of a not yet identified cellular proteinase. Furthermore, it was shown 
that PV1 2Apro could be modified by caspases (Bovee et al., 1998; Wyckoff et al., 1992; 
Zamora et al., 2002). 
PV and HRV 2Apro cleave both isoforms of eIF4GI and II in vivo (Gradi et al., 1998a; 
Gradi et al., 2003). HRV2 2Apro recognizes the sequence TLSTR*GPPR on eIF4GI and 
PLLNV*GSRR in eIF4GII (Gradi et al., 2003). HRV2 2Apro binds eIF4GI in a distinct region 
from the cleavage site (Foeger et al., 2002). Furthermore, the residues 669 to 674 have an 
important role in the binding process (Foeger et al., 2002). The binding site is probably used 
to dock the proteinase at some distance from the cleavage site. This shows that the cleavage 
of eIF4G by 2Apro is a multi-step reaction in which the proteinase binds the substrate and 
afterwards cleaves it (Foeger et al., 2002). 
 PV and CVB3 2Apro cleave the polyA binding protein (PABP) which is involved in 
several aspects of mRNA metabolism and participates directly in translation initiation 
(Joachims et al., 1999; Svitkin et al., 2001). The cleavage of PABP seems to correlate better 
with the host translation shut-off than the cleavage of eIF4G isoforms (Kerekatte et al., 
1999). 
 HRV14 2Apro cleaves cytokeratin 8, a member of the intermediate filament family that 
form the cytoskeleton together with actin filaments (Seipelt et al., 2000).  CVB3 2Apro cleaves 
dystrophin in myocytes leading to cardiomyopathy (Badorff et al., 1999). PV 2Apro cleaves the 
TATA-box binding protein (TBP) (Yalamanchili et al., 1997a), reducing transcriptional activity 
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of the cell. PV 2Apro also cleaves two nuclear pore complex (NPC) proteins, Nup153 and 
Nup62 (Park et al., 2008). 
 Picornaviral 2Apro are also involved in apoptosis. CVB3 2Apro is able to induce 
apoptosis through caspase 8 mediated activation of caspase 3 (Chau et al., 2007). The 2Apro 
of PV1 and several HRV serotypes induce apoptosis through activation of caspase 3 
(Calandria et al., 2004; Deszcz et al., 2005; Deszcz et al., 2004; Goldstaub et al., 2000). 
 
1.2  Translation initiation 
 1.2.1  Cap-dependent translation 
 In eukaryotes, more than 10 initiation factors (eIF) are involved in the initiation of 
protein synthesis. The initiation of translation starts with the formation of the 43S complex by 
association of the initiator Met-tRNA with the GTPase initiation factor eIF2a (bound to a 
guanosine triphosphate (GTP)), the 40S ribosomal subunit and several initiation factors 
(eIF1, eIF3, eIF5 and eIF1A) (Hershey and Merrick, 2000; Lopez-Lastra et al., 2005) (figure 
12).  
 
Figure 12: Diagram of translation initiation in eukaryotes (Lopez-Lastra et al., 2005). 
 
The capped mRNA is recognized by the complex eIF4F which consists of the cap 
binding protein eIF4E, the scaffolding protein eIF4G and the RNA helicase eIF4A (Hershey 
and Merrick, 2000). This complex binds the 43S pre-initiation complex through interaction of 
eIF4G with eIF3 (Hentze, 1997; Pain, 1996) and begins to unwind and scan the mRNA for 
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the correct AUG codon. This activity is dependent on ATP hydrolysis. Once the initiation 
codon is found, eIF2a hydrolyzes the bound GTP and the pre-initiation factors dissociate 
from the small subunit (Pollard et al., 2002). Finally, the large ribosomal subunit binds the 
small subunit and protein synthesis starts. 
 Of the factors mentioned above, two are relevant for this work, eIF4G and eIF4E. 
 
 1.2.1.1 eIF4G 
 The scaffolding protein eIF4G is a protein of 220 kDa, formerly named p220 and eIF-
4γ brings together components of the protein synthesis initiation mechanism (Gradi et al., 
1998a; LeFebvre et al., 2006). Two homologues sharing 46% identity have been identified in 
mammals (Gradi et al., 1998a). Disruption of both isoforms of eIF4G in yeast is lethal (Goyer 
et al., 1993). 
 Human eIF4G can be divided in three domains. The N-terminal domain contains the 
binding sites for PABP and eIF4E (Imataka et al., 1998; Mader et al., 1995). eIF3, eIF4A and 
RNA bind to the central domain (Imataka and Sonenberg, 1997; Pestova et al., 1996b). The 
C-terminal domain contains a second binding site for eIF4A (Imataka and Sonenberg, 1997) 
and a binding site for the protein kinase MnkI (Pyronnet et al., 1999). These sites are shown 
on figure 13. eIF4G is also specifically cleaved by the picornaviral proteinases Lbpro and 
2Apro. 
 
 
Figure 13: Schematic drawing of eIF4GI. Binding sites for PABP, eIF4E, eIF4A, eIF3 and Mnk as 
well as cleavage sites of the picornaviral 2Apro and Lbpro are shown. Adapted from Jackson, 2002 and 
R. Cencic, PhD thesis 2005. 
 
 The N-terminal domain is essential for cap-dependent translation as it contains the 
eIF4E binding site. The central domain is important for cap-independent translation (Pestova 
et al., 1996b) and the C-terminal domain has a regulatory function, not being essential for the 
activity of eIF4G (Morino et al., 2000). 
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 The interaction of eIF4G with PABP and eIF4E simultaneously brings together the 3’ 
and 5’ ends of the mRNA forming a pseudo-circular structure which regulates and stimulates 
translation initiation (Wells et al., 1998) (figure 14).  
 
 
Figure 14: Schematic representation of the initiation translation complex. eIF4G binds PABP and 
eIF4E bringing together the 3’ and 5’ ends of the mRNA forming a pseudo-circular structure which 
regulates and stimulates translation initiation (Lopez-Lastra et al., 2005). 
 
 1.2.1.2 eIF4E  
 eIF4E, also known as the cap binding protein (CBP), recognizes and binds the 
capped mRNA directly (Haghighat and Sonenberg, 1997). eIF4E is involved in the selection 
of mRNAs; it therefore plays a role in the regulation of translation (Hershey and Merrick, 
2000). 
The interaction between eIF4E and the mRNA seems to be regulated by 
phosphorylation. However, it is not necessary for its function as unphosphrylated eIF4E 
stimulates translation in vitro (Svitkin et al., 1996). In fact, phosphorylation diminishes the 
ability of eIF4E to bind capped mRNA (Scheper et al., 2002). eIF4E phosphorylation is 
modulated in response to environmental stress such as heat shock (Duncan et al., 1987) or 
viral infection (Feigenblum and Schneider, 1993; Kleijn et al., 1996).   
Upon eIF4E binding, eIF4G residues 393 to 490 fold into a closed ring-shaped 
structure of five helical segments (Gross et al., 2003). These interactions are required for 
optimal growth and maintenance of polysome structure in vivo, in yeast (Gross et al., 2003). 
  
1.2.2 Cap-independent translation 
 Upon picornaviral infection, the cap-dependent translation is inhibited due to the 
cleavage of eIF4G by picornaviral proteinases. The viral translation is then mediated by the 
IRES structure present in the viral genome. The IRES structures can recruite the ribosome to 
an initiator AUG codon (Belsham and Jackson, 2000).  
The IRES mediated translation requires almost the complete set of initiation factors 
except for eIF4E (Pestova et al., 1996a; Pestova et al., 1996b). The complex of eIF4A and 
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the central domain of eIF4G, missing the eIF4E binding site, can replace the cap-binding 
protein complex eIF4F during the formation of the  48S pre-initiation complex (Lopez-Lastra 
et al., 2005) (figure 12). However, the eIFs are not always necessary for cap-independent 
translation. The hepatitis C virus IRES binds directly the 40S complex without requiring any 
initiation factor (Ji et al., 2004; Kolupaeva et al., 2000). Thus, the difference of cap-
independent from cap-dependent translation relies on how the cleaved eIF4G is anchored to 
the RNA (Ehrenfeld and Teterina, 2002). The central domain of eIF4G binds directly to the 
IRES sequence, upstream of the initiation site (Kolupaeva et al., 1998; Pestova et al., 
1996b). Additionally, it was shown that the central region of eIF4G is sufficient to deliver a 
functional ribosomal subunit to mRNA (De Gregorio et al., 1999). 
Cap-independent translation seems to occur also on cellular proteins under certain 
conditions as heat shock or mitosis, in which cellular IRES appear to be involved (Cornelis et 
al., 2000). However, it is not generally accepted that IRES are involved in cellular translation. 
Some regions earlier identified as IRES turned out to be cryptic promoters or splicing sites 
(Kozak, 2005; Kozak, 2007). This subject is still controversial (Kozak, 2001; Schneider et al., 
2001) 
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2 Aim of the work 
 
 The aim of the work was to investigate and characterize the 2Apro of HRV2 and 
HRV14. Although they carry out the same reactions, these two proteins have different 
properties and characteristics. 
HRV2 and HRV14 2Apro cleave their respective polyproteins at similar rates, in 
contrast, HRV14 2Apro cleaves eIF4GI and II slower than HRV2 2Apro, both in vitro and in vivo 
(Gradi et al., 1998b; Svitkin et al., 1999).  
What is the structural basis for the observed differences? Based on the structure of 
HRV2 2Apro, we wanted to perform site directed mutagenesis experiments in order to identify 
residues that are involved in the difference of specificity presented by these proteinases. 
However, the low level of identity between HRV2 2Apro and HRV14 2Apro (40%) limits the 
information which can be sained from the HRV2 2Apro. Therefore, we set out to purify and 
crystallize HRV14 2Apro. We believe that the determination of this structure would shed light 
on the specificities and mechanisms of the two 2Apro. 
How do the picornaviral proteinases interact with eIF4G? We wanted to obtain 
information on the nature of the interactions of these proteinases with eIF4G. For that, we 
planned to purify a fragment of eIF4GII containing the cleavage sites of HRV2 2Apro and the 
Lbpro of FMDV as well as the binding sites for the Lbpro and eIF4E. We wanted to crystallize 
and perform NMR experiments with this fragment in order to gain information on its 
interaction with Lbpro and eIF4E. eIF4E is believed to induce changes in the eIF4G structure 
which are better recognized by the viral proteinases (Gross et al., 2003; Haghighat et al., 
1996; Hershey et al., 1999).  
Does 2Apro interact with others cellular proteins? We planned to use the tandem 
affinity purification (TAP) method developed by Rigaut et al., (1999) to identify new cellular 
partners for 2Apro  
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3 Materials and methods 
 
3.1  Tissue culture 
 3.1.1  Cell lines 
 Spodoptera frugiperda Sf9 insect cells and HeLa cells Ohio were obtained from 
European Collection of Cell Cultures (ECACC). HEK 293T cells (CRL-11268) were obtained 
from the American Type Culture Collection (ATCC). 
 
 3.1.2  Media and solutions 
Dulbecco’s Modified Eagle Medium, Gibco BRL (DMEM) was suplemented with 10% 
(v/v) Foetal Calf Serum (FCS) (Gibco BRL), 1% (v/v) 100x Penicillin/Streptomycin (Gibco 
BRL) and 1% (v/v) 200 mM L-Glutamine (Gibco BRL). This medium was used for monolayer 
culture of HeLa and HEK 293T cells. 
 Minimum Essential Medium Eagle Joklik Modification (S-MEM) from Sigma was 
supplemented with 7% Horse serum (Gibco), 1% (v/v) 100x Penicillin/Streptomycin (Gibco 
BRL), 1% (v/v) 200 mM L-Glutamine (Gibco BRL), 1% (v/v) non essential aminoacids (Bio 
Whitaker™) and 1% (v/v) Pluronic F-68 (Sigma, 10% w/v). Suspension cultures of HeLa cells 
were grown in this medium. 
 SF 900 II SFM (Gibco BRL) medium, used for monolayer and suspension cultures of 
Sf9 cells, was supplemented with 2% FCS (Gibco), 1% (v/v) 100x Penicillin/Streptomycin 
(Gibco BRL) and 1% (v/v) 200 mM L-Glutamine (Gibco BRL). 
 Reduced Serum Medium modified of MEM (Eagle's) (OPTI-MEM Gibco BRL) was 
used for transfection of HEK 293T cells. 
For transfection of Sf9 cells we used Grace’s Insect Cell Culture Medium Modified 
(Gibco BRL). 
  The buffer used to wash the cells was Phosphate Buffered Saline (PBS). The 10 x 
stock contains 14 mM KH2PO4, 27 mM KCl, 43 mM Na2HPO4 and 1370 mM NaCl dissolved 
in H2O.  
 The antibiotic solutions were prepared in 1x PBS and contained 60 mg/L Penicillin G 
potassium salt, 100 mg/L of Streptomycine sulphate and 58 mg/L of glutamine. 
 The cells were detached from the culture flasks using a solution od 0.5% trypsin and 
0.53 mM EDTA  (TE) (Gibco BRL). 
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 3.1.3  Cell culture 
 3.1.3.1  HeLa and HEK 293T cells 
 Cells were cultured either in Petri-dishes or flasks (Nunc, Corning) with DMEM 
medium supplemented with FCS, antibiotics and glutamine (see 3.1.2) at 37°C in presence 
of 5% CO2. Before reaching complete confluence, the cells were washed with 1x PBS and 
incubated with just enough TE (see 3.1.2) to cover the cells at 37°C for no more than 5 
minutes. Once detached from the surface, the cells were taken up in fresh medium and 
transferred to a new flask at a suitable dilution. 
 For preparation of HeLa S10 extracts (see 3.5.2.2) HeLa cells were also grown in 
suspension. A suspension culture was set up from 5 confluent 175 cm2 flasks that were split 
and transferred into a glass spinner flask containing one litre of S-MEM medium (see 3.1.2). 
The cultures were kept at 37°C with 5% CO2 and the cell density was mantained between 
2x105 and 8x105 cells/ml. 
 
 3.1.3.2  Sf9 insect cells 
 Cells were cultured in flasks (Nunc, Corning) or in glass conical flasks for the liquid 
cultures with SF 900 II SFM medium supplemented with FCS, antibiotics and glutamine (see 
3.1.2) at 27°C in a humidified chamber. Before reaching complete confluence or a density 
superior to 2x106 cells/ml, the cells were split. For the monolayer culture, the cells were 
washed with 1x PBS and fresh medium was added. The cells were detached from the flask 
by scraping with a glass Pasteur pipette and transferred to a new flask at a suitable dilution. 
The liquid cultures were simply diluted in fresh medium at a suitable dilution and kept with 
rotation at 120 rpm. 
 
 3.1.4  Cell counting 
 After the cells were trypsinised and detached from the flask surface, they were taken 
up in a known volume of fresh medium. 10 µl of the cell suspension were loaded onto a 
haemocytometer (Neubauer improved counting chamber) and cells were counted under a 
light microscope.  
 
 3.1.5  Freezing and thawing of cells 
 HEK 293T cells growing logarithmically were washed twice with 1x PBS, trypsinized, 
taken up in fresh medium and centrifuged at 1000 rpm for 5 minutes at 4°C. The supernatant 
was disposed off and the cells were washed with 1x PBS and spun down at 1000 rpm for 5 
minutes at 4°C. The cells were finally resuspended in 90% FCS and 10% DMSO, transferred 
into cryo tubes (Nunc) and stored at -80°C in a freezing container (Nalgene) for two days 
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before transfer to liquid nitrogen for long term storage. The same procedure was used for Sf9 
cells except that they were grown in suspension and were stored in Sf-900 II SFM medium 
containing 7.5% DMSO. The cell density of the stocks was 2x106 cells/ml. 
 The recovery from the liquid nitrogen was done by quickly warming the cells to 37°C 
in a water bath for 2 to 3 minutes and transferring them to 10 ml of fresh medium. A 
centrifugation at 1200 rpm for 4 minutes at room temperature followed and the pellet was 
resuspended in fresh medium and added to a new flask. Sf9 cells were kept in monolayer 
culture during the adaptation from 20% FCS to 2% FCS supplemented medium and then 
were transferred to suspension cultures. 
 
3.2  Bacterial culture 
 3.2.1  Bacterial strains 
 The bacterial strain used for modification and amplification of plasmids was E. coli 
Top10F´ (F-mcrAΔ(mrr-hsdRMS-mrcBC) Φ80lacZΔm15ΔlacX74recA1deoRaraD139(ara-leu)7697 
galU galK rpsL (StrR) endA1 nupG) (Invitrogen). For expression of recombinant proteins we 
used the strains E. coli BL21 (DE3) LysS (hsdD gal (λcIts857 ind1 Sam7 nin5 lacUV5-T7gene1) 
(Novagen) and E.coli JM101 (SupE thi Δ(lac-proAB) F’ [traD36 proAB+ lacIq lacZΔM15) 
(Pharmacia). The strain E. coli DH10Bac™ (F- mcrA Δ(mrr-hsdRMS-mcrBC) Ф80lacZΔM15 
ΔlacX74 recA1 endA1 araD139 Δ(ara, leu)7697 galU galK λ-rpsL nupG / bMON14272 / pMON7124) 
(Invitrogen) was used to introduce genes into a baculovirus shuttle vector (bacmid). 
  
 3.2.2  Media and antibiotics 
 Luria-Bertani (LB) medium (Roth) contains 10 g/l of tryptone, 5 g/l of yeast extract 
and 10 g/l of NaCl. The pH is adjusted 7.0 and the medium is autoclaved before use. 
Another medium used for bacterial growth was the Terrific Broth (TB) medium which 
is prepared with 12 g/l bacto-tryptone, 24 g/l yeast extract and 4 ml/l glycerol. After 
autocleavage a solution of 100 ml/l of 0.17 M KH2PO4/ 0.72 M K2HPO4 is added. 
 To express recombinant proteins labelled with 15N, the bacteria are grown in minimal 
medium. To obtain this medium we prepare a solution of 33.7 mM Na2HPO4.2H2O, 22 mM 
KH2PO4, 8.5 mM NaCl and 18.7 mM 15NH4Cl. This solution is autoclaved and added to a 
filtered sterilized solution of 2 mM MgSO4, 1% trace elements, 0.4% glucose, 0.3 mM CaCl2, 
1 µg/ml biotine, 1 µg/ml thiamine and suitable antibiotics.  
 The solid bacteria medium is obtained by addition of 1.5% Bacto-agar (Roth) to liquid 
media before autoclaving. When the medium temperature reaches 50°C, antibiotics are 
added to the final concentrations and poured into Petri dishes.  
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The antibiotics used in this work were Ampicillin sodium salt (Sigma) dissolved in H2O 
(100mg/ml) and Chloramphenicol (Calbiochem) dissolved in absolute ethanol (34 mg/ml). 
The working dilutions of these antibiotics were 100 µg/ml. 
 
 3.2.3  Plasmids 
 Table 4 shows the plasmids used throughout this work. 
 
Plasmid Function 
pCITE-1 (Novagen) In vitro transcription 
pCITE-A1 (pCITE-1 modified by Andreas 
Roetzer (Roetzer, 2004)) 
In vitro transcription 
pET3b (Novagen) Protein expression in bacteria 
pET 11d (Novagen)  Protein expression in bacteria 
pGEX-6P-1 (Amersham Pharmacia Biosciences) Protein expression in bacteria 
pBluescript I KS (Stratagene) Blunt end cloning 
pMZI (J. K. Greenblatt) Protein expression in mammalian cells 
pVgRXR (Invitrogen) Transfection of mammalian cells 
pFastBac (Invitrogen) Transformation of the bacterial strain E. 
coli DH10Bac™ 
pproExHTA (Invitrogen) Protein expression in bacteria 
 
Table 4: List of the plasmids used in this work. The origin of each plasmid is shown in brackets. 
 
3.2.4  Preparation of competent cells 
A 3 ml overnight culture was diluted into 200 ml LB medium and incubated at 37°C 
with rotation at 180 rpm. When the cell density reached an OD600 of 0.6, the bacteria were 
collected into 50 ml sterile falcon tubes  and centrifuged for 10 minutes at 4300 rpm at 4°C 
(Heraeus Megafuge 1.0R). The pellet was resuspended in 25 ml of ice cold 0.1 M CaCl2, 
incubated for 25 minutes on ice and centrifuged as described above. The pellet was taken in 
10 ml of ice cold 0.1 M CaCl2 and kept at 4°C overnight without rotation. 2 ml of 80% glycerol 
were added and mixed gently with the bacterial solution, which was then divided in 200 µl 
aliquots, snap frozen in liquid nitrogen and stored at -80°C. 
 
3.2.5  Transformation 
An aliquot of competent cells was thawed on ice for 10 minutes and incubated with 
DNA (10 µl of a ligation or 1 µl of a plasmid) for 15 minutes on ice. A heat shock was then 
                                                                                                                          3. Materials and methods 
 30
applied to the cells for 45 seconds at 42°C. The cells were chilled on ice for 2 to 3 minutes, 
upon which 400 µl of LB medium was added.  The cells were incubated at 37°C for 30 
minutes and plated in Petri-dishes containing the appropriate medium and antibiotics. 
Incubation at 37°C overnight followed. 
 
3.3  DNA methods 
 3.3.1  Preparation of plasmid DNA from bacteria 
 3.3.1.1  DNA miniprep 
 A 3 ml culture of bacteria grown overnight was harvested by centrifugation at 14,000 
rpm for 30 seconds at room temperature (eppendorf centrifuge 5415 C) and the cell pellet 
resuspended in 100 µl of Solution I (50 mM glucose, 25 mM Tris-HCl pH 8.0  and 10 mM 
EDTA). To lyse the cells, 200 µl of Solution II (0.2 N NaOH,1 % (w/v) SDS) were added, the 
suspension was mixed gently and incubated for not more than 5 minutes at room 
temperature. Precipitation of proteins and chromosomal DNA was done by addition of 150 µl 
Solution III (3 M potassium acetate, 11.5 % (v/v) acetic acid) and again gentle mixing. 
Alternatively, the solutions S1, S2 and S3 from the Nucleobond AX plasmid Midi Kit 
(Macherey-Nagel) were used. The precipitate was separated by centrifugation for 5 min at 
14,000 rpm at 4°C (eppendorf centrifuge 5417 R). The supernatant containing the plasmid 
DNA was transferred to a new tube and the DNA was precipitated by addition of 1 ml of 
absolute ethanol. The DNA pellet was dissolved in 200 µl of TEB buffer (10 mM Tris-HCl pH 
8.0, 1 mM EDTA) and mixed with 200 µl of 5 M LiCl. After centrifugation 5 minutes at 14,000 
rpm at 4°C (eppendorf centrifuge 5417 R), the supernatant was transferred to a new tube 
and the DNA again precipitated with 1 ml of absolute ethanol. Finally the DNA pellet was 
resuspended in an appropriate volume of H2O. This plasmid quality is suitable for digestions 
(include 10 % (v/v) RNAse A (Sigma) at a concentration of 0.1 mg/ml) and sequencing 
reactions. 
 
 3.3.1.2  DNA midiprep 
 Higher amounts of pure plasmid DNA (up to 500 µg) were obtained with the 
Nucleobond AX plasmid Midi Kit (Macherey-Nagel) used according to the instructions of the 
manufacturer. 
 
 3.3.2  DNA separation on agarose gels 
 DNA was mixed with 1/10 of the total volume of 10x loading buffer (1 mM EDTA pH 
8.0, 0.1 % (w/v) Orange G, 10 % (w/v) Ficoll in 0.5x TAE (20 mM Tris base, 5 mM sodium 
acetate, 1 mM EDTA, adjust to pH 8.2 with HCl)) and separated according to size on 
                                                                                                                          3. Materials and methods 
 31
agarose (GenXpress) gels. Depending on the size of DNA to be separated, the percentage 
of agarose dissolved in 0.5x TAE was between 0.7 and 1.5 % (w/v). Gels were run with 2 to 
8 V/cm (power pac 300, Biorad) in 0.5x TAE in wide mini-sub® or mini-sub® cell GT tanks 
(Biorad) and DNA was visualized after ethidium bromide staining (dilute 10 mg/ml stock 
solution 1:10,000 in 0.5x TAE) under UV (ultraviolet) light. The intensity of the DNA was 
compared to a λDNA (promega) HindIII digested marker (see Appendix B). 
 
3.3.3  Enzymatic reactions 
3.3.3.1  Restriction digestions of DNA 
 Restriction endonucleases and 10x reaction buffers (New England Biolabs) were 
used following the instructions of the manufacturer. Analytical digestions were performed in a 
total volume of 20 µl with 0.5 to 1 µg DNA and preparative digestions in a total volume of 100 
µl with 2 to 5 µg DNA. 
 
 3.3.3.2  Ligation of DNA Fragments with T4 DNA Ligase 
A typical 20 µl reaction contained 50 ng of restricted vector DNA and 20 ng of insert 
DNA in 1 mM ATP, 1x T4- DNA ligase buffer (30 mM Tris-HCl pH 7.8, 10 mM MgCl2, 10 mM 
DTT, 1 mM ATP) and 0.5 µl T4-DNA ligase (New England Biolabs, 400 U/µl). The reactions 
were incubated from 4 hours to overnight at room temperature. 
 
3.3.3.3  Phosphorylation of DNA 5´ ends 
Phosphorylation of 5´ ends was performed using T4 Polynucleotide Kinase (New 
England Biolabs, 5 U/µg DNA) in the buffer supplied with the enzyme (70 mM Tris-HCl pH 
7.6, 10 mM MgCl2, 5 mM DTT) and 1 mM ATP. The reaction was incubated for 30 min at 
37°C prior to phenol/CHCl3 extraction and ethanol precipitation (see 3.3.4.1 and 3.3.4.2). 
 
3.3.3.4  Filling-in of DNA 5´ recessed ends 
0.5 µl of T4 DNA polymerase (New England Biolabs, 3 U/µl) were added to a fresh 
PCR product (see 3.3.6) prior to its purification and incubated 10 minutes at 37°C. The 
reaction was then stopped with 0.5 µl of a 0.5 M EDTA solution pH 8.0. The DNA was 
extracted with phenol/CHCl3 and precipitated with ethanol (see 3.3.4.1 and 3.3.4.2). 
 
3.3.3.5  Dephosphorylation of DNA 5´ ends 
In order to avoid self-ligation, cleaved vectors were incubated with 1 U/pmol DNA 
ends of calf intestine phosphatase (CIP) (New England Biolabs) in 20 mM Tris-HCl pH 8.0 for 
45 minutes at 37°C. The enzyme was inactivated by incubation at 65°C for 45 minutes. 
Afterwards, the reaction mixture was purified by elution from an agarose gel (see 3.3.4.3).  
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3.3.4  Purification of DNA Solutions 
3.3.4.1  Phenol/Chloroform extractions 
To purify DNA from enzymes or other proteins and to remove other contaminants, 1% 
(v/v) 0.5 M EDTA pH 8.0 and 1 volume of Tris-HCl pH 7.5 saturated phenol (Sambrok et al., 
1989) were added to the DNA solution and vortexed for 5 to 10 seconds. Phases were 
separated by centrifugation for 2 min at 14,000 rpm at room temperature (eppendorf 
centrifuge 5415 D) and the upper aqueous phase transferred into a new tube. After re-
extraction with 1 volume of CHCl3, the upper aqueous phase was ethanol precipitated (see 
below). 
 
3.3.4.2  Ethanol Precipitation 
To purify or concentrate DNA, 10 % (v/v) 3 M sodium acetate pH 5.6 and 2 volumes 
of absolute ethanol were added to the DNA solution. The mixture was incubated at -20°C for 
at least 20 minutes and centrifuged for 15 min at 14,000 rpm at room temperature (eppendorf 
centrifuge 5415 D). After discarding the supernatant, the pellet was air dried and taken up in 
an appropriate volume of H2O. 
 
3.3.4.3  Elution of DNA Fragments from the Gel 
Elution of DNA from agarose gels was performed with the Wizard® SV Gel and PCR 
Clean-Up System kit from Promega. The instructions of manufacturer were followed. 
 
3.3.5  DNA quantification 
The concentration of DNA solutions was determined by UV spectroscopy at 260 nm 
in a photometer (BioPhotometer, eppendorf). OD260 of 1 corresponds to 50 µg/ml of DNA. 
Dilutions of 1/100 of the DNA solutions were prepared in H2O and measured against a blank 
containing only H2O.  
 
3.3.6  Amplification of DNA fragments by PCR (polymerase chain 
reaction) 
A standard PCR reaction of 50 µl contained 10 ng of template DNA, 0.2 µg of each 
primer, 1x Taq-polymerase buffer (supplemented with the enzyme), 0.2 mM dNTPs 
(Invitrogen) and 0.6 U DyNAzyme II (Finnzyme) or 3 U of Pfu DNA polymerase I (Promega) 
(for PCR products larger than 800 base pairs or to be cloned in expression vectors). The 
aqueous solution was overlaid with one drop of mineral oil and the PCR reaction was done in 
a Perkin Elmer DNA Thermal Cycler (Perkin) machine. DNA was denaturated at 94°C and 
amplified in 20 to 35 cycles of denaturating at 94°C for 30 seconds, 30 to 90 seconds of 
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annealing temperature (based on the melting temperature of the primers) and 30 to 90 
seconds of extension temperature at 72°C (68°C for PfuI (Promega)). A final step of 
extension temperature was done for 10 minutes at 72°C (68°C for PfuI (Promega)). 
 
3.3.7  Site directed mutagenesis 
3.3.7.1  Cassette Cloning 
Cassette cloning consists in substituting, through digestion and ligation, a small DNA 
fragment (up to 40 to 50 nucleotides) with a new fragment bearing the desired mutations. 
Two primers complementary to each other, containing the desired mutations and the same 
restriction sites used to digest the vector, were phosphorylated and ligated into a digested 
and dephosphorylated vector (see 3.3.3.3 and 3.3.3.5).  
Before the ligation reaction, the primers had been phosphorylated. 1 µg of each 
primer was added to 1 mM ATP, 1x PNK (polynucleotide kinase) reaction buffer (70 mM Tris-
HCl, 10 mM MgCl2, 5 mM dithiothreitol (DTT), pH 7.6), 5 U of PNK (New England Biolabs) 
and H2O in a total volume of 20 µl. The solution was overlaid with one drop of mineral oil and 
a single cycle of incubation at 37°C for 30 minutes, 90°C for 30 seconds and 37°C for 5 
minutes was done using a Perkin Elmer DNA Thermal Cycler (Perkin) machine.  
The ligations were transformed into E. coli Top 10 F´ (Invitrogen) and the new 
plasmid bearing the desired mutations was extracted and purified (see 3.2.5 and 3.3.3.2). 
 
3.3.7.2  Cycle PCR 
This method allows the introduction of a mutation by amplifying the complete plasmid. 
The proof reading Pfu DNA Polymerase I (Promega) and a PCR machine with a heated lid 
(T3 Thermocycler Biometra) were used. The mutagenesis was performed using two primers 
complementary to each other bearing the mutation. Base pair exchange of up to 6 
nucleotides is possible with this method. The mutated nucleotides lay in the middle of the 
primer, flanked by 12 wild type nucleotides. To introduce the mutations, 20 cycles of 
denaturing at 95°C for 2 minutes, 1 minute at usually 40°C (depending on the number of 
nucleotides to be exchanged) and elongation for 2 minutes per kb of the template at 68°C, 
were performed. The PCR reaction was set up with different dilutions of DNA (1 µg, 1 µg 
1:10, 1 µg 1:100) (see 3.3.6). As a negative control a PCR was performed without the 
primers. 10 µl of the PCR reaction were tested on an agarose gel (see 3.3.2). The remaining 
40 µl were digested with 1 µl DpnI (20 U/µl, New England Biolabs) for at least 5 hours to 
remove the methylated template DNA. 10 µl of the undigested DNA were used for 
transformation in E.Coli Top 10 F´ (see 3.2.5).  
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3.3.8  Sequencing reactions 
DNA sequencing was performed using the ABI PRISM 310 Genetic Analyzer and the 
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) according to the 
instructions of the manufacturer. Dilution of the BigDye Terminator mix with 5x sequencing 
buffer (100 mM Tris-HCl pH 9.0, 10 mM MgCl2) was optional. The sequencing reaction was 
composed as follows: 0.2 µg plasmid DNA, 1 µl primer (4 to10 pmol/µl), 2 µl BigDye 
Terminator mix, 3 µl 5x sequencing buffer added to water in a total volume of 20 µl.                  
The reaction was performed in a heated lid thermocycler (T3 Thermocycler Biometra). 
30 cycles were performed with 30 sec at 96°C, 10 sec at 50°C and 4 min at 60°C. The 
reaction was cleaned by spinning through Millipore UltrafreeMC columns packed with 
Sephadex G-50 (DNA-grade, Pharmacia) for 3 minutes at 2500 rpm. 
Alternatively the DNA samples and primers were sent to be sequenced in the Service 
Department of IMP (Institute of Molecular Pathology) Vienna, headed by Gotthold Schaffner. 
 
3.3.9  List of primers 
3.3.9.1  Primers for cloning 
Label Sequence and description (orientation 5’ to 3’) 
 
TIM979 ACTGGAATTCGGTTTAGGACCGCGG 
Sense primer to introduce HRV14 2Apro in the vector pGEX-6P1; EcoRI site 
TIM1302 CCGGTAATTAAGAAGAGGAAAGGTGACATTAAATCCCGTGGTTTAGGACCGC 
Sense oligo to introduce Arg in P1 position of HRV14 VP1 2Apro; AgeI, SacII sites 
TIM1303 GGTCCTAAACCACGGGATTTAATGTCACCTTTCCTCTTCTTAATTA 
Antisense oligo to introduce Arg in P1 position of HRV14 VP1 2Apro; AgeI, SacII 
sites 
TIM1304 CCGGTAATTAAGAAGAGGAAAGGTGACATTAAATCCTATGGTCCAGGACCGC 
Sense oligo to introduce Leu in P2’ position of HRV14 VP1 2Apro; AgeI, SacII sites 
TIM1305 
 
 
TIM1315 
GGTCCTGGACCATAGGATTTAATGTCACCTTTCCTCTTCTTAATTA 
Antisense oligo to introduce Leu in P2’ position of HRV14 VP1 2Apro; AgeI, SacII 
sites 
CCGGTAATTAAGAAGAGGCGGACAACCCTTAGCACCTATGGGCCCCCACGGC 
Sense oligo to introduce Tyr in P1 position of HRV14 VP1-(eIF4GI)- 2Apro; AgeI, 
SacII sites 
TIM1316 CGTGGGGGCCCATAGGTGCTAAGGGTTGTCCGCCTCTTCTTAATTA 
Antisense oligo to introduce Tyr in P1 position of HRV14 VP1-(eIF4GI)- 2Apro; 
AgeI, SacII sites 
TIM1322 ATACAGGAAAGTCCGTACTATCCCAAA 
Sense primer to introduce the mutation E84P in HRV2 2Apro 
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Label Sequence and description (orientation 5’ to 3’) 
 
TIM1323 TTTGGGATAGTACGGACTTTCCTGTAT 
Antisense primer to introduce the mutation E84P in HRV2 2Apro 
TIM1324 ATTGAAGGAAGCGAGTATTACCCAAGT 
Sense primer to introduce the mutations N86S P87E in HRV14 2Apro 
TIM1325 ACTTGGGTAATACTCGCTTCCTTCAAT 
Antisense primer to introduce the mutations N86S P87E in HRV14 2Apro 
TIM1327 CCGGTAATTAAGAAGAGGAAAGGTGACATTTCATCCTATGGTTTAGGACCGC 
Sense oligo to introduce Ser in P3 position of HRV14 VP1 2Apro; AgeI, SacII sites 
TIM1328 GGTCCTAAACCATAGGATGAAATGTCACCTTTCCTCTTCTTAATTA 
Antisense oligo to introduce Ser in P3 position of HRV14 VP1 2Apro; AgeI, SacII 
sites 
TIM1329 ATTGAAGGAAACGAGTATTACCCAAGT 
Sense primer to introduce the mutation P87E in HRV14 2Apro 
TIM1330 ACTTGGGTAATACTCGTTTCCTTCAAT 
Antisense primer to introduce the mutation P87E in HRV14 2Apro 
TIM1331 CATGCCATGGGTTTAGGACCTAGGTACGG 
Sense primer to introduce HRV14 2Apro in pET11d-TAPtag; NcoI site 
TIM1332 CATGCCATGGCCTGTTCCTCTGCGATACA 
Antisense primer to introduce HRV14 2Apro in pET11d-TAPtag; NcoI site 
TIM1333 CATGCCATGGGCCCCAGTGACATGTATGT 
Sense primer to introduce HRV2 2Apro in pET11d-TAPtag; NcoI site 
TIM1334 CCATGCCATGGCTTGTTCTTCAGCACAATG 
Antisense primer to introduce HRV2 2Apro in pET11d-TAPtag; NcoI site 
TIM1336 CATGGGATCCATGTCCCCTATACTAGGT 
Sense primer to introduce the GST tag plus PreScission cleavage site in the vector 
pFastBac; BamHI site 
TIM1337 CATGGAATTCGGGCCCCTGGAACAGAAC 
Antisense primer to introduce the GST tag plus PreScission cleavage site in the 
vector pFastBac; BamHI site 
TIM1338 ATCTGGATTGAAGAAAACCCTTATTAC 
Sense primer to introduce the mutation G85E in HRV14 2Apro 
TIM1339 GTAATAAGGGTTTTCTTCAATCCAGAT 
Antisense primer to introduce the mutation G85E in HRV14 2Apro 
TIM1340 ATCTGGATTGAAGAAAGCGAGTATTAC 
Sense primer to introduce the mutations G85E N86S P87E in HRV14 2Apro 
TIM1341 GTAATACTCGCTTTCTTCAATCCAGAT 
Antisense primer to introduce the mutations G85E N86S P87E in HRV14 2Apro 
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Label Sequence and description (orientation 5’ to 3’) 
 
TIM1342 TATGAAATACAGGGAAGTGAGTACTAT 
Sense primer to introduce the mutation E82G in HRV2 2Apro 
TIM1343 ATAGTACTCACTTCCCTGTATTTCATA 
Antisense primer to introduce the mutation E82G in HRV2 2Apro 
TIM1344 CCCCTCTCCACCAAAGATCTGACCACA 
Sense primer to introduce the BglII restriction site upstream the PV1-VP1 2Apro 
cleavage site; BglII site 
TIM1345 TGTGGTCAGATCTTTGGTGGAGAGGGG 
Antisense primer to introduce the BglII restriction site upstream the PV1-VP1 2Apro 
cleavage site; BglII site 
TIM1346 
 
 
TIM1347 
AACAAAGCGGTGTATACTGCAGGTTAC 
Sense primer to introduce the BstZ17 I restriction site downstream the PV1-VP1 
2Apro cleavage site; BstZ17 I site 
GTAACCTGCAGTATACACCGCTTTGTT 
Antisense primer to introduce the BstZ17 I restriction site downstream the PV1-
VP1 2Apro cleavage site; BstZ17 I site 
TIM1348   GATCTGACCACACGTGGATTCGGACACCAAAACAAAGCGGTGTA 
                 Sense oligo to introduce Arg in P1 position of PV1-VP1 2Apro; BglII, BstZ17 I sites 
TIM1349 TACACCGCTTTGTTTTGGTGTCCGAATCCACGTGTGGTCA 
Antisense oligo to introduce Arg in P1 position of PV1-VP1 2Apro; BglII, BstZ17 I 
sites 
TIM1353 GAATTCGCCATCACAGTCCAGAGA 
Sense primer to introduce eIF4GII residues 445 to 744 in the vector pFastBac; 
EcoRI site 
TIM1354 GAATTCCTATTAATCGGCTTGGCTGTCTCG 
Antisense primer to introduce eIF4GII residues 445 to 744 in the vector pFastBac; 
EcoRI site 
TIM1392 GGGGTTGGGCCGTGCGAGCCAGGAGAC 
Sense primer to introduce the mutation A104C in HRV14 2Apro 
TIM1393 GTCTCCTGGCTCGCACGGCCCAACCCC 
Antisense primer to introduce the mutation A104C in HRV14 2Apro 
TIM1394 GGGGTTGGGCCGTCAGAGCCAGGAGAC 
Sense primer to introduce the mutation A104S in HRV14 2Apro 
TIM1395 GTCTCCTGGCTCTGACGGCCCAACCCC 
Antisense primer to introduce the mutation A104S in HRV14 2Apro 
TIM1396 GGTGAGGGCCCTGCTGAACCAGGTGAC 
Sense primer to introduce the mutation C101A in HRV2 2Apro 
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Label Sequence and description (orientation 5’ to 3’) 
 
TIM1397 GTCACCTGGTTCAGCAGGGCCCTCACC 
Antisense primer to introduce the mutation C101A in HRV2 2Apro 
TIM1398 GGTGAGGGCCCTAGTGAACCAGGTGAC 
Sense primer to introduce the mutation C101S in HRV2 2Apro 
TIM1399 GTCACCTGGTTCACTAGGGCCCTCACC 
Antisense primer to introduce the mutation C101S in HRV2 2Apro 
TIM1411 CTCGAGTCATTAGTGGTGGTGGTGGTGGTGCTGTTCCTCTGCGATACA 
Antisense primer to introduce HRV14 2Apro plus a His tag in the vector pGEX-6P1; 
XhoI site 
TIM1472 GCGGAATTCTTTCATCCTGAAAGAGACC 
Sense primer to introduce eIF4GII  residues 552 to 744 in the vector pGEX-6P1; 
EcoRI site 
TIM1473 GCGGAATTCTCACTAATCATCGGCTTGGCTGTC 
Antisense primer to introduce eIF4GII residues 552 to 744 in the vector pGEX-6P1; 
EcoRI site 
TIM1474 CACCGCTCGAGATGGGCCCCAGTGACATGTATG 
Sense primer to introduce HRV2 2Apro in the vector pMZI; XhoI site 
TIM1475 CGCGCACATATGTTGTTCTTCAGCACAATGG 
Antisense primer to introduce HRV2 2Apro in the vector pMZI; NdeI site 
TIM1476 CACCGCTCGAGATGGGTTTAGGACCTAGGTACG 
Sense primer to introduce HRV14 2Apro in the vector pMZI; XhoI site 
TIM1477 CGCGCACATATGCTGTTCCTCTGCGATACAC 
Antisense primer to introduce HRV14 2Apro in the vector pMZI; NdeI site 
TIM1492 GCGGAATTCTCACTAGTGGTGGTGGTGGTGGTGATCATCGGCTTGGCTGTC 
Antisense primer to introduce eIF4GII residues 552 to 744 plus a His tag in the 
vector pGEX-6P1; EcoRI site 
TIM1518 GACCGCTCGAGATGGAATTCCACATGCCTCAGATCACT 
Sense primer to introduce HIV 1 protease  in the vector pMZI; XhoI, EcoRI sites 
TIM1519 GCACATATGTCGAAGGATCCCAATTCCCAAGAAATT 
Antisense primer to introduce HIV 1 protease  in the vector pMZI; NdeI, BamHI 
sites 
TIM1520 
 
TIM1521 
GACCGCTCGAGATGGGCCCCTATGGACATCAATC 
Sense primer to introduce CBV4 2Apro in the vector pMZI; XhoI site 
CGCGCACATATGCTGTTCCATTGCATCATC 
Antisense primer to introduce CBV4 2Apro in the vector pMZI; NdeI site 
TIM1522 GACCGCTCGAGATGGAACTGACACTGTAC 
Sense primer to introduce FMDV Lbpro in the vector pMZI; XhoI site 
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Label Sequence and description (orientation 5’ to 3’) 
 
TIM1523 CGCGCACATATGTTTGAGCTTGCGTTGAACC 
Antisense primer to introduce FMDV Lbpro in the vector pMZI; NdeI site 
TIM1532 CTTTAAATTTTTCGTCAATTGGGATCC 
Sense primer to delete two stop codons in HIV 1 protease cloned in the vector 
pMZI; MfeI, BamHI sites 
TIM1533 GGATCCCAATTGACGAAAAATTTAAAG 
Antisense primer to delete two stop codons in HIV 1 protease cloned in the vector 
pMZI; MfeI, BamHI sites 
TIM1544 CGCGCCATGGGATTTCATCCTGAAAGAGACC 
Sense primer to introduce eIF4GII residues 552 to 744 in the vector pET11d; NcoI 
site 
TIM1545 GCGCCCATGGTCACTAGTGGTGGTGGTGGTGGTGATCATCGGCTTGGCTGTC 
Antisense primer to introduce eIF4GII residues 552 to 744 plus a His tag in the 
vector pET11d; NcoI site 
TIM1546 CGCGCCATGGGTTTAGGACCTAGGTAC 
Sense primer to introduce HRV14 2Apro in the vector pET11d; NcoI site 
TIM1547 GCGGATCCTCACTAGTGGTGGTGGTGGTGGTGCTGTTCCTCTGCGATAC 
Antisense primer to introduce HRV14 2Apro plus a His tag in the vector pET11d; 
BamHI site 
 
Table 5: List of primers used for cloning experiments. 
 
3.3.9.2  Primers for sequencing 
Label Sequence (orientation 5’ to 3’) 
 
Target 
TIM31 GTTTGCTGAATCAGG HRV14 VP1; 
antisense 
TIM69 CACATCAATAGGGCGCA HRV14 2Apro; 
sense 
TIM197 TCAATGCTTGAAGGAGC pGEX-6P1 and 
pFastBac-GST 
inserts; sense 
TIM258 GAATTCGATCCCTTGTTCTTCAGCACA HRV2 2Apro; 
antisense 
TIM315 CCCACAAATTGATAAG pGEX-6P1 and 
pFastBac-GST 
inserts; sense 
                                                                                                                          3. Materials and methods 
 39
Label Sequence (orientation 5’ to 3’) 
 
Target 
TIM326 GGAATTCTGGCCCCAGTGACATGTA HRV2 2Apro; 
sense 
TIM768 GAATCGGGATCCCTATCACTGTTCCTCTGCGATACACTC HRV14 2Apro; 
antisense 
TIM847 CCAGGAGACGCCGGTGGGATT HRV14 2Apro; 
sense 
TIM848 AATCCCACCGGCGTCTCCTGG HRV14 2Apro; 
antisense 
TIM967 ACCAGGTGACGCAGGTGGAAAGT HRV2 2Apro; 
sense 
TIM1109 TCTGAGATGCATGAATCTATTTTGGTATCTTATTCATCA HRV2 2Apro; 
sense 
TIM1312 ATACATCAAGGTTTAGTG HRV14 2Apro; 
sense 
TIM1331 CATGCCATGGGTTTAGGACCTAGGTACGG HRV14 2Apro; 
sense 
TIM1332 
 
TIM1333 
CATGCCATGGCCTGTTCCTCTGCGATACA 
 
CATGCCATGGGCCCCAGTGACATGTATGT 
HRV14 2Apro; 
antisense 
HRV2 2Apro; 
sense 
TIM1334 CATGCCATGGCTTGTTCTTCAGCACAATG HRV2 2Apro; 
antisense 
TIM1336 CATGGGATCCATGTCCCCTATACTAGGT 
 
GST; sense 
TIM1337 CATGGAATTCGGGCCCCTGGAACAGAAC 
 
GST; antisense 
TIM1346 AACAAAGCGGTGTATACTGCAGGTTAC 
 
PV1 2Apro; sense 
TIM1350 GACCAAGGTCACCTCCAA 
 
PV1 2Apro; sense 
TIM1351 TCCATGGCTTCTTCTTCG PV1 2Apro; 
antisense 
TIM1391 CTACAAATGTGGTATGGC pFastBac inserts; 
antisense 
TIM1518 GACCGCTCGAGATGGAATTCCACATGCCTCAGATCAC HIV 1 protease; 
sense 
TIM1519 GCACATATGTCGAAGGATCCCAATTCCCAAGAAATT 
 
HIV 1 protease; 
antisense 
                                                                                                                          3. Materials and methods 
 40
Label Sequence (orientation 5’ to 3’) 
 
Target 
TIM1520 GACCGCTCGAGATGGGCCCCTATGGACATCAATC CBV4 2Apro; 
sense 
TIM1521 CGCGCACATATGCTGTTCCATTGCATCATC 
 
CBV4 2Apro; 
antisense 
TIM1522 GACCGCTCGAGATGGAACTGACACTGTAC FMDV Lbpro; 
sense 
TIM1523 CGCGCACATATGTTTGAGCTTGCGTTGAACC 
 
FMDV Lbpro; 
antisense 
M13(-40) GTTTTCCCAGTCACGAC Bacmid 
(Invitrogen) 
inserts; sense 
M13 rev CAGGAAACAGCTATGAC Bacmid 
(Invitrogen) 
inserts; antisense 
T7promoter TAATACGACTCACTATAGGG pET11d inserts; 
sense 
T7terminator GCTAGTTATTGCTCAGCGG pET11d inserts; 
antisense 
 
Table 6: List of primers used for sequencing. 
 
3.4  RNA methods 
 3.4.1  In vitro transcription 
 2 to 5 µg of plasmid DNA were used to perform in vitro transcription experiments. 
First, the plasmid DNA was cleaved with a restriction enzyme cleaving just downstream of 
the protein coding sequence. Then, the linearized DNA was purified performing a 
phenol/CHCl3 extraction followed by ethanol precipitation (see 3.3.4.1 and 3.3.4.2) and 
resuspension in H2O. Finally, a typical transcription reaction composed of the cleaved 
plasmid DNA, 5 mM DTT, 1x transcription buffer (40 mM Tris-HCl, pH 7.9, 10 mM NaCl, 6 
mM MgCl2, 2mM spermidine) (Promega), 0.25 mM of all four NTPs (Amersham), 120 U 
RNasin (Promega) and 18 U of T7 RNA Polymerase (Promega) was performed in a total 
volume of 100 µl for 90 minutes at 37°C. 
  The template DNA was removed after the reaction by addition of 30 U DNase I 
(Invitrogen) and 40 U RNasin (Promega) followed by an incubation of 20 min at 37°C. The 
RNA was extracted with phenol/CHCl3 (see 3.3.4.1) and precipitated with 1/5 volumes of 8 M 
NH4OAc and 2.5 volumes of absolute ethanol for a maximum of 15 minutes at -80°C. After 
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centrifugation for 15 minutes at 14,000 rpm at 4°C (eppendorf centrifuge 5417 R), the RNA 
pellet was washed with 500 µl 70 % ethanol and resuspended in 25 µl of H2O. The quality of 
the RNA was checked on an agarose gel containing 0.1 % (w/v) SDS. Before staining the gel 
with ethidium bromide (10 mg/ml stock solution 1:10,000 in 0.5x TAE), the SDS was 
removed by shaking the gel in H2O for 30 to 60 minutes.   
 
 3.4.2  In vitro translation 
 Translation reactions were performed at 30°C in a volume of 10 µl (or multiples of 10 
µl, depending on how many aliquots needed to be taken at different time points) and 
composed of 70% of Rabbit Reticulocyte Lysate (RRL) (Promega), 8 U of RNasin (40 U/µl, 
Promega), 20 µM of amino acids mix without methionine (Promega), 4 µCi of [35S]-
Methionine (37 TBq/mmol, Hartmann Analytics) and 10 to 50 ng of RNA. 
After pre-incubation for 2 minutes at 30°C, translation was started by addition of the 
RNA. At different time points, aliquots were taken and the reaction was stopped by adding 
1/10 volumes of 20 mM unlabelled cysteine/methionine in Laemmli sample buffer and 
moving the samples to ice. In the experiments using the inhibitor zVAM.fmk, the inhibitor was 
added 10 minutes after translation initiation. Negative controls were done with DMSO (the 
solvent of zVAM.fmk) and without RNA. 
Translation products were analysed by the polyacrylamide gel electrophoresis system 
described by Dasso & Jackson (1989) and fluography (see 3.5.6.3 and 3.5.6.4) or by 
Western Blot Analysis (see 3.5.7). The volumes loaded on the polyacrylamide gels were 2 µl 
of a 10 µl reaction for the fluography and 3 µl of a 10 µl reaction for the Western Blot 
Analysis. 
 
3.5  Protein methods 
 3.5.1  Protein expression 
 3.5.1.1  Protein expression in LB and TB media 
 Expression of recombinant proteins was performed in E. coli BL21(DE3)LysS for pET 
vectors or in E. coli JM101 for pGEX vectors. A single colony was grown in LB or TB media 
containing the suitable antibiotics. The LB or TB media were inoculated 1:10 with the 
overnight culture. The culture was incubated at 37°C on a shaker at 160 to 180 rpm. Once 
the cell density reached an OD600 between 0.5 and 0.6, induction with the appropriate 
concentration of IPTG (Isopropyl β-D-1-thiogalactopyranoside) was started depending on the 
protein being expressed. The temperature was shifted to 20°C, 30°C or maintained at 37°C 
(this was also protein specific) and the cells were incubated for several hours or overnight. 
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Cells were harvested by centrifugation at 5000 rpm, 10 min, 4°C on Sorvall RC5C or RC5C 
plus centrifuges. The cell pellets were snap-frozen in liquid nitrogen and stored at -80°C. 
  
 3.5.1.2  Protein expression in M9 minimal medium 
 Protein expression in M9 Minimal medium was performed in E. coli BL21(DE3)LysS. 
A single colony was inoculated in M9 minimal medium containing the appropriate antibiotics. 
The M9 minimal medium was inoculated with 1% of the pre-culture and incubated at 37°C on 
a shaker at 160 rpm. Once the cell density reached an OD600 above 0.5, induction with 0.1 
mM IPTG was started and the cells incubated for 5 hours shaking at 37°C. Cells were 
harvested by centrifugation at 5000 rpm, 10 min, 4°C on Sorvall RC5C or RC5C plus 
centrifuges. The cell pellets were snap-frozen in liquid nitrogen and stored at -80°C. 
 
3.5.1.3  Protein expression in Sf9 cells 
The protein expression in insect Sf9 cells was performed using the Bac-to-Bac® 
Baculovirus Expression System from Invitrogen. The instructions of the manufacturer were 
followed.  
 
3.5.1.3.1  Transfection of Sf9 cells to generate a recombinant baculovirus 
9x105 Sf9 cells/well were seeded in a 6 well plate in 2ml of Sf-900 II SFM complete 
media (containing 50 units/ml penicillin and 50 µg/ml streptomycin). The plate was incubated 
at 27°C for 1 hour to allow the cells to attach. The transfection samples were prepared in 12 
x 75 mm sterile tubes. 2 µg of purified bacmid were diluted in 100 µl of unsupplemented 
Grace’s media and in other tube 6 µl of Cellfectin® Reagent (Invitrogen) were also diluted in 
100 µl of unsupplemented Grace’s media. The diluted bacmid and Cellfectin® Reagent were 
then combined, mixed gently and incubated for 45 minutes at room temperature. Meanwhile 
the cells were washed two times with 2 ml of unsupplemented Grace’s media. After the 
incubation, 0.8 ml of unsupplemented Grace’s media were added to the transfection mix and 
this was added to the cells. An incubation period of 5 hours at 27°C followed, after which the 
transfection mix was removed and 2 ml of complete growth media (Sf-900 II SFM media 
containing 50 units/ml penicillin and 50 µg/ml streptomycin) were added to the cells. The 
plate was incubated in a humidified incubator at 27°C for 72 hours (time at which the viral 
infection was visible).  
 
3.5.1.3.2  Preparation of the P1 viral stock and amplification 
The media of the transfection was collected and transferred to a 15 ml falcon. After a 
centrifugation at 800 rpm for 5 minutes at room temperature, the supernatant was transferred 
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to a new falcon tube. This corresponds to the P1 viral stock. Short term storage was at 4°C 
protected from light; long term storage was at -80°C, also protected from light. 
The amplification of the viral stock was done as recommended by the manual Bac-to-
Bac® Baculovirus Expression System from Invitrogen. 2 x 106 cells/ well were seeded in a 6 
well plate in 2ml of Sf-900 II SFM complete media. The plate was incubated at 27°C for 1 
hour to allow the cells to attach. 400 µl of the P1 viral stock were added to each well and the 
plate was incubated at 27°C in a humidified chamber for 48 hours. The isolation of the viral 
stock P2 was as for viral stock P1. 
 
3.5.1.3.3  Virus titer determination using end-point dilution 
5x103 cells/well in Sf-900 II SFM complete media (100µl) were seeded in a 96 well 
plate and incubated 1 hour at room temperature to allow the cells to attach. Dilutions of the 
viral stock from 10-2 to 10-12 in Sf-900 II SFM complete media were prepared. 100 µl of each 
dilution were added to the cells (12 wells per dilution). One row of 12 wells was not infected 
and left for control. An incubation at 27°C in a humidified chamber followed for 6 to 10 days. 
After that, the number of infected wells was counted. The wells considered infected 
contained lysed cells and the wells non-infected contained a confluent layer of cells. The 
method used to determine the virus titer was the one described by Reed and Muench (Reed 
and Muench., 1938).  
 
3.5.1.3.4  Expression of the recombinant protein 
A time course experiment was done to determine the optimal level of expression. 
6x105 cells/well were seeded on a 24 well plate in Sf-900 II SFM complete media and 
incubated 1 hour at room temperature to allow the cells to attach. The media was removed 
and replaced with 300 ml of fresh one. The viral stock was added at a MOI (multiplicity of 
infection) of 5 and the plate was incubated at 27°C in a humidified chamber. The 
supernatants were harvested at the time points 24, 48, 72 and 96 hours. The samples were 
boiled with ½ volumes of 2x Laemli sample buffer for 5 minutes and analyzed on SDS-PAGE 
gels (see 3.5.6.1). 
Once the conditions for expression were optimized the method was scaled up to 
liquid cultures of 200 ml. The cells were transferred to 1 litre conical flasks at a concentration 
of 2x106 cell/ml in Sf-900 II SFM complete media and directly infected with the appropriate 
amount of viral stock. The incubation was at 27°C in a humid chamber with constant rotation 
at 120 rpm. After expression, the cells were harvested by centrifugation at 1200 rpm, 5 
minutes at 4°C. The supernatant was then treated with glutathione sepharose beads in order 
to purify the recombinant protein. 
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3.5.2  Preparation of cell extracts 
3.5.2.1  Bacterial crude cell extracts 
The bacterial pellets stored at -80°C after expression were thawed on ice and 
resuspended in 30 ml/litre of expression of the appropriate buffer. Cell disruption was 
achieved by sonication using the device Homogenizer Sonopuls HD 200 from Bandelin. The 
probe tip used was the MS 73D at a 40% cycle 4 times 30 seconds and one continuous cycle 
for 30 seconds, on ice. The samples were centrifuged at 18,000 rpm in Sorvall RC5C or 
RC5C plus centrifuges, for 30 minutes at 4°C. For small scale experiments the pellets were 
resuspended in 1 to 1.5 ml of buffer and sonicated at a 20% cycle twice for 30 seconds and 
one continuous cycle for 30 seconds, on ice. The centrifugation to separate the soluble 
fraction (supernatant) from the unsoluble one (pellet), was done in an eppendorf centrifuge 
5417R at 14,000 rpm for 30 minutes at 4°C.  
The buffers used to ressuspend the bacterial pellets varied with the proteins being 
purified. HRV2 2Apro, eIF4GII and eIF4E were resuspended in buffer A (50 mM Tris-HCl pH 
8.0,  1 mM EDTA, 5 mM DTT, 5% glycerol, 50 mM NaCl). HRV14 2Apro was also 
resuspended in buffer A, however at pH 9.0. In some experiments eIF4E was resuspended 
in LCB buffer (20 mM Hepes pH 7.5, 0.2 mM EDTA, 100 mM KCl). All the proteins used in 
GST pull down assays were taken up in ΔX buffer (150 mM NaCl, 10 mM EDTA, 50 mM Tris-
HCl pH 7.4). 
 
3.5.2.2  HeLa S10 extracts 
A 1 litre suspension culture (see 3.1.3.1) of HeLa Ohio Flow cells in logarithmic phase 
(4 to 5x105 cells/ml) was harvested at 1200 rpm, 10 min, 4oC (Beckmann J6-HC centrifuge). 
Cells were then washed one time with 50 ml of ice cold 1x PBS and twice with 25 ml of ice 
cold 1x PBS. After each wash, the cells were spun down at 1000 rpm for 8 minutes at 4°C on 
a Heraeaus Megafuge 1.0R centrifuge. The pellet was taken in 1.5 volumes of hypotonic 
lysis buffer (2 to 3 ml) (10 mM HEPES-KOH pH 7.2, 10 mM KOAc, 1.5 mM Mg(OAc)2, 2 mM 
DTT) and left on ice for 10 minutes to allow the cells to swell. The lysis and homogenization 
occurred by application of 250 to 300 strokes of a suitable Wheaton Dounce homogenizer. 
The lysis was controlled by staining the cells with trypan blue and observing them at a light 
microscope (more than 95% of the cells should be lysed). The cells were transferred to a 30 
ml glass tube (Correx) and centrifuged at 4°C for 5 minutes at 3000 rpm to remove the cell 
debris and nuclei. The speed was increased to 13,000 rpm for another 20 minutes in order to 
separate the mitochondria. The centrifugation was done in a Sorvall RC5C plus centrifuge 
with a Sorvall HB-4 rotor. The white lipid layers visible on the supernatant were removed. 
The extract was dialysed for 3 hours (see 3.5.4.1) against 1 litre of dialysis buffer (10 mM 
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HEPES-KOH pH 7.2, 90 mM KOAc, 1.5 mM Mg(OAc)2, 1 mM DTT), transferred to a clean 30 
ml glass tube (Correx) and centrifuged at 13,000 rpm for 10 minutes at 4°C (Sorvall HB-4 
rotor). After removing the lipid layer, aliquots of 380 µl were prepared, snap-frozen in liquid 
nitrogen and stored at -80°C. The extract concentration was between 15 and 20 mg/ml.  
 
3.5.3  Protein purification 
3.5.3.1  Batch purification 
3.5.3.1.1  binding to glutathione sepharose beads 
An aliquot of 1 ml glutathione sepharose beads (Amersham Biosciences) per litre of 
expression was washed three times with the appropriate buffer, mixed with bacterial extract 
containing the GST fusion protein (see 3.5.2.1) and incubated for 4 hours to overnight at 4 °C 
with rotation for binding. Unbound proteins to the beads were removed by washing the beads 
3 times with the appropriate buffer.   Beads with bound GST fusion proteins were stored as 
50 % slurry in buffer at -80 °C. Aliquots were checked on an SDS- PAGE. 
 
3.5.3.1.2  Cleavage with preScissionTM Protease 
The cleavage of the fusion protein from the GST tag was done by incubation for 24 
hours rotation at 4 °C with preScissionTM Protease (Amersham Biosciences, 1 U/100 µg 
protein). Supernatants were separated by centrifugation at 1500 rpm for 1 minute at 4°C 
(eppendorf centrifuge 5417R) and beads washed 3 times with buffer, keeping the 
supernatants. The protein could then be purified by Size Exclusion Chromatography (see 
3.5.3.2.3). 
 
3.5.3.1.3  GST pull down 
Glutathione sepharose beads coated with GST fusion proteins were incubated in ΔX 
buffer (see 3.5.2.1) with 8 µl of RRL (Promega) for 2 hours at 4°C. After washing 3 times with 
ΔX buffer the proteins were eluted by boiling in Laemmli sample buffer for 5 minutes. The 
samples were resolved by electrophoresis and visualized by ECL detection of Western blot 
membranes (see 3.5.7) 
 
3.5.3.1.4  binding to m7GTP beads 
 eIF4E samples eluted from a Mono 10/10 column (see 3.5.3.2.2) were dialysed 
against binding buffer (20 mM MOPS pH 7.6, 0.25 mM DTT, 0.1 mM EDTA, 50 mM NaF, 100 
mM KCl) for 3 times for 1 hour at 4°C (see 3.5.4.1). After dialysis, the protein samples were 
incubated with 100 µl of m7GTP beads (Amersham Biosciences) per 500 µl of sample, 
overnight at 4°C with rotation. After washing the unbound proteins 3 times with binding 
                                                                                                                          3. Materials and methods 
 46
buffer, the eIF4E was eluted by addition of 500 µl of elution buffer (20 mM MOPS pH 7.6, 
0.25 mM DTT, 0.1 mM EDTA, 50 mM NaF, 550 mM KCl) and incubation for 3 hours at 4°C 
with rotation. The centrifugations were done at 1500 rpm for 1 minute at 4°C on an eppendorf 
centrifuge 5417R. 
 
3.5.3.2  FPLC purification methods 
Protein purification was performed based on size exclusion, affinity and anion 
exchange, using the ÄKTA FPLC (Fast Protein Liquid Chromatography) system from 
Amersham Biosciences. All the columns were purchased from Amersham Biosciences. 2 ml 
fractions were collected using an automatic fraction collector connected to the ÄKTA FPLC 
system. Purification experiments and cleaning of the columns were performed according to 
the instructions of the manufacturer. Fractions were analysed by SDS-PAGE (see 3.5.6.1). 
 
 3.5.3.2.1  Affinity purification 
 Proteins bearing a His tag were purified using the HisTrap FF 1 ml affinity column. 
Protein samples of 30 to 60 ml were loaded on the column and eluted with a gradient of 
imidazole. The gradient program was as follows: 5 column volumes of 100% binding buffer 
(50 mM Tris- HCl pH 8.0 or 9.0 (depending on the protein being purified), 50 mM NaCl), 20 
column volumes of 0% to 100% of elution buffer (50 mM Tris- HCl pH 8.0 or 9.0 (depending 
on the protein being purified), 50 mM NaCl, 500 mM imidazole) and 5 column volumes of 
100% elution buffer.  
  
 3.5.3.2.2  Anion Exchange Chromatography 
Proteins differing in electrostatic charge were separated via anion exchange 
chromatography. Protein samples containing 5 to10 mg protein were loaded on a MonoQ 
10/10 with a column volume of 8 ml. The proteins were eluted by using a gradient of NaCl. 
The gradient program was as follows: 2.5 column volumes of 100% binding buffer (50 mM 
Tris-HCl pH 8.0, 1 mM EDTA, 5 mM DTT, 5% glycerol, 50 mM NaCl), 2.5 column volumes of 
0% to 20% of elution buffer (50 mM Tris-HCl pH 8.0, 1 mM EDTA, 5 mM DTT, 5% glycerol, 1 
M NaCl), 15 column volumes of 20% to 60% of elution buffer, 2.5 column volumes of 60% to 
100% of elution buffer and 2.5 column volumes of 100% elution buffer. 
 
3.5.3.2.3  Size Exclusion Chromatography 
Purification of proteins based on molecular weight differences was performed via size 
exclusion chromatography. Sample volumes of 0.5 to 2 ml were loaded in a HiLoad 26/60 
Superdex 75 prep grade column. The samples were separated by passing 1.2 column 
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volumes of buffer A (50 mM Tris-HCl pH 8.0 or 9.0 (depending on the protein being purified), 
1 mM EDTA, 5 mM DTT, 5% glycerol, 50 mM NaCl). 
. 
 3.5.3.5  TAP purification 
 3.5.3.5.1  Strategy 1 (adapted from Rigaut G. et al. 1999) 
 The TAP (tandem affinity purification) method allows the purification of protein 
complexes under native conditions, without prior knowledge of their composition, which are 
then identified by mass spectroscopy (MS). This method is fast and can be used with a 
relatively small number of cells. The TAP tag consists of two proteins, protein A of 
Staphylococcus aureus (15.3 kDa) and a calmodulin binding peptide (CaBP, 3.0 kDa), which 
are separated by the cleavage sequence recognized by the Tobacco Etch Virus (TEV) 
protease (Rigaut et al., 1999). 
 The expression of the proteins of interest was done in BL21(DES3)LysS cells (see 
3.5.1.1). The pellet of 1 litre expression was resuspended in 12 ml of buffer A (50 mM Tris-
HCl pH 8.0, 1 mM EDTA, 5 mM DTT, 5% glycerol, 50 mM NaCl) and sonicated (see 3.5.2.1). 
The centrifugations to separate soluble from insoluble fractions were performed at 16,000 
rpm for 35 minutes at 4°C. The supernatant (soluble fration), supplemented with 10 mM of 
Tris-HCl pH 8.0, 150 mM of NaCl and 0.1% Igepal CA-630 (Sigma) (final concentrations), 
was added to 600 µl of IgG sepharose beads (Amersham), previously washed 3 times with 2 
ml of IPP150 buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Igepal CA-630 (Sigma)). 
The incubation was done at 4°C for 2 hours with rotation. After incubation the IgG sepharose 
beads were spun down, the supernatant was removed and the beads were washed 3 times 
with 2 ml of TEV cleavage buffer (10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.1% Igepal CA-
630 (Sigma), 0.5 mM EDTA, 1 mM DTT (added just before use)). The IgG sepharose beads 
were then divided in two fresh tubes (approximately 300 µl of beads per tube), one for the 
negative control (no incubation with HeLa S10 extracts) and one for incubation with the HeLa 
S10 extracts. The positive controls were incubated with 50 mg of Hela S10 extracts for 2 
hours at 4°C with rotation. After spinning down, the supernatant was removed and the beads 
were washed 3 times with 2 ml of IPP150 buffer and 3 times with TEV cleavage buffer. 300 
µl of TEV cleavage buffer plus 100 units of TEV protease (Invitrogen) were added to the IgG 
sepharose beads and incubated overnight at 4°C with rotation.  The IgG sepharose beads 
were spun down and the supernatant was collected to a fresh tube, to which 1 volume of 
IPP150 calmodulin binding buffer (10 mM β-mercaptoethanol, 10 mM Tris-HCl pH 8.0, 150 
mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 2 mM CaCl2, 0.1% Igepal CA-630 (Sigma)) 
was added. The IgG sepharose beads were washed 3 times with 300 µl of IPP150 
calmodulin binding buffer. The supernatants from the washing steps were added to the same 
tube containing the first eluate. The final 1200 µl were added to 200 µl of calmodulin beads 
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(Stratagen), previously washed with 3 times with 2 ml of IPP150 calmodulin binding buffer. 
The mix was incubated at 4°C for 90 minutes with rotation. The beads were spun down, the 
supernatant was removed and the beads were washed 3 times with 2 ml of calmodulin 
binding buffer. The elution was performed with IPP150 calmodulin elution buffer (10 mM β-
mercaptoethanol, 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 
2 mM EGTA, 0.1% Igepal CA-630 (Sigma)). 200 µl of elution buffer were added to the beads 
and incubated 5 minutes at room temperature with agitation. The supernatant was collected 
after the beads were spinned down. 5 different 200 µl fractions were eluted. All the 
centrifugations to spin down beads were done at 1500 rpm for 1 minute at 4°C. 
 
Protein precipitation 
 The precipitation procedure was as described by Ozols (1990). A solution of sodium 
deoxicholate (20 mg/ml) was added to the samples to a final concentration of 150 µg/ml 
followed by incubation at 4°C for 30 minutes with rotation. A 20% solution of trichloroacetic 
acid (TCA) was added to a final concentration of 6% and the mix was incubated on ice for 1 
hour. The sample was centrifuged at 2500 rpm at 4°C for 45 minutes. The supernatant was 
removed and the pellet was ressuspended in 50 µl of 150 mM NaHCO3 pH 8.8; 43.8 mM 
Tris-HCl pH 6.8 and 3% SDS. After protein quantification (see section 3.5.5) the samples 
were sent for analysis by mass spectroscopy. 
 
 3.5.3.5.2  Strategy 2 (adapted from Anne–Claude Gingras 2003) 
 The genes of interest were cloned in the vector pMZI, which contains a TAP tag and 
was constructed to transiently transfect human cells (Zeghouf et al., 2004). The expression 
of the proteins was carried out using the Ecdysone-Inducible Mammalian Expression System 
from Invitrogen. The cell line used for the experiments was the HEK 293T. 
 
 Transfection and protein expression 
 2x106 cells/well were seeded in a 6 well plate in antibiotic-free media one day prior to 
transfection. Cells were 80 to 90% confluent on the day of the transfection. 2 µg of the pMZI 
vector carrying the gene of interest plus 2 µg of the vector pVgRXR from the expression 
system (Invitrogen) were diluted in 250 µl of OptiMEM media (Gibco) at room temperature 
and divided in 5 aliquots of 50 µl. 10 µl of lipofectamin 2000 (Invitrogen) were also diluted 
and throughly mixed in 250 µl of OptiMEM medium and incubated at room temperature for 5 
minutes. 50 µl of the lipofectamin 2000 solution were added to each aliquot of the tubes 
containing the plasmid DNA. The final mix was incubated at room temperature for 20 
minutes. Meanwhile, the cells were washed with 1 ml of 1x PBS and 1.5 ml of DMEM (Gibco) 
supplemented with 2% FCS, antibiotic-free was added. The 5 aliquots of 100 µl containing 
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lipofectamine and DNA were distributed equally over the well. The transfected cells were 
incubated at 37°C in a humidified chamber for 4 hours. Then, the cells were trypsinized with 
200 µl of trypsin/EDTA solution (Gibco) (see 3.1.3.1), neutralized by addition of 800 µl of 
DMEM (Gibco) supplemented with 10% FCS, antibiotic-free and seeded in a 150 mm cell 
culture dish. The cells were incubated overnight at 37°C in a humidified chamber in 30 ml of 
DMEM (Gibco) supplemented with 10% FCS, antibiotic-free. On the next day, the media was 
changed to DMEM (Gibco) supplemented with 10% FCS and 50 units/ml penicillin and 50 
µg/ml streptomycin plus the desired concentration of ponasterone A (Invitrogen) to start the 
induction of protein expression. Large scale experiments were induced for 48 hours.  
Small scale experiments were performed in 6 well plates in which 200 µl of the 
trypsinized transfected cells were used. 
 
 Protein purification 
 The cells were washed 3 times with 10 ml of 1x PBS and then were lysed in 1 ml of 
lysis buffer (10% glycerol, 50 mM HEPES-KOH pH 8.0, 100 mM KCl, 2 mM EDTA, 0.1% 
Igepal CA-630 (Sigma), 2 mM DTT, 1x sigma protease inhibitor, 10 mM NaF, 0.25 mM 
NaOVO3, 5 nM calyculin A, 50 mM β-glycerolphosphate) for 30 minutes at 37°C and 
harvested by scraping. To improve the protein recovery, two cycles of freeze and thaw in 
liquid nitrogen intercalated with 37°C incubation were done. The cell debris was spun down 
for 10 minutes at 14,000 rpm at 4°C. The supernatant was recovered and incubated, in 
batch, with 100 µl of IgG sepharose beads (Amersham) (previously washed 3 times with 1 ml 
of lysis buffer), at 4°C for 2 hours with rotation. The beads were spun down and the 
supernatant removed. The beads were then washed 3 times with 1 ml of lysis buffer and 3 
times with 1 ml of TEV buffer (10 mM Hepes-KOH pH 8.0, 150 mM NaCl, 0.1% Igepal CA-
630 (Sigma), 0.5 mM EDTA, 1 mM DTT). 300 µl of TEV buffer plus 100 units of TEV 
protease (Invitrogen) were added to the IgG sepharose beads and incubated overnight at 
4°C with rotation. Afterwards, the IgG sepharose beads were spun down and the supernatant 
was transferred into a fresh tube to which 1 volume of calmodulin binding buffer (10 mM β-
mercaptoethanol, 10 mM Hepes-KOH pH 8.0, 150 mM NaCl, 1 mM MgOAd, 1 mM imidazole, 
0.1% Igepal CA-630 (Sigma), 2 mM CaCl2) was added. The IgG sepharose beads were 
washed 3 times with 300 µl of calmodulin binding buffer; the supernatants from the washing 
steps were then added to the first supernatant. The final 1200 µl were added to 100 µl of 
calmodulin beads (Stratagen) (previously washed 3 times with 1 ml of calmodulin binding 
buffer). 1/250 volumes of 1M CaCl2 were added to the mix and incubated at 4°C for 90 
minutes with rotation. The mix was spun down, the supernatant was removed and the 
calmodulin beads were washed 2 times with calmodulin binding buffer and 3 times with 
calmodulin rinsing buffer (50 mM NH4HCO3, 75 mM NaCl, 1 mM MgOAc, 1 mM imidazole, 2 
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mM CaCl2). The protein elution was done by addition of 200 µl of calmodulin elution buffer 
(50 mM NH4HCO3, 25 mM EGTA), followed by incubation at room temperature for 5 minutes 
with agitation. The calmodulin beads were spun down and the supernatant recovered to a 
fresh tube. The elution was repeated 4 times. The final eluates were frozen at -80°C until 
protein quantification and mass spectroscopy analysis. 
All the spin-down centrifugations were done at 4°C, 1500 rpm for 1 minute.  
 
3.5.4  Buffer exchange and protein concentration 
 3.5.4.1  Dialysis 
Dialysis was used for buffer changing. The protein solution was introduced into a bag 
of a semi-permeable membrane made of cellulose acetate with a cut-off of 10 kDa prepared 
as recommended by the manufacturer (Sigma). The sample was dialysed against the desired 
buffer. A ratio of 100 times the volume of buffer compared to sample volume was used. 
Dialysis was performed at 4°C in a beaker under slow stirring of the bag from 3 hours to 
overnight. During the dialysis process the buffer was changed from 2 to 3 times. 
 
 3.5.4.2  Protein concentration 
 Amicon Ultra Centrifugal Filter Devices (Millipore) were used to concentrate protein 
samples. The instructions of the manufacturers were followed. The centrifugations were 
carried out at 4°C at maximum speed on a Megafuge 1.0R Hearaeus centrifuge for volumes 
inferior to 4 ml and on an eppendorf centrifuge 5810R for volumes from 4 to 15 ml.  
 
3.5.5  Protein quantification 
 Quantification of proteins was performed with the kit BCA - Protein Assay Reagent A 
from Pierce. The quantification was done following the microplate procedure provided with 
the kit. 
 The Nanodrop spectrophotometer ND-1000 from Peqlab was also used to quantify 
protein samples. The instructions of the manufacturer were followed. 
 
 3.5.6  SDS- Poly-Acrylamide Gel Electrophreis (SDS-PAGE) 
3.5.6.1  SDS-PAGE (Laemmli, 1970) 
SDS-Poly-Acrylamide Gel Electrophoresis (PAGE) was performed in Hoefer slab gel 
units or in the mini-PROTEAN® 3 system from Biorad, assembled according to the 
instructions of the manufacturers. The separating gel was poured, overlaid with 70% ethanol 
and rinsed with H2O after polymerization. Afterwards, the stacking gel was prepared, the gel 
unit assembled and the gel overlaid with 1 x running buffer (25 mM Tris base, 0.2 M Glycine, 
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0.1 % (w/v) SDS). Protein samples mixed with Laemmli sample buffer (10 % (v/v) Glycerol, 5 
% (v/v) β-Mercaptoethanol, 3 % (w/v) SDS, 62 mM Tris, 5 % (w/v) Bromophenol Blue, pH 
adjusted to 6.8 with HCl) were denatured for 5 min (20 minutes in case of bacterial cultures 
taken in 1x Laemmli sample buffer) at 95 °C and loaded onto the gel. Separation of protein 
samples including a protein marker (Biorad prestained protein marker, 161-0373 (see 
appendix B)) was performed at up to 20 mA in a power pac 300 from Biorad. 
 
Acrylamide content                        6 %            10 %            12.5 %             15 %     
4x Lower Gel Buffer (ml)               1.5              1.5               1.5                   1.5       
30 % Acryl-/Bisacrylamide (ml)     1.2              2                  2.5                   3   
H2O (ml)                                        3.3              2.5               2                      1.5 
10 % APS (µl)                                36               36                36                    36 
TEMED (µl)                                   3.6              3.6               3.6                   3.6 
 
Table 7: Composition of Separating Gels (Laemmli, 1970). APS: Ammonium peroxidisulafte; 
TEMED: N,N,N´,N´-Tetramethyl-ethylene diamine. 
 
The lower gel buffer (LGB) is kept in stock 4x concentrated and contains 1.5 M Tris 
base pH 8.8 and 0.4 % SDS. The  upper gel buffer (UGB) is also kept in 4x concentarted 
stocks and is composed of 0.5 M Tris base pH 6.8 and 0.4 % SDS. 
The stoks of acrylamide/bisacrylamide are prepared by dissolving 29% acrylamide 
(w/v) and 1% N,N´Methylene Bisacrylamide (w/v) in H2O, followed by filtration. 
The stacking gel solution is prepared by adding 12.5 ml of UGB and 6.5 ml of 30% 
acrylamide to 31 ml of H2O. For each gel, 2 ml of this solution are mixed with 12 µl 10 % 
(w/v) APS and 4 µl TEMED before pouring. 
 
3.5.6.2  SDS-PAGE Gradient gels 
 Gradient gels were prepared from two starting mixes containing 7% and 20% 
bis/acrylamide. The solutions were combined gradually with the help of a mixer and pumped 
into the gel units with Minipuls 2 pump from Gilson. 
 
 3.5.6.3  SDS-PAGE (Dasso and Jackson, 1989) 
In order to better separate in vitro translation products, a protocol resulting in higher 
resolution of proteins was used (Dasso and Jackson, 1989). Acrylamide and bisacrylamide 
were prepared as separate solutions and only mixed directly before preparing the SDS-
PAGE. The composition of the separating gel was as listed in table 8. 
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 Acrylamide content                             6 %     12.5 %     15 %       17.5 %        20 % 
 4x Lower Gel Buffer (ml)                    1.5       1.5           1.5          1.5              1.5 
 30 % (w/v) Acrylamide (ml)                1.2       2.5           3             3.5              4 
 2.5 % (w/v) Bisacrylamide (ml)           0.209   0.209      0.209      0.209          0.209 
 H2O (ml)                                             3.06     1.8           1.26        0.758          0.261 
10 % (w/v) APS (µl)                            30        30            30           30               30 
TEMED (µl)                                         3          3              3             3                 3 
 
Table 8: Composition of separating gels (Dasso & Jackson, 1989). 
 
The stacking gel was composed of 333 µl 30 % (w/v) acrylamide, 104 µl 2.5 % (w/v) 
bisacrylamide, 500 µl 4x UGB, 1.06 ml H2O, 20 µl 10 % (w/v) APS and 2 µl TEMED. When 
the translation products were detected by radiolabelling and fluography (3.5.6.4); the [14C]-
labelled protein marker CFA626 from Amersham Biosciences was used (see appendix B). 
 
 3.5.6.4  Fluorography 
 [35S]-methionine labelled proteins were separated on SDS-PAGE. The gel was 
washed twice for 15 minutes at room temperature with rotation in Enhancer solution (1M 
sodium salicylate, 45% methanol) to increase the signal and lower the background. After 
drying with vaccum on WhatmanTM 3MM paper, the gel was exposed to a KODAK BioMax 
MR film overnight at -80°C. 
 
3.5.6.5  Coomassie Staining of Polyacrylamide Gels 
 The gels were stained by incubation for 1 hour in commassie staining buffer (0.4 % 
(w/v) Biorad Commassie Brilliant Blue R250, 45 % (v/v) methanol, 10 % (v/v) acetic acid, 
filter before use) and destained by exchanging the staining buffer by water and boiling the gel 
for several times in the microwave. Gels were vacuum-dried (Slab Gel Dryer SGD 4050, 
Savant) on WhatmanTM 3MM paper for 1 hour at 80°C. 
 
3.5.6.6  Silver Staining of Polyacrylamide Gels 
 In order to obtain higher detection sensitivity, proteins were visualized by silver 
staining. Proteins were fixed by incubating the gels for 1 hr in fixing solution (50 % methanol, 
12 % acetic acid, 0.05 % formaldehyde). Subsequently, the gels were washed three times for 
20 minutes with 50 % ethanol. For sensitization, gels were placed in 0.02 % Na2S2O3 for 1 
minute and washed three times 20 seconds with H2O. The gels were then incubated with 
staining solution (0.2 % AgNO3, 0.075 % formaldehyde) for 20 minutes and washed twice for 
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20 seconds with H2O. Proteins were developed with developing solution (6% Na2CO3, 
0.0004% Na2S2O3.5H2O, 0.05% formaldehyde) for 10 minutes or until the protein bands 
became visible. Washing was done twice for 2 minutes with H2O. The development was 
stopped by incubation with stopping solution (50 % methanol, 12 % acetic acid) for 10 min 
and the final washing was performed in 50% methanol for 20 minutes. 
 
3.5.7  Western blot analysis 
 For western blot analysis, protein samples and prestained protein marker (Biorad 
prestained protein marker, 161-0373 (see appendix B)) were separated on SDS-PAGE. The 
proteins were then transferred onto a membrane. For that, ImmobilonTM-P Transfer 
Membrane (Millipore) was pre-soaked in methanol and placed together with 4 pieces of 
WhatmanTM 3MM paper and 2 pads in the plastic support (Biocom). The transfer was 
performed in the omniPAGE Blot mini (Biocom) filled with transfer buffer (1 % (w/v) glycine, 
20 % (v/v) methanol, 25 mM Tris base pH 8.8) for 2 hrs at 400 mA. The transfer efficiency 
was verified by staining the membrane with Ponceau S solution (Sigma) and washing with 
H2O. 
The immunoblot analysis was started by saturating the non-specific binding sites via 
incubation with blocking buffer (0.2 % Tween 20, 0.2 % I-Block (Tropix)                        
in 1x PBS) for 30 minutes shaking. Subsequently, the membrane was incubated with the 
primary antibody for 1 hour or overnight (in presence of 0.002% NaN3) at 4°C with rotation, 
followed by three times washing for 10 minutes in 1x PBS/T (1.4 mM KH2PO4, 2.7 mM KC, 
4.3 mM Na2HPO4, 137 mM NaCl, 0.1% Tween 20). Incubation with the secondary antibody 
followed for 1 hour at 4°C with rotation.  
For detection of alkaline phosphatase (AP) conjugated secondary antibodies, the 
membrane was washed with tap water and incubated with 5 ml alkaline phosphatase buffer 
(5 mM MgCl2, 100 mM NaCl, 100 mM Tris-HCl pH 9.6) supplemented with 25 µl NBT (Nitro 
blue tetrazolium) (5 % (w/v) in 90 % dimethylformamide) and 25 µl BCIP (2.5 % (w/v) 5-
bromo-4-chloro-3-indolyl phosphate disodium salt, Sigma) until the proteins were visible (1 to 
2 minutes). The colour reaction was stopped with H2O. 
For horseradish peroxidase conjugated (HRP) antibodies, the detection was 
performed with the Super Signal® West Pico chemiluminescent substrate kit from Pierce. 
After incubation with the secondary antibody the membrane was washed three times 10 
minutes with 1x PBS/T and 2 times 10 minutes with 1x PBS and covered with a 1:1 mix of 
solutions of the detection kit for 5 minutes. The solution was removed and the membrane 
was wrapped in SaranWrap and exposed to an autoradiography film (CL-X Posuse™ Film, 
Pierce). 
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Primary antibodies 
 
Dilution  
rabbit anti eIF4GI (N-terminal, antiserum, gift from 
R. Rhoads, Shreveport, LA)   
1:8000 
rabbit anti β-actin (polyclonal, Sigma) 1:200 
rabbit anti PABP (polyclonal, gift from Luiza 
Deszcz, MFPL) 
1:1000 
mouse anti eIF1α (polyclonal, gift from J. 
Pelletier, McGill Uni., Montreal) 
1:2000 
rabbit anti HRV2 2Apro (antiserum, gift from 
Andrea Reischl, MedUni Vienna) 
1:1000 
goat anti GST (polyclonal, GE Healthcare) 1:10,000 
 
Table 9: List of primary antibodies used in this work. 
 
 
Secondary antibodies 
 
dilution 
His Probe™ HRP conjugated  (Pierce) 1:10,000 
anti rabbit HRP conjugated (Jackson) 1:20,000 
anti goat HRP conjugated (Jackson) 1:20,000 
anti rabbit AP conjugated (Sigma) 1:5000 
anti mouse AP conjugated (Biorad) 1:10,000 
 
Table 10: List of secondary antibodies used in this work. 
 
3.5.8  Maldi-Tof Mass Spectroscopy analysis 
Maldi-TOF MS (Matrix assisted laser desorption ionization time of flight mass 
spectrometry) allows the identification of proteins that are separated by SDS-PAGE (see 
3.5.6.1) and e.g. silverstained (see 3.5.6.6) and digested enzymatically, preferentially with 
trypsin. The peptide masses from the enzymatic digest are then compared to theoretical 
mass values in the databases by using the Mascot and Peptide Search softwares. The 
measurements were done at the Mass Spectrometry Facility of Max F. Perutz Laboratories 
headed by Professor Gustav Ammerer. 
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3.5.9  NMR (Nuclear Magnetic Resonance) 
NMR is a method used to determine the structure of a protein in solution and 
investigate protein dynamics. The influence of a ligand on protein structure and/or dynamics 
can be measured in the absence or presence of for example a substrate. The measurements 
were done by Dr. Georg Kontaxis at the Computational and Structural Biology department of 
Max F. Perutz Laboratories. 
 
3.5.10  Determination of protein melting point 
Protein stability can be measured by determination of its melting temperature, which 
is defined as the temperature at which the protein denatures. When a protein is heated 
above its characteristic thermal stability point (protein melting point) significant unfolding 
leads to exposed hydrophobic chains. This phenomenon can be measured by addition of a 
specific dye which is non-fluorescent in a hydrophilic environment and fluorescent in a 
hydrophobic environment (Yeh et al., 2006). The protein is mixed with the dye and the 
temperature of the mix is increased constantly. When the protein reaches the melting point, it 
starts to unfold and consequently exposes the hydrophobic residues, which trigger the dye to 
emit fluorescence allowing the determination of the melting temperature easily. 
The purified proteins were mixed with the SYPRO Orange dye (Invitrogen) in several 
dilutions, from 0.1 to 1 mg of protein mixed with 1x to 150x concentrated dye (see table 11). 
The dilutions were made to find the optimal ratio Protein/dye. The melting temperature was 
measured in a real-time PCR machine (Biorad) using a single cycle from 20°C to 95°C, in 
which the temperature was increased 1°C each 30 seconds. 
 
 
Protein (mg) SYPRO Orange dye (x times concentrated) 
0,1 10x 5x 1x 
0,2 30x 15x 5x 
0,3 50x 30x 10x 
0,5 150x 100x 50x 
1 150x 100x 50x 
 
Table 11: Dilutions of protein/SYPRO Orange dye for protein melting point detection. 
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 3.5.11  Enzymatic reactions of proteins 
To measure the cleavage of β-actin and eIF1α by HRV2 and HRV14 2Apro, 8µl of RRL 
(promega) or 50 mg of HeLa cell extracts (see 3.5.2.2) were incubated with 100 ng of HRV2 
and HRV14 2Apro at 30°C (overnight with the HeLa extracts and 2 hours with the RRLs) in 
buffer A (50 mM Tris-HCl pH 8.0 , 50 mM NaCl, 1 mM EDTA, 5 mM DTT, 5% glycerol). the 
total volume was 10 µl. The reaction was stopped by placing the sample on ice and adding 
10 µl of 2x Laemmli sample buffer. Controls were made with non-incubated samples and 
incubation with buffer only. The samples were then analyzed by SDS-PAGE (3.5.6.1), 
followed by immunoblotting using the appropriate antibody (3.5.7). 
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4 Results 
 
4.1  Specificity of HRV 2A proteinases  
The 2Apro used in this work are from HRV2, which belongs to the genetic group A and 
enters the cell via LDL receptor; and HRV14, a member of the genetic group B which binds 
to ICAM-I. Our work was focused on investigating the substrate specificity of the 2Apro of 
these two viruses.  
  
4.1.1  Polyprotein and eIF4GI processing  
HRV2 and HRV14 2Apro share only 40% identity at the amino acid level. The kinetics 
of both proteins for self cleavage is very similar. For HRV2 2Apro in the rabbit reticulocyte 
lysate (RRL), 50% of the self-cleavage of VP1-2Apro is complete at 20 minutes and the 
complete cleavage is achieved between 60 and 120 minutes (figure 15A). HRV14 2Apro 
reaches 50% cleavage at 30 minutes and finishes self-processing between the first and 
second hours as HRV2 2Apro (figure 15B). 
 
 
Figure 15: Fluorography of a 17.5% SDS-PAGE showing an in vitro translation experiment. A) 
HRV2 VP1-2Apro wild-type; B) HRV14 VP1-2Apro wild-type. RRLs were incubated with or without 10 
ng/µl of the indicated mRNAs as described in section 3.4.2. 10 µl samples were taken at the indicated 
time points after mRNA addition and protein synthesis was terminated by addition of unlabeled 
methionine and cysteine and Laemmli Sample Buffer. Aliquots were analyzed on SDS-PAGE for 
protein synthesis and thus self-processing of 2Apro. Lane 9 corresponds to the negative control 
(without RNA) taken at the latest time point. 
 
RRLs contain the eIF4GI and II, which are cleaved by 2Apro. Therefore, we can 
observe eIF4GI cleavage by 2Apro by simply analysing the extracts where the proteinases 
were translated via western blot against eIF4GI. In contrast with self cleavage, we observed 
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that the cleavage of eIF4GI does not occur at similar rates for HRV2 and HRV14 2Apro. HRV2 
2Apro cleaves the translation factor during the first hour whilst HRV14 2Apro cleavage is only 
observed after two hours and is not complete after five hours. Figure 16 shows an 
immunoblot against eIF4GI of the same samples of figure 15. 
 
 
Figure 16: Immunoblot of 6% SDS-PAGE of the samples from figure 15 showing cleavage of 
eIF4GI by A) HRV2 VP1-2Apro and B) HRV14 VP1-2Apro. The proteins were detected by 
immunoblotting using the eIF4GI N-terminal antiserum (1:8000).  
 
 We compared the HRV2 and HRV14 2Apro cleavage sites with the eIF4GI cleavage 
site recognized by HRV2 2Apro. The cleavage sites of HRV2 and HRV14 are shown in table 
12. The HRV14 2Apro cleavage sites of eIF4GI and II have not been determined yet. 
However, CV and PV cleave eIF4GI at the same sequence as HRV2 2Apro (Lamphear et al., 
1993; Zamora et al., 2002). This supports the possibility that HRV14 2Apro recognizes the 
same sequence on eIF4GI. In order to determine whether the eIF4GI cleavage site can be 
recognized in the context of the polyprotein, we substituted the cleavage sequence on the 
polyprotein by the sequence recognized by HRV2 2Apro in eIF4GI. The result is presented in 
figure 17. HRV2 2Apro self-processing of the new cleavage site is slower than that of the wild 
type, but the eIF4GI cleavage sequence is well tolerated in the polyprotein context (figure 
17A). However, HRV14 2Apro is not able to recognize this sequence in the same context. The 
first indications of cleavage could only be observed 180 minutes after translation initiation 
(figure 17B). 
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Substrate 
Cleavage sites 
         P         *   P’     
       54321         1234 
HRV 2 polyprotein IITTA (850) * GPSD 
HRV14 polyprotein DIKSY (856) * GLGP 
PV1 polyprotein DLTTY (881) * GFGH 
eIF4GI TLSTR (681) * GPPR 
eIF4GII PLLNV (699) * GSRR 
 
Table 12: 2Apro cleavage sites on the respective polyproteins and eIF4G homologues. The viral 
polyprotein sequences represent the C terminus of VP1 and the N terminus of 2Apro, respectively. 
Numbers in bold indicate the positions of amino acid residues relative to the cleavage site. The 
numbers in brackets refer to the P1 residue in the polyproteins and eIF4G isoforms. The cleavage 
sites on eIF4G isoforms are the ones recognized by HRV2 2Apro (Gradi et al., 2003). 
 
 
Figure 17: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV2 and HRV14 
VP1-2Apro bearing the eIF4GI cleavage site. A) HRV2 VP1-(eIF4GI)-2Apro; B) HRV14 VP1-(eIF4GI)-
2Apro. RRLs were incubated with or without 10 ng/µl of the indicated mRNAs as described in section 
3.4.2. Samples were taken at the indicated time points after mRNA addition and protein synthesis was 
terminated by addition of unlabeled methionine and cysteine and Laemmli Sample Buffer. Aliquots 
were analyzed on SDS-PAGE for protein synthesis and thus self-processing of 2Apro. Lane 9 
correspond to the negative control (without RNA) taken at the latest time point. 
 
After observing such a different result for the two proteinases, we wanted to know in 
more detail which residues are responsible for such a difference. The cleavage sequences of 
HRV14 2Apro and eIF4GI differ significantly at the positions P3 (serine instead of lysine), P1 
(arginine instead of tyrosine) and P2’ to P4’ (ProProArg instead of LeuGlyPro) (the 
nomenclature Pn-P1-P1’-Pn’ is that of Schechter and Berger 1967). To find out which of 
these substitutions were responsible for the absence of cleavage, we decided to change the 
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eIF4GI cleavage sequence back to the HRV14 wild type by introducing one residue at the 
time. As the P1 position is known to be important in defining specificity in chymotrypsin-like 
enzymes (Brändén and Tooze, 1999), we chose to start by replacing the P1 arginine with 
tyrosine (figure 18). Indeed this substitution was sufficient to restore HRV14 2Apro self-
cleavage to almost wild type levels. 
 
 
 
Figure 18: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 VP1-2Apro 
bearing the eIF4GI cleavage site in which the P1 residue arginine was substituted by tyrosine. 
RRLs were incubated with or without 10 ng/µl of the indicated mRNAs as described in section 3.4.2. 
Samples were taken at the indicated time points after mRNA addition and protein synthesis was 
terminated by addition of unlabeled methionine and cysteine and Laemmli Sample Buffer. Aliquots 
were analyzed for protein synthesis by SDS-PAGE and thus self-processing of 2Apro. Lane 8 
correspond to the negative control (without RNA) taken at the latest time point. 
 
To see whether the tyrosine at P1 position is also crucial for recognition of the 
cleavage site in the wild type sequence, we performed the reverse experiment. Replacing the 
wild type tyrosine by an arginine gave us the construct HRV14 VP1 (Y289R) 2Apro. Figure 
19A shows that the HRV14 2Apro can no longer perform self-cleavage, even after 7 hours of 
translation. However, some non-specific protein degradation is observed after 2 hours. As 
controls, we used the constructs HRV14 VP1 (K287S) 2Apro and HRV14 VP1 2Apro L2P 
which contain a serine at P3 position and a proline at P2’ position respectively (as in the 
eIF4GI cleavage sequence). These mutations do not affect HRV14 2Apro performance 
whatsoever (figure 19B and 19C). The band seen at 30 kDa visible in figures 19B and 19C is 
an unspecific product formed by the RRL itself as it is present also in the negative control. In 
conclusion, these results show that HRV2 and HRV14 2Apro differ markedly in their specificity 
at P1. HRV2 2Apro can accept arginine at P1 whereas HRV14 2Apro cannot. 
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Figure 19: Fluorography of a 17.5% SDS-PAGE showing processing of HRV14 VP1-2Apro 
containing several substitutions at the cleavage site. A) HRV14 VP1 (Y289R) 2Apro; B)  HRV14 
VP1 (K287S) 2Apro C) HRV14 VP1 2Apro L2P. RRLs were incubated with or without 10 ng/µl of the 
indicated mRNAs as described in section 3.4.2. 10 µl samples were taken at the indicated time points 
after mRNA addition and protein synthesis terminated by addition of unlabeled methionine and 
cysteine and Laemmli Sample Buffer. Aliquots were analyzed for protein synthesis by SDS-PAGE and 
thus self-processing of 2Apro. Lanes 7 and 8 in panel A are the negative control at 60 and 420 minutes 
respectively. Lanes 8 and 6 in panel B and C respectively correspond to the negative control (without 
RNA) taken at the latest time points. 
 
The HRV14 genome is more similar to enteroviruses than to other rhinoviruses 
(Wang et al., 1998) and the cleavage site of HRV14 2Apro on the polyprotein is more related 
to PV than to other rhinoviruses (table 12). The amino acid identity between the HRV14 2Apro 
and PV1 is 47% (figure 20); the residue at position P1 is tyrosine for both proteinases (table 
12). For these reasons, we decided to replace the P1 tyrosine on PV1 cleavage site by an 
arginine and see whether the PV1 2Apro is affected as HRV14 2Apro. The pCITE PV1 VP1 
2Apro (constructed by Andreas Roetzer (Roetzer, 2004)) was modified into pCITE PV1 VP1 
(Y302R) 2Apro. Figure 21 shows that the presence of an arginine at P1 site slightly delays 
PV1 2Apro self-processing. 50% cleavage of the wild type substrate is reached between 30 
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and 60 minutes, whilst for the mutant it happens between 60 and 120 minutes. In conclusion, 
PV1 2Apro self-processing differs from that of HRV14 2Apro. 
 
 
 
Figure 20: Sequence alignment between HRV14 2Apro and PV1 2Apro. HRV 14 2Apro shares 47% 
with PV1 2Apro. Conserved residues are represented in blue.  
 
 
Figure 21: Fluorography of a 17.5% SDS-PAGE showing the processing of PV1 VP1-2Apro wild 
type (A) and a mutant containing an arginine at P1 site (B). A) PV1 VP1 2Apro wild type; B) PV1 
VP1 (Y302R) 2Apro. RRLs were incubated with or without 10 ng/µl of the indicated mRNAs as 
described in section 3.4.2. Samples were taken at the indicated time points after mRNA addition and 
protein synthesis terminated by addition of unlabeled methionine and cysteine and Laemmli Sample 
Buffer. Aliquots were analyzed for protein synthesis by SDS-PAGE and thus self-processing of 2Apro. 
Lanes 9 correspond to the negative control (without RNA) taken at the latest time point. 
 
After these observations, we used the structure of HRV2 2Apro solved by Petersen et 
al. (1999) to look for non-conserved regions that might be important for the interaction 
between the active site of the proteinase and the substrate. One of these regions is formed 
by the residues 82 to 85 (85 to 88 in HRV14 2Apro) which form one side of the substrate-
binding cleft (Petersen et al., 1999). These residues are part of a β-hairpin loop named the 
dityrosine flap that rotates and allows the proteinase to accommodate the P2 threonine in 
HRV2 2Apro (Petersen et al., 1999). We thought that this might be an important region as it is 
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in close contact with the substrate and is not conserved between HRV2 and HRV14. The 
replacement of these residues on the HRV14 2Apro that contains an arginine at P1 by the 
equivalent residues of HRV2 2Apro did not have any effect on the recognition of the substrate 
(figure 22, A to D). HRV14 2Apro is still unable to recognize the cleavage sequence and all 
the material remains unprocessed. The opposite experiment replacing the residues 82 to 85 
on HRV2 2Apro, bearing the eIF4GI cleavage sequence, by the corresponding residues of 
HRV14 2Apro also did not have any effect on the performance of the HRV2 2Apro (figure 22, E 
and F). 
 
Figure 22: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 and HRV2 
VP1-2Apro bearing several mutations on the 2Apro sequence. A) HRV14 VP1 (Y289R) 2Apro P87E; 
B) HRV14 VP1 (Y289R) 2Apro N86S P87E; C) HRV14 VP1 (Y289R) 2Apro G85E; D) HRV14 VP1 
(Y289R) 2Apro G85E N86S P87E; E) HRV2 VP1-(eIF4GI)-2Apro E84P; F) HRV2 VP1-(eIF4GI)-2Apro 
E82G. RRLs were incubated with or without 10 ng/µl of the indicated mRNAs as described in section 
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3.4.2. Samples were taken at the indicated time points after mRNA addition and protein synthesis 
terminated by addition of unlabeled methionine and cysteine and Laemmli Sample Buffer. Aliquots 
were analyzed for protein synthesis by SDS-PAGE and thus self-processing of 2Apro. Lanes 9 
correspond to the negative control (without RNA) taken at the latest time point. 
 
 Further analysis of HRV2 2Apro structure showed that the side chain of Cys101 
protrudes into the S1 pocket (figure 23). This is the site on the enzyme that recognizes the 
P1 substrate residue. At the bottom of the pocket, the presence of Glu102 provides a 
negative charge which presumably assists in accepting the positive charge of the arginine at 
position P1 (Petersen et al., 1999) (figure 23). The equivalent residues to Cys101 and 
Glu102 in HRV14 2Apro are Ala104 and Glu105, respectively. Therefore, we wanted to know 
whether the replacement of the Ala104 for a cysteine would influence the performance of 
HRV14 VP1 (Y289R) 2Apro. 
 
 
 
Figure 23: The structure of HRV2 2Apro. Ribbon diagrams of the overall structure of HRV2 2Apro. The 
single α-helix is shown in green, the β-strands of the N-terminal and C-terminal domains are shown in 
silver and deep blue, respectively. The three residues of the catalytic triad (His18, Asp35 and Cys106) 
are shown as well as the residues Cys101 and Glu102. Residues 82 to 85 are marked with a black 
rectangle.The figure was generated using the program Molscript (Kraulis, 1991) and was a kindly 
prepared by Christina Mayer. 
 
We obtained further support for investigating this residue by analysing 2Apro sequences of 
other picornaviruses. This revealed that the residue at position 101 (for HRV2 2Apro) is 
related to the residue at the P1 site (table 13). Group A rhinoviruses contain an alanine, 
phenylalanine or valine at the P1 site and always a cysteine at position 101. Group B 
rhinoviruses and all three serotypes of polioviruses have a tyrosine at the P1 site and an 
alanine at position 104 (correspondent to 101 in HRV2 2Apro). Finally coxsackie B1, B3, B4, 
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B5 and B6 viruses contain a threonine at the P1 site and a serine at position correspondent 
to 101 in HRV2 2Apro (table 13).  
 
 
 
Table 13: Occupancy of the P1 residue of the 2Apro cleavage site and residue 101 or its 
equivalent of 2Apro. The numbers refer to the residue position on the 2Apro. The P1 or equivalent 
residues are shown in bold face. The active site residue cysteine (residue 106 in HRV2 2Apro) is 
underlined. The sequence identifiers are: POLG_HRV2; POLG_HRV89; POLG_HRV14; 
POLG_POL1M AND POLG_CXB4J (Sousa et al., 2006). 
 
In the light of these relationships, we also decided to replace the Ala104 in HRV14 2Apro by 
serine. Indeed the activity of HRV14 2Apro is partially recovered in both mutants (figure 24). 
The cleavage product is observed after 1 hour of translation, in contrast with the wild type 
alanine at position 104, in which no cleavage product is observed even after 7 hours of 
translation (figure 19A). The mutant with a serine at residue 104 is more efficient than the 
mutant bearing a cysteine at the same position (compare figure 24A with figure 24B). 
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Figure 24: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 VP1-2Apro 
containing an arginine at the P1 site and a mutation in position 104. A) HRV14 VP1 (Y289R) 
2Apro A104C; B) HRV14 VP1 (Y289R) 2Apro A104S. RRLs were incubated with or without 10 ng/µl of 
the indicated mRNAs as described in section 3.4.2. 10 µl samples were taken at the indicated time 
points after mRNA addition and protein synthesis terminated by addition of unlabeled methionine and 
cysteine and Laemmli Sample Buffer. Aliquots were analyzed for protein synthesis by SDS-PAGE and 
thus self-processing of 2Apro. Lanes 9 correspond to the negative control (without RNA) taken at the 
latest time point. 
 
In an additional experiment we wanted to investigate whether the change from a 
cysteine to an alanine (and serine, like in CBV4) in position 101 (equivalent residue to 104 in 
HRV14 2Apro) in HRV2 2Apro would also affect self-processing. Figure 25 shows that the 
processing of HRV2 VP1 2Apro C101A and HRV2 VP1 2Apro C101S are not affected by these 
mutations. The activity of HRV2 2Apro remains at wild type levels. It seems that the residue at 
this position is important for the acceptance of bulky residues at the P1 site but not when the 
P1 residue has a small side chain such as alanine. 
 
 
Figure 25: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV2 VP1-2Apro 
containing a mutation in position 101. A) HRV2 VP1 2Apro C101A; B) HRV2 VP1 2Apro C101S. 
RRLs were incubated with or without 10 ng/µl of the indicated mRNAs as described in section 3.4.2. 
Samples were taken at the indicated time points after mRNA addition and protein synthesis terminated 
by addition of unlabeled methionine and cysteine and Laemmli Sample Buffer. Aliquots were analyzed 
for protein synthesis by SDS-PAGE and thus self-processing of 2Apro. Lanes 9 correspond to the 
negative control (without RNA) taken at the latest time point. 
 
4.1.2  Specific inhibition of 2Apro by zVAD.fmk and zVAM.fmk 
Recently, Deszcz et al. (2004) showed that human rhinoviruses are inhibited by the 
caspase inhibitor zVAD.fmk, which was developed to inhibit caspases (fmk binds to SH 
groups of an adjacent cysteine residue causing irreversible inhibition) (Deszcz et al., 2004).  
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The inhibitor is methylated on the aspartic acid residue so that it can cross the cell 
membrane. Once inside the cell, endogenous esterases remove the methyl group, allowing 
the compound to inhibit caspases. Rhinoviral replication is blocked due to specific inhibition 
of the 2Apro by the methylated form of zVAD.fmk. The methyl group satisfies the preference 
of HRV2 2Apro for hydrophobic residues at P1. As the aspartic acid is not accepted at this 
position by HRV 2Apro, the unmethylated form of zVAD.fmk has no inhibitory effect.  
Based on these observations, Deszcz et al. (2006) designed a new inhibitor derived 
from zVAD.fmk. The aspartate was replaced by a methionine, which had been shown to be a 
better substrate than alanine for HRV2 2Apro (Skern et al., 1991). The new compound was 
named zVAM.fmk and has no influence on caspase inhibition. Therefore, zVAM.fmk is a 
specific inhibitor of HRV 2A proteinases (Deszcz et al., 2006). It inhibits 2Apro from several 
rhinoviruses (HRV2, HRV14 and HRV16) both in vivo and in vitro as well as CVB4 in vitro.  
 We wanted to know whether this inhibitor is also effective against PV in vitro. 
Therefore, we used the pCITE vector containing the sequence of VP1 and 2Apro of PV1 
(construct from Andreas Roetzer (Roetzer, 2004)) to obtain the RNA. This RNA was in vitro 
translated in presence and absence of zVAM.fmk. In a initial time course experiment of 1 
hour, we tried to inhibit PV1 2Apro by adding 50 µM of zVAM.fmk. The inhibitor was added 10 
minutes after translation initiation; control reaction mixtures contained DMSO only, as 
zVAM.fmk is dissolved in DMSO. This concentration was shown to inhibit HRV14 2Apro 
(Deszcz et al., 2006); however, it has no effect on PV1 2Apro (figure 26A). Therefore, we 
raised the concentration of zVAM.fmk to 100 µM and 200 µM. Once again zVAM.fmk was 
added 10 minutes after initiation of protein synthesis. Figure 26B shows that zVAM.fmk has 
no effect in the self-processing of PV1 2Apro in vitro, even at concentrations as high as 200 
µM. 
 
 
 
Figure 26: 17.5% SDS-PAGE showing the inhibition of self-processing of HRV2 and HRV14 
2Apro by zVAM.fmk. A) Autoradiogram of a time course of in vitro translation of PV1 VP1 2Apro. Ten 
minutes after the start of protein synthesis, zVAM.fmk was added to a final concentration of 50 µM. 
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Samples were taken at the times indicated, and 2Apro self-cleavage from VP1 was examined. In lane 
7, translation was performed using 0.05% DMSO only, and lane 8 shows the negative control without 
RNA taken at the latest time point. B) Autoradiogram of the in vitro translation products of RNAs from 
PV1 VP1 2Apro. Ten minutes after the start of protein synthesis, zVAM.fmk was added to a final 
concentration of 200 µM, 100 µM, or 50 µM (lanes 1 to 3). After 60 min of translation, samples were 
taken and analyzed. Lane 4 shows 60 minutes translation of the RNAs without any inhibitor; 
translation was also performed in the presence of 0.2% DMSO only (lane 5) and without RNA (lane 6).  
 
4.2  Analysis of HRV14 2Apro  
4.2.1 Expression and purification 
 It was shown in section 4.1.1 that HRV14 2Apro has a different substrate specificity 
compared to HRV2 2Apro. HRV2 2Apro cleaves a substrate bearing an arginine at P1 position; 
HRV14 2Apro is unable to do so unless the residue in position 104 is a cysteine or a serine. 
Even then, the cleavage is delayed and incomplete compared to wild type levels. Another 
important difference observed was the cleavage of eIF4GI and II. eIF4GI cleavage by HRV14 
2Apro is significantly delayed compared to HRV2 2Apro (figure 16) and the same is true for 
eIF4GII (Schmid, 2002). Moreover, the susceptibility of HRV14 2Apro to the inhibitor 
zVAM.fmk seems to be different from that of HRV2 2Apro. HRV14 2Apro is more sensitive to 
zVAM.fmk in self-processing and more resistant to the inhibitor during the intermolecular 
cleavage; this is opposite to the results with HRV2 2Apro (Deszcz et al., 2006). 
To find explanations for these differences, we wished to obtain the three-dimensional 
structure of HRV14 2Apro. Therefore, we set out to clone the HRV14 2Apro C109A (the 
inactive form of the proteinase) carrying a C-terminal His tag into the plasmid pGEX-6P1, 
which contains an N-terminal GST tag (figure 27).  
 
 
Figure 27: Cloning strategy to introduce the inactive form of HRV14 2Apro carrying a His tag 
into pGEX-6P-1. pGEX-6P-1-HRV14 2Apro C109A. The ORFs were amplified with primers containing 
EcoRI (primer named TIM979) and XhoI (primer named TIM1411) restriction sites. The reverse primer 
contained also 6 histidines before two stop codons. 
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The inclusion of the His tag was based on previous results. The expression of HRV14 2Apro 
with a GST tag alone gave two products: the complete 2Apro and a truncated form which was 
lacking the C-terminus (Cencic, 2005).  We thought that by introducing an additional C-
terminal tag, we would be able to purify the intact 2Apro. The introduction of the His tag 
indeed prevented the formation of the truncated form as can be observed in figure 28B. After 
cleavage from the GST tag, there was only one band visible corresponding to the intact 
protein with the His tag. The binding of the protein to Ni2+ column showed that the His tag 
was present, and therefore that the protein was not truncated (figure 29B).   
As the pGEX-6P1 vector is under control of the tac promoter, we used the bacterial 
strain JM101 for the expression. These cells contain the lacIq gene that encodes a repressor 
protein which binds to lac operator sequences and blocks transcription of down-stream 
sequences. However, the lacIq gene product dissociates from the lac operator in the 
presence of IPTG (Amann et al., 1988). The optimal conditions to express this protein were 
0.1 mM of IPTG and incubation at 16°C for 5 hours (figure 28A). The volume of bacterial 
culture was 2 litres. 
 
 
 
Figure 28: Coomassie stained SDS-PAGE (10% (A) and 15% (B) polyacrylamide) of the 
expression of HRV14 2Apro-GST-His (A) and the protein after incubation with PreScission 
proteinase (Amersham) (B). Protein standards in kDa are shown in line M. A) T: total fraction; I: 
insoluble fraction; S: soluble fraction. The expression was carried out at 16°C with 0.1 mM IPTG for 5 
hours. Lanes 1 to 3 show the uninduced samples, lanes 4 to 6 the induced samples. 2µl of each 
sample were loaded on the gel (0.02% of the sample total volume). B) 40 units of PreScission 
proteinase (Amersham) were added to the soluble fraction and incubated with glutathione-sepharose 
beads. Lane 1 shows the beads after washing; lanes 2 to 4 show the collected supernatants with the 
HRV14 2Apro-His. 10µl of each sample were loaded (1% of the sample total volume).  
 
After binding and cleavage from the glutathione beads (figure 28B) in buffer A, the fractions 
were pooled and dialysed against phosphate buffer (500 mM NaCl, 20 mM Na-phosphate pH 
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7.4) according to the manufacturer of the His Trap FF 1ml column (Amersham Biosciences) 
instructions. Unfortunately, the protein precipitated in the new buffer. 
We repeated the expression using the same conditions described above and 
obtained similar results. However, this time we loaded the sample on the His Trap FF 1ml 
column (Amersham Biosciences) without changing the buffer. The column was equilibrated 
with Binding Buffer (50 mM NaCl and 50 mM Tris-HCl pH 8.0) and the sample was eluted 
with Elution Buffer (50 mM NaCl, 50 mM Tris-HCl pH 8.0, 500 mM imidazole) (figure 29A). 
However, the DTT present in the sample (which was diluted in 50mM Tris-HCl pH 8.0, 50 
mM NaCl, 1mM EDTA 5 mM DTT and 5% glycerol) was enough to alter the column 
properties (its colour changed from light green to dark brown) and most of the protein did not 
bind to the column. Nevertheless, we examined the fractions and pooled those from lanes 3 
to 7 (figure 29B) and stored them at 4°C.  
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Figure 29: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 
ml (Amersham). The UV units are presented in micro-arbitrary units and each fraction corresponds to 
2 ml. B) Coomassie stained 15% SDS-PAGE of the fractions collected. Lane 1 shows the soluble 
fraction before loading the column (3µl of 12 ml) and lanes 2 to 7 show the fractions collected (10µl of 
2ml). Protein standards in kDa are shown in line M.  
 
After two days at 4°C, the protein had however once again precipitated. To verify the 
reasons for the precipitation, we dialysed the sample overnight against buffer A at pH 9.0, at 
4°C. This was sufficient to re-dissolve the protein. Therefore, we decided to use buffers at pH 
9.0 for future purifications. 
 For the next purification, we expressed 8 litres of bacterial culture under the same 
conditions described above, except that the buffer used to dissolve the pellet was 50 mM 
NaCl and 50 mM Tris-HCl pH 9.0. The major part of the expressed HRV14 2Apro was 
insoluble (figure 30A). However, we incubated the soluble fraction with glutathione-
sepharose beads (1 mL of beads per litre of culture) and found a high amount of fusion 
protein. Figure 30B shows the amount of HRV14 2Apro cleaved from 1 mL of beads.  
 
 
 
Figure 30: Coomassie stained 12.5% SDS-PAGE of the expression of HRV14 2Apro-GST-His (A) 
and the protein after incubation with PreScission protease (Amersham) (B). A) T: total fraction; I: 
insoluble fraction; S: soluble fraction. The expression was carried out at 16°C with 0.1 mM IPTG 
overnight. Lanes 1 to 3 show the uninduced samples; lanes 4 to 6 the induced samples; 1.5µl of the 
samples was loaded (0.01% of the sample total volume). B) 40 units of PreScission protease 
(Amersham) were added to the soluble fraction and incubated with glutathione-sepharose beads. 
Lane 1 shows the beads after washing; lanes 2 to 4 show the collected supernatants with the HRV14 
2Apro-His. 10µl of the samples were loaded (1% of the sample total volume). Protein standards in kDa 
are shown in line M. 
 
After pooling all the fractions, we had a final volume of 24 mL of protein solution which were 
loaded on a His Trap FF 1ml column (Amersham Biosciences), previously equilibrated with 
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the same buffer in which the protein was ressuspended. The elution buffer contained 50 mM 
NaCl, 50 mM Tris-HCl pH 9.0 and 500 mM imidazole. Figure 31A shows the chromatogram 
of the purification and the protein eluted from the column. 
 
 
 
Figure 31: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 
ml (Amersham). The UV units are presented in micro-arbitrary units and each fraction corresponds to 
2 ml. B) Coomassie stained 12.5% SDS-PAGE of the fractions collected. Lane 1 shows the 
soluble fraction before loading the column (3µl of 24 ml); lane 2 the flow-through; lane 3 the collected 
waste fraction and lanes 4 to 6 show the fractions collected (10µl of 2ml), which correspond to the 
fractions A2 to A4 from the peak observed on the chromatogram. Protein standards in kDa are shown 
in line M.  
 
The fractions from lane 4 to 6 were pooled, concentrated to 2 mL and injected on a HiLoad 
26/60 Superdex prep grade column (Amersham Biosciences) for separation by gel filtration. 
As figure 32B shows, most of the protein is eluted with the flow through, which corresponds 
to peak 1 of figure 32A.  
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Figure 32: A) Chromatogram of gel filtration performed on a superdex 26/60 column. The UV 
units are presented in micro-arbitrary units and each fraction corresponds to 2 ml. B) Coomassie 
stained 12.5% SDS-PAGE of the fractions collected. Lane 1 shows the sample before loading the 
column (10µl of 2ml); lanes 2 to 5 show the fractions of peak 1 of the chromatogram; lanes 6 to 9 
show the fractions peak 2 (10μl of 2 ml). Peaks 3 and 4 had no protein (data not shown). Protein 
standards in kDa are shown in line M.  
 
However, peak 2 (figure 32A) contained some highly purified protein. After pooling the 
samples from lanes 6 to 9 (figure 32B), they were concentrated from 10 ml to 400 µl. The 
final concentration was 2,83 mg/ml (figure 33). 
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Figure 33: Coomassie stained 12.5% SDS-PAGE of the concentrated HRV14 2Apro-His.  Protein 
standards in kDa are shown in line M. The amount of loaded protein was 2 µg. 
 
As the protein was very pure, we decided to proceed with the preliminary experiments 
for crystallization. The first step consists in the determination of the melting temperature of 
the protein, which gives information on the folding state of a protein (Yeh et al., 2006). For 
that, a fluorescent dye, which is sensitive to the nature of the solvent in which it is diluted, is 
mixed with the protein. The dye is non-fluorescent in a hydrophilic environment and 
fluorescent in a hydrophobic environment (Yeh et al., 2006). The protein is mixed with the 
dye and the temperature of the mix is constantly increased. When the protein reaches its 
melting point, it starts to unfold and consequently exposes the hydrophobic residues, which 
trigger the dye to emit fluorescence allowing a simple determination of the melting 
temperature. A typical melting temperature curve presents a sigmoid shape, from which is 
possible to determine the melting temperature of the tested sample (figure 34). 
 
 
 
Figure 34: Determination of the melting temperature of a protein. A) Graphic showing a typical 
melting temperature curves of a purified protein.  B) Graphic showing the derivative of (A) indicating 
that the melting temperature is about 40°C. Each line represents a different dilution of protein and dye. 
Data obtained from the N2B/3 proteinase from tick-born encephalitis virus, provided by Martina Kurz 
and Zhu Junping. 
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The purified HRV14 2Apro was mixed with the SYPRO Orange dye (Invitrogen) in several 
dilutions. The melting temperature was measured in a real-time PCR machine (Biorad) using 
a single cycle from 20°C to 95°C in which the temperature was increased 1°C every 30 
seconds. However, the final graphic shows a decrease in fluorescence. This indicates that 
the HRV14 2Apro is unstructured at room temperature, most likely aggregated (figure 35).  
 
 
 
Figure 35: Graphic showing the melting temperature curve of HRV14 2Apro-His. Each line 
represents a different dilution of protein and dye (see section 3.5.10, table 11 for the setup of the mix 
of protein with SYPRO). 
 
The next step was to change the strategy to increase further the expression whilst 
reducing the purification steps by removing the GST tag. HRV14 2Apro C109A was amplified 
and introduced together with a His tag in the pET11d vector using the restriction sites NcoI 
and BamHI (figure 36). This plasmid was then transferred to the bacteria strain 
BL21(DE3)LysS. These cells carry a chromosomal copy of the T7 RNA polymerase gene 
under control of the lacUV5 promoter, which make them suitable to express genes cloned in 
appropriate T7 expression vectors such as pET11d. Additionally, this strain of BL21 cells 
encodes the T7 lysozyme, an inhibitor of T7 RNA polymerase. The expression of this 
inhibitor suppresses basal expression of T7 RNA polymerase prior to induction (Studier, 
1991). 
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Figure 36: Cloning strategy to introduce the inactive form of HRV14 2Apro carrying a His tag 
into pET11d. pET11d-HRV14 2Apro C109A His. The ORFs were amplified with primers containing 
NcoI (primer named TIM1546) and BamHI (primer named TIM1547) restriction sites. TIM1547 
contains also 6 histidines before two stop codons. 
 
We tested several temperatures, concentrations of IPTG and times of incubation. The 
conditions which gave the highest amount of soluble protein turned out to be an overnight 
incubation 1 of litre of bacterial culture at 16°C with 0.03 mM IPTG (figure 37, compare lanes 
3, 6 and 9). 
 
 
 
Figure 37: Coomassie stained 12.5% SDS-PAGE of the expression HRV14 2Apro-His.  T: total 
fraction; I: insoluble fraction; S: soluble fraction. The expression was carried out at 16°C with 0.01 and 
0.03mM IPTG overnight. Lanes 1 to 3 show the uninduced samples; lanes 4 to 6 the induced samples 
with 0.01mM IPTG; lanes 7 to 9 show the induced samples with 0.03mM IPTG. 3µl of the samples 
was loaded (0.005% of the sample total volume). Protein standards in kDa are shown in line M.  
 
The bacterial pellet was dissolved in 30 mL of 50 mM NaCl and 50 mM Tris-HCl pH 9.0 and 
loaded on a His Trap FF 1ml column (Amersham Biosciences) pre-equilibrated with the 
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same buffer. The protein was eluted with 50 mM NaCl, 50 mM Tris-HCl pH 9.0 and 500 mM 
IPTG. Figure 38 shows the results. 
 
 
 
 
Figure 38: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 
ml (Amersham). The UV units are presented in micro-arbitrary units and each fraction corresponds to 
2 ml. B) Coomassie stained 12.5% SDS-PAGE of the fractions collected. Lane 1 shows the 
soluble fraction before loading the column (3µl of 60 ml); lane 2 the soluble fraction after loading the 
column (flow through) (3µl of 60 ml) and lanes 3 to 18 show the fractions collected (10µl of 2ml) of 
peak 1 (see (A)). Protein standards in kDa are shown in line M. C) Coomassie stained 12.5% SDS-
PAGE of the concentrated (pool of lanes 9 to 13 of panel B) HRV14 2Apro-His. 
 
The fractions from lanes 9 to 13 of figure 38B were pooled and concentrated to 900 µl (figure 
38C) and loaded on a HiLoad 26/60 Superdex prep grade column (Amersham Biosciences) 
for separation by gel filtration (figure 39). Once again, most of the protein is eluted with the 
flow through (peak 1, figure 39A); this probably indicates aggregation. For this reason, we did 
not proceed to the melting temperature determination. Optimization of the purification method 
is thus necessary. One possibility is to increase the concentration of NaCl in future 
purifications. Unfotunately, these experiments fall out of the time frame of this project. 
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Figure 39: A) Cromatogram of gel filtration performed on a superdex 26/60 column. The UV 
units are presented in micro-arbitrary units and each fraction corresponds to 2 ml. B) and C) 
Coomassie stained 12.5% SDS-PAGE of the fractions collected. Lane 1 on panel B shows the 
sample before loading the column (10µl of 900 µl); lanes 2 to 7 show the fractions of peak 1 of the 
chromatogram; lanes 1 to 9 of panel C show the fractions corresponding to peak 2 of the 
chromatogram (10μl of 2 ml).  Protein standards in kDa are shown in lines M.  
 
4.3  Analysis of eIF4GII 
4.3.1  Expression and purification 
 eIF4G is a scaffolding protein which brings the capped mRNA and the ribosome 
together. This protein is cleaved during picornaviral replication (Etchison et al., 1982) leading 
to the so called cellular translation shut-off, allowing the viruses to take over the ribosome 
and express their own proteins as the viral translation is cap independent. eIF4G has two 
isoforms, eIF4GI and eIF4GII, which have the same function in the cell (Gradi et al., 1998a). 
The translation shut-off, induced by the viral infection is only achieved when both isoforms 
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are cleaved (Svitkin et al., 1999). There is evidence that the cleavage of eIF4G by 
picornaviral proteinases is more efficient in the presence of the initiation factor eIF4E. It is 
believed that eIF4E may induce a change in the eIF4G structure that is better recognized by 
the viral proteinases (Gross et al., 2003; Haghighat et al., 1996; Hershey et al., 1999). To 
investigate this idea, we set out to obtain structural data on the interaction of eIF4G with 
eIF4E and picornaviral proteinases. We began with eIF4G, selecting a fragment of eIF4GII 
comprising the residues 445 to 744 that contain the cleavage sites recognized by HRV2 2Apro 
and FMDV Lbpro, the binding site for eIF4E and the binding sites for FMDV Lbpro and HRV2 
2Apro. 
We started by using the plasmid pGEX-6P1- eIF4GII (aa 445 to 744) with the flag tag 
(a gift from A. Gradi, figure 40).  
 
 
 
Figure 40: Scheme for the pGEX-6P1-eIF4GII-(aa 445-744)-FLAG vector provided by A. Gradi. 
 
JM101 cells were transformed with the plasmid and the expression of eIF4GII was induced 
with IPTG. We tested several expression conditions, using different temperatures, different 
concentrations of IPTG and different times of incubation. Figure 41 shows a typical 
expression at 37°C with 0.1 mM IPTG for 5.5 hours. We never saw a clear over-expression 
of the protein. Nevertheless, we incubated the soluble fraction with glutathione-sepharose 
beads and we could observe that the protein which has a molecular weight of 64 kDa, was 
present (figure 41, lane 7). 
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Figure 41: Coomassie stained 10% SDS-PAGE of the expression eIF4GII-GST aminoacids 445 
to 744. Lane M shows the protein standards in kDa. T: total fraction; I: insoluble fraction; S: soluble 
fraction. The expression was carried out at 37°C with 0.1 mM IPTG for 5.5 hours. Lanes 1 to 3 show 
the uninduced samples; lanes 4 to 6 the induced samples; lane 7 the soluble fraction after incubation 
with glutathione-sepharose beads (B) and line 8 shows the supernatant after incubation with the 
beads (S); the volume loaded was 5µl (0.02% of the sample total volume).  
 
After expressing 4 litres of bacterial culture using the same conditions used for the 
experiment illustrated in figure 41, we incubated the soluble fraction with 1 ml of glutathione 
beads per litre of expression and subsequently incubated the same beads (after washing) 
with preScission proteinase. Figure 42 shows a coomassie stained gel with 0.3% of the total 
amount of eIF4GII (3 ml) after cleavage from the glutathione beads. The eIF4GII fragment 
has a molecular weight of 37 kDa after cleavage. GST tag remained in the beads (lane 1). 
The higher molecular weight bands show uncleaved material and the bacterial chaperonin 
GroEL which was identified by mass spectroscopy and will be mentioned later (lanes 2 to 4). 
 
 
 
Figure 42: Coomassie stained 10% SDS-PAGE of eIF4GII aminoacids 445 to 744 after cleavage 
from the GST-tag. 40 units of PreScission protease (Amersham) were added to the soluble fraction 
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incubated with glutathione-sepharose beads. Lane 1 shows the beads after washing with the GST tag; 
lanes 2 to 4 show the collected supernatants with the 37 kDa fragment corresponding to eIF4GII, 
uncleaved material and the bacterial chaperonin GroEL which was identified by mass spectroscopy. 
Protein standards in kDa are shown in line M. 10µl of the samples were loaded (1% of the sample total 
volume).  
 
The samples from lanes 2 to 4 were pooled and concentrated to 2 ml and loaded on a 
HiLoad 26/60 Superdex prep grade column (Amersham Biosciences) for gel filtration (figure 
43A) 
 
 
 
Figure 43: A) Chromatogram of gel filtration of the sample from figure 42, after being 
concentrated to 2 ml, performed on a superdex 26/60 column. The UV units are presented in 
micro-arbitrary units and each fraction corresponds to 2 ml. B) Coomassie stained 10% SDS-PAGE 
of the fractions corresponding to peak 1 and 2 respectively. Protein standards in kDa are shown 
in line M. 10µl of the samples were loaded (0.5% of the sample total volume).  
 
The fractions of lanes 12 to 15 and lanes 16 to 18 of figure 43B were pooled and 
concentrated to 700 µl and 1.5 ml, respectively. Figure 44 shows a coomassie stained gel 
with 5µl of each sample after concentration.  
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Figure 44: Coomassie stained 10% SDS-PAGE of the pooled and concentrated fractions of 
eIF4GII.  Lane 1 corresponds to lanes 12 to 15 of figure 43B and lane 2 to lanes 16 to 18 lanes of 
figure 43B. Protein standards in kDa are shown in line M. 5µl of the samples were loaded (0.7% (line 
1) and 0.3% (line 2) of the sample total volume).  
 
As the amount of protein obtained (0.8 mg) and the purity were not sufficient, we decided to 
change the strategy of purification and use an insect cell purification system. We used the 
Sf9 cells and the Bac-to-Bac Baculovirus Expression System from Invitrogen.  
 First, we started by introducing the GST tag (amplified from the vector pGEX-6P1) 
into the pFastBac vector using the restriction sites BamHI and EcoRI (figure 45A). Secondly 
we introduced the eIF4GII, amplified from the pGEX-6P1- eIF4GII (aa 445 to 744) flag tag, 
using the restriction site for EcoRI, on both 5’ and 3’ ends. The vector was digested with 
EcoRI and the eIF4GII DNA was introduced at the C-terminus of the GST tag (figure 45B).  
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Figure 45: Cloning strategy to introduce the GST tag and eIF4GII residues 445 to 744 into the 
pFastBac vector (Invitrogen). A) The tag was amplified from the pGEX-6P-1(Amersham Pharmacia 
Biosciences) vector with the primers TIM1336 and TIM1337  and introduced into pFastBac. B) The 
eIF4GII, amplified with the primers TIM1353 and TIM1354, was then introduced in the EcoRI 
restriction site. 
 
The new vector pFastBac-GST-eIF4GII aa 445 to 744 was used to transform DH10Bac™ 
cells from Bac-to-Bac Baculovirus Expression System. These cells contain enzymes that 
help to integrate the construct into the baculovirus genome. After confirming that the 
integration of the eIF4GII with the GST tag was correct, the DNA was used to infect Sf9 cell 
which are susceptible to the infection by the baculovirus of the system used. As the 
baculovirus replicates, it also expresses the protein added to its genome. After the virus has 
induced cell lysis, the expressed protein can be collected from the supernatant. 
Figure 46 shows a western blot performed after the infection of 6 x 105 Sf9 cells in 24 well 
plates. After 48 hours of infection with an MOI of 5, the expression of eIF4GII-GSTtag is 
evident (figure 46B). 
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Figure 46: immunoblot of 12.5% SDS-PAGE showing the expression of eIF4GII-GST. The 
proteins were detected by immunoblotting using the GST antiserum (1:1000). The left panel shows the 
non infected samples and the right panel the infected ones. Samples were collected at 24, 48, 72 and 
96 hours post infection (lanes 1, 2, 3, 4, respectively). 10µl of the samples plus 10 µl of Laemli sample 
buffer were loaded (3.3% of the sample total volume).  Protein standards in kDa are shown on the left 
side of the panels. 
 
The experiment was scaled up to 200 ml suspension culture with a cell density of 
2x106 Sf9 cells/ml (see section 3.5.1.3.4). The supernatant was collected after 48 hours and 
incubated with glutathione-sepharose beads, after which the eIF4GII was cleaved from the 
GST tag with PreScission proteinase (Amersham) and eluted from the beads (figure 47). 
Surprisingly, the gel did not show a band with the predicted size of the eIF4GII fragment (37 
kDa). The slowest migrating band (above 37 kDa) appearing in lane 3 of figure 47 was too 
large to be eIF4GII after cleavage. As the size of this band is similar to that of PreScission 
proteinase (data not shown) we assumed that it is the PreScission proteinase itself. 
 
 
Figure 47: Coomassie stained 10% SDS-PAGE of eIF4GII after incubation with PreScission 
protease (Amersham). Lanes 1 and 2 show purified GST (5 and 3 µl respectively); lane 3 shows the 
supernatant collected from the glutathione-sepharose beads (5µl of 1 ml). Protein standards in kDa 
are shown in line M. 
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Figure 47 (lane 3), also shows three bands at the length of the GST tag. The upper 
band running at about 25 kDa in lane 3 is the GST tag (compare size with purified GST in 
lanes 1 and 2). We think that the remaining two bands can be eIF4GII after PreScission 
cleavage. We considered this hypothesis because PreScission proteinase is itself HRV14 
3Cpro which is known to recognize Gln*Gly sequences for cleavage. The eIF4GII fragment 
that we expressed also contains the Gln*Gly sequence (red in figure 48). Although the 
adjacent residues to the Gln*Gly site are not those favoured by HRV14 3Cpro (Cordingley et 
al., 1990; Long et al., 1989), we believe that the HRV14 3Cpro which cleaved the protein from 
the GST tag could also have cleaved the expressesd eIF4GII fragment. An argument that 
support our hypothesis is that FMDV 3Cpro was shown to cleave eIF4GI in a different site 
from that expected for 3Cpro, at the sequence Glu711*Pro712 (figure 48) (Strong and 
Belsham, 2004).  
The reason why this fragment purified from Sf9 cells was cleaved whereas the same 
fragment purified from bacteria was not may indicate that the expression in eukaryotic cells 
could have introduced some post-translational modifications that affected the folding of the 
protein, making it recognizable by the HRV14 3Cpro. 
  
 
 
Figure 48: fragment of eIF4GII (residues 445 to 744) cloned in pGEX-6P1 (Amersham). Red 
marks the putative cleavage site for PreScission protease (HRV14 3Cpro) (Amersham); blue shows the 
eIF4E binding site; the orange line shows the residues important for Lbpro binding in eIF4GI and the 
red line shows the residues important for 2Apro binding in eIF4GI (Foeger et al., 2002). The cleavage 
sites for 2Apro and Lbpro are marked (Gradi et al., 2004). Finally the cleavage site of FMDV 3Cpro 
correspondent to eIF4GI is also marked (Strong and Belsham, 2004). The numbers on the left refer to 
the first residue of eIF4GII on each line. 
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Since the fragment C-terminal to the Gln*Gly sequence contains all the regions we 
are interested in, we decided to clone it in the pGEX-6P1 vector and try to express it again in 
bacteria, as this is a simpler system. The new eIF4GII fragment starts with the aminoacid 
Phe552 and ends with a His tag after the Glu744. The insert was amplified from the vector 
pGEX-6P1- eIF4GII (aa 552 to 744) flag tag introducing the restriction sites for EcoRI. Once 
again the plasmid pGEX-6P1 was digested with EcoRI and the insert was introduced after 
the 3’ end of the GST tag (Figure 49).  
 
 
 
Figure 49: Cloning strategy to introduce the fragment corresponding to the residues 552 to 744 
of eIF4GII into pGEX-6P-1. pGEX-6P-1-eIF4GII 552-744. The ORFs were amplified with the primers 
TIM1472 and TIM1354.  
 
The amount of expressed protein from pGEX-6P-1-eIF4GII 552-744 was higher than with the 
larger fragment; however the recovery after incubation with glutathione beads was still not 
high enough for structural studies (figure 50). 
 
 
 
Figure 50: Coomassie stained 10% SDS-PAGE of the expression eIF4GII-GST-His aminoacids 
552 to 744 (A) and the protein after incubation with PreScission protease (Amersham) (B). A) T: 
total fraction; I: insoluble fraction; S: soluble fraction. The expression was carried out at 20°C with 0.5 
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mM IPTG overnight. Lanes 1 to 3 show the uninduced samples; lanes 4 to 6 the induced samples; 3µl 
of the samples were loaded (0.015% of the sample total volume). B) 40 units of PreScission protease 
(Amersham) were added to the soluble fraction and incubated with glutathione-sepharose beads. 
Lane 1 shows the beads after washing; lanes 2 to 4 show the collected supernatants with the eIF4GII. 
10µl of the samples were loaded (1% of the sample total volume). The upper arrow indicates a protein 
which is systematically co-purified with eIF4GII and was identified as GroEL chaperone from E. coli by 
mass spectroscopy (excised band of lane 2). Protein standards in kDa are shown in line M. 
 
The excised band on lane 3 (figure 50B) corresponds to a protein which was systematically 
co-purified with the eIF4GII fragment. We thought that it could be a binding partner. 
Consequently, we sent it for mass spectroscopy identification. The results showed that this 
protein is the E. coli chaperone GroEL (data not shown).  
As the yield and purity of the new eIF4GII fragment were not satisfactory, we decided 
to try the expression using a different plasmid and a different bacteria strain. The chosen 
plasmid was the pET11d (Novagen) which can be expressed with the cells BL21(DE3)LysS. 
The smaller fragment of eIF4GII (aminoacids 552 to 744) with the C-terminal His tag was 
introduced into the pET11d plasmid using the restriction enzyme NcoI. The new plasmid was 
named pET11d-eIF4GII aa 552 to 744 His tag (figure 51). 
 
 
 
Figure 51: Cloning strategy to introduce the fragment corresponding to the residues 552 to 744 
of eIF4GII carrying a His tag into pET11d. pET11d-eIF4GII 552-744 His. The ORFs were amplified 
with the primers TIM1544 and TIM1545. TIM 1545 contains also 6 histidines before two stop codons. 
 
We started by optimizing the expression at small scale (25 ml of bacterial culture), 
trying several temperatures, concentrations of IPTG and times of incubation. Figure 52A 
shows that the protein is well expressed and soluble at 37°C with 0.1mM IPTG for 5 hours. 
As the band that we thought to correspond to eIF4GII runs at a higher molecular weight than 
the predicted (22.2 kDa, compare with figure 50B), we performed some experiments to 
confirm the content of this band. Figure 52B presents a western blot against the His tag 
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showing that the band above 25 kDa corresponds to the eIF4GII fragment. The reason why 
eIF4GII is only visible in the total and soluble fractions might be due to the low efficiency of 
the sonication, as the amount of protein is rather low in the insoluble fraction (figure 52A, 
lane 5).  The probe used for detection was a nickel (Ni2+) activated derivative of horseradish 
peroxidase (HRP) (HisProbe™-HRP, Pierce) prepared to detect poly-histidine-tagged 
proteins. Additionally, a sample of this band was sent for mass spectroscopy analysis, which 
confirmed that this protein is indeed the eIF4GII fragment (data not shown). 
 
 
 
Figure 52: Coomassie stained 12.5% SDS-PAGE of the expression eIF4GII-GST aminoacids 552 
to 744.  A) Lane M shows the protein standards in kDa. T: total fraction; I: insoluble fraction; S: soluble 
fraction. The expression was carried out at 37°C with 0.1 mM IPTG for 5 hours. Lanes 1 to 3 show the 
uninduced samples; lanes 4 to 6 the induced samples. 3µl of the samples were loaded (0.005% of the 
sample total volume). B) Immunoblot of 12.5% SDS-PAGE showing the expression of eIF4GII 
(induced fractions corresponding to lane 4 to 6 of figure 52A). The proteins were detected by 
immunoblotting using an anti-histidine probe: nickel (Ni2+) activated derivative of horseradish 
peroxidase (1:10,000) (HisProbe™-HRP, Pierce).  
 
The conditions chosen for expression at large scale were the same shown in figure 52A for 
the small scale. We incubated 1 litre of bacterial culture at 37°C for 5 hours with 0.1 mM of 
IPTG. The soluble fraction was loaded on a His Trap FF 1ml column (Amersham 
Biosciences) equilibrated with 50 mM NaCl, 50 mM Tris-HCl pH 8.0. The proteins were 
eluted by a gradient of imidazole (elution buffer: 50 mM NaCl, 50 mM Tris-HCl pH 8.0, 500 
mM imidazole). Figure 53A shows the result of the FPLC purification, in which one single 
peak can be observed. 10 µl of each fraction from the FPLC purification were loaded on a 
12.5% SDS-PAGE. The fractions 9 to 15, corresponding to the peak seen in figure 53A 
contain a band with the expected molecular weight for the eIF4GII fragment expressed 
(figure 53B). 
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Figure 53: A) Chromatogram of eIF4GII-His aminoacid 552 to 744 performed on a HisTrap 
column 1 ml (Amersham). The UV units are presented in micro-arbitrary units and each fraction 
corresponds to 2 ml. B) Commassie stained 10% SDS-PAGE of the fractions collected. Lane 1 
shows the total fraction before loading the column (3µl of 60 ml); lane 2 the soluble fraction before 
loading the column (3µl of 60 ml); lane 3 the flow-through and lanes 4 to 18 show the fractions 
collected (10µl of 2ml). Protein standards in kDa are shown in line M.  
 
The fractions of lanes 9 to 10 and 11 to 15, containing the eIF4GII fragment (figure 53, panel 
B) were pooled separately and dialysed against buffer A overnight (in order to remove the 
imidazole). Afterwards the two samples were concentred to 600 µl each (figure 54).  
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Figure 54: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions of 
eIF4GII.  Lane 1 corresponds to the pool of lanes 9 and 10 of figure 53B and lane 2 corresponds to 
the pool of lanes 11 to 15 of figure 53B. Protein standards in kDa are shown in line M. 2µl of 600 µl of 
the samples were loaded).  
 
These two samples were pooled together to a total volume of 1.2 ml and loaded on a HiLoad 
26/60 Superdex prep grade column (Amersham Biosciences) for separation by gel filtration 
(figure 55A). The fractions corresponding to the peaks 1 and 2 are shown in figure 55B.  
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Figure 55: A) Chromatogram of gel filtration performed on a superdex 26/60 column. The UV 
units are presented in micro-arbitrary units and each fraction corresponds to 2 ml. B) Commassie 
stained 10% SDS-PAGE of the fractions collected. Lane 1 shows the sample before loading the 
column (10µl of 1.2 ml); lanes 2 to 9 show the fractions of peak 1 of the chromatogram; lanes 10 to 18 
show the fractions correspondent peak 2 of the chromatogram (10μl of 2 ml).  Protein standards in 
kDa are shown in line M.  
 
Fractions of lane 13 to lane 16 of figure 55B (a total amount of 8 ml) were pooled and 
concentrated to 600 µl. The concentration of the purified protein was 2.4 mg/ml; a sample of 
5 µg was examined for purity on a polyacrilamide gel (figure 56). 
 
 
Figure 56: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions 13 to 
16 of eIF4GII of figure 55B.  Protein standards in kDa are shown in line M. The amount of sample 
loaded was 5 µg. 
  
The next step was to determine the melting temperature of the purified eIF4GII, in 
order to find the best conditions to set up the crystals. For that SYPRO Orange dye 
(Invitrogen) was used. As explained in section 4.2.1, this dye is sensitive to the nature of the 
solvent in which it is diluted when it is mixed with the protein. The determination of the 
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melting temperature of a protein can give information about its folding status. Unfortunately, 
the eIF4GII fragment tested seems to be unstructured in solution, as the results show no 
melting temperature curve (figure 57). For comparison with a typical melting curve of a 
correctly folded protein see figure 34. 
 
 
 
Figure 57: Melting temperature curve of eIF4GII-His amino acids 552 to 744. Each line represents 
a different dilution of protein (see section 3.5.10, table 11 for the setup of the mix of protein with 
SYPRO). 
 
 4.3.2  NMR analysis 
 An alternative way to determine protein structures by crystallography is nuclear 
magnetic resonance (NMR). NMR is based on a quantum mechanical magnetic 
phenomenon of the nucleus named spin (I). The hydrogen nucleus (1H) has a half integer 
spin and is the most important nucleus to study proteins. Other relevant nuclei for biological 
studies are 15N, 13C and 31P. The “spinning” nucleus can be pictured as a rotative positive 
charge which generates a magnetic field. Without an external magnetic field, the direction of 
the axis of spin is random; however, when such a field is present each “nuclear magnet” 
adopts a specific orientation. For nuclei with spin -1/2, two orientations are possible, a low 
energy state (α) and a high energy state (β).  α aligns in the same direction as the applied 
field and β aligns at the opposite direction. The spins in the α state are slightly more 
abundant than the spins in the β state, which makes NMR an intrinsically insensitive 
technique. 
The NMR phenomenon corresponds to transition between α and β energy levels and 
it occurs when an appropriate amount of energy (resonance) is supplied to the system by a 
pulse of electromagnetic radiation at a frequency of vL. The higher the external magnetic 
field, the greater is the difference in energy between the α and β states and the more 
sensitive is the NMR experiment. Despite the intrinsic insensitivity of the technique, NMR is 
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very useful when applied to small molecules. It gives information on molecular dynamics, 
protein folding and intra and intermolecular interactions. Additionally, the method is carried 
out in solution, resembling the native physiological conditions. 
  
Chemical shift 
The electrons that surround the nucleus “shield” it from the static field, B0 as they also 
interact with the magnetic field. The electron density is directly proportional to the shielding, 
so the higher the electron density the lower is the resonance frequency. Thus, nuclei that are 
bonded to electronegative atoms experience NMR transitions of higher energy. The 
resonance frequencies, in NMR are expressed in independent manner of B0: the chemical 
shift scale (δ). 
δppm = (vobs – vref) / v0 * 106 
 
in which vobs is the frequency of a resonance of interest, v0 is the spectrometer frequency and 
vref is the frequency of a signal from a chosen reference compound. The units of chemical 
shift are dimensionless and expressed in parts per million (ppm). This allows NMR spectra 
from spectrometers with different operating frequencies to be compared directly. The 
reference substance is dependent on the nucleus under analysis. It was conventioned that 
the ppm scale should show the zero at the right side. An “upfield” shift corresponds to an 
increase in nuclear shielding and a lower resonance frequency. Chemical shifts in proteins 
are influenced by noncovalent interactions, namely hydrogen bonding and proximity and 
relative orientation of carbonyl groups and aromatic rings. These interactions can give 
information of the local environment of a nucleus in a protein and are a function of the 
secondary and tertiary structures. For example, upfield shifts are observed in α-helices 
whereas β-sheets are shifted to lower fields. 
 Chemical shifts are very sensitive to a large number of variables such as structural, 
electronic, magnetic and dynamic. Chemical shifts give a tremendous amount of information 
on the system under investigation. For instance, large shift dispersion indicates that a protein 
is well structured and suitable for further measurements and calculations. Figure 58 shows a 
typical spectrum of a well structured protein. In this case, the shift dispersion is between 1 
and 7 ppm. 
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Figure 58: Superimposition of 1H-15N-HSQC of 15NLbproC51A and 1H-15N-HSQC of 15N/13C 
LbproC51A. The 15N labelled sample is drawn in blue and the double labelled one in red. The two 
spectra are shifted somewhat to make the corresponding peaks better visible. Thus, they lie next to 
and not on top of each other. Figure taken from R. Cencic PhD thesis, 2005. 
 
Relaxation time 
 Another important concept is the relaxation time. Relaxation corresponds to a 
process by which the excited spin state, responsible for the NMR signal, returns to 
equilibrium. Two relaxation mechanisms can be observed: longitudinal relaxation (T1) which 
measures the exchange of a spin excess of energy with the surroundings and how difficult 
the process is; and transversal relaxation (T2) which measures how efficient is the exchange 
of energy between spins. An isolated nuclear spin would present rather long relaxation times; 
however, within molecules, relaxation can be induced by exchange of energy with the 
surrounding or other spins in the same molecule. The relaxation rates are specifically related 
to molecule motion and are very important to study molecular dynamics. 
In order to begin the determination of the NMR structure of eIF4GII, we expressed the 
protein in minimal medium containing 15N labelled ammonium chloride as the sole source of 
nitrogen. The conditions of the expression were the same used to express pET11d-eIF4GII 
aa 552 to 744 His tag, and the plasmid was the also the same. Figure 59 shows the FPLC 
chromatogram after purification on the His Trap FF 1ml column (Amersham Biosciences) and 
the fractions correspondent to the peaks observed. 
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Figure 59: A) Chromatogram of eIF4GII-His aminoacid 552 to 744 performed on a HisTrap 
column 1 ml (Amersham). The UV units are presented in micro-arbitrary units and each fraction 
corresponds to 2 ml. B) and C) Commassie stained 10% SDS-PAGE of the fractions collected. 
Lane 1 on panel B shows the soluble fraction before loading the column (3µl of 60 ml); lane 2 the flow-
through and lanes 3 to 9 and 1 to 4 of panel C show the fractions collected (10µl of 2ml). Protein 
standards in kDa are shown in line M.  
 
Fractions of lines 1 to 4 of figure 59C (8 ml) were pooled and concentrated to 250 µl (figure 
60). The concentration of the protein is 150 µM. This concentration is far form optimal as the 
measurements are normally done at concentrations higher than 1 mM. Nevertheless, we 
decided to perform a preliminary measurement. As for NMR experiments the proteins do not 
need to be highly pure, we did not perform a gel filtration. Instead the sample was directly 
measured. 
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Figure 60: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions of 
eIF4GII.  Protein standards in kDa are shown in line M. 2 µg of protein were loaded. 
 
The measurements were done by Georg Kontaxis (MFPL). The measurements were 
done at 25°C with 5% D2O in buffer A (50 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM EDTA, 5 
mM DTT, 5% glycerol) in a 800 MHz Varian Inova device. Figure 61 shows the spectrum of 
15N-eIF4GII alone in red. There is only a small 1H shift dispersion which is between 7.5 and 9 
ppm. This, as explained above, indicates that the protein is not well structured. One possible 
reason for these results is that eIF4GII might need another factor, such as eIF4E (Gross et 
al., 2003; Haghighat et al., 1996; Hershey et al., 1999) or Lbpro, to acquire a defined 
structure. We added Lbpro at a four fold excess; however, no differences were observed (blue 
spectrum, figure 61). The remaining factor to check was eIF4E and we decided to purify this 
protein to see whether this idea is correct. 
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Figure 61: Superimposition of 15N-eIF4GII (red) and 15N-eIF4GII plus FMDV Lb (blue). The 1H shift 
dispersion between 7.5 and 9 ppm indicates that the protein is not folded. 
 
4.3.3  eIF4E expression and purification 
As the attempts to crystallize and obtain the NMR structure of a fragment of eIF4GII 
(which contains the binding site for eIF4E, see section 4.3.2) were not successful, we 
decided to express and purify the mouse eIF4E. We chose the mouse isoform because it 
shares 98% identity with the human eIF4E and it was already cloned in an expression vector. 
It was shown previously that Lbpro can cleave eIF4GI more efficiently in the presence of 
eIF4E (Gradi et al., 2004). eIF4E induces a change on eIF4GI conformation that makes it 
accessible to the proteinase. For this reason, we wanted to add eIF4E to the labelled 
eIF4GII, in order to perform new NMR measurements and see whether eIF4GII acquires a 
folded structure. 
 We started the expression using the vector pET3b-meIF4EΔ27 which lacks the first 
27 amino acids at the N-terminus, making the protein more stable (a kind gift from Jerry 
Pelletier, McGill University, Montreal). It also lacks a tag. The binding sites for the cap 
structure, 4EBP and eIF4G remain in the truncated protein. The protein was well expressed 
with the conditions used (30°C with 0.1 mM IPTG for 5 hours); however, it was completely 
insoluble, under these conditions (figure 62). 
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Figure 62: Commassie stained 12.5% SDS-PAGE of the expression eIF4EΔ27.  T: total fraction; I: 
insoluble fraction; S: soluble fraction. The expression was carried out at 30°C with 0.1 mM IPTG for 5 
hours. Lanes 1 to 3 show the uninduced samples; lanes 4 to 6 the induced samples; 3.5µl of the 
samples were loaded (0.012% of the sample total volume). Protein standards in kDa are shown in line 
M.  
 
As there was a second plasmid available (gift from Regina Cencic, McGill University, 
Montreal), we decided to try to express it instead of trying other conditions with the first 
plasmid. The new plasmid is named pproExHTA-meIF4E wt which contains the complete 
sequence of the mouse eIF4E and an N-terminal His tag (figure 63).  
 
 
 
Figure 63: Scheme for the ppro ExHTA-meIF4E vector provided by Regina Cencic. 
 
Once again, we tested several expression conditions, using different media for 
expression and different buffers for the cell extracts. Figure 64 shows four different 
conditions used to express eIF4E. The expression was carried out at 16°C with 0.1 mM IPTG 
for 5 hours in all cases. The growth media and the buffers used to resuspend the pellets 
were different (see section 3.2.2 and for buffers composition section 3.5.2.1). In panel A, the 
expression was done in Terrific Broth (TB) medium and the pellet was resuspended in buffer 
A.  Panel B shows the expression in TB medium and ressuspension of the pellet in Lysis Cell 
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Buffer (LCB) buffer. In panel C the expression was carried out in Luria Bertoni (LB) medium 
and the pellet was taken in buffer A. Finally, in panel D the expression was done in LB 
medium and the pellet was resuspended in LCB buffer. The optimal procedure was 
expression in TB medium. The buffer used to resuspend the soluble fraction was buffer A. 
 
 
 
Figure 64: Commassie stained 12.5% SDS-PAGE of the expression eIF4E.  T: total fraction; I: 
insoluble fraction; S: soluble fraction. The expression was carried out at 16°C with 0.1 mM IPTG for 5 
hours. Lanes 1 to 3 show the uninduced samples; lanes 4 to 6 the induced samples; 3.5µl of the 
samples were loaded (0.35% of the sample total volume). Protein standards in kDa are shown in line 
M. A) Expression in TB medium and pellet ressuspended in buffer A; B) Expression in TB medium 
and pellet ressuspended in LCB buffer; C) Expression in LB medium and pellet ressuspended in buffer 
A; D) Expression in LB medium and pellet ressuspended in LCB buffer; E) Immunoblot of 12.5% SDS-
PAGE showing the fraction of lane 6 of panel A blotted against an anti histidine serum (HisProbe™-
HRP, Pierce) (1:10,000). 
 
As a first attempt at purification, we loaded the soluble fraction on a His Trap FF 1ml 
column (Amersham Biosciences) equilibrated with 50 mM NaCl, 50 mM Tris-HCl pH 8.0. The 
proteins were eluted by a gradient of imidazole (elution buffer: 50 mM NaCl, 50 mM Tris-HCl 
pH 8.0, 500 mM imidazole). However, eIF4E failed to bind the column (data not shown). After 
repeating the expression, we decided to use a mono Q 10/10 column (figure 65) for 
purification. 
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Figure 65: A) Chromatogram of eIF4E performed on a MonoQ 10/10 column (Amersham). The 
UV units are presented in micro-arbitrary units and each fraction corresponds to 2 ml. B) and C) 
Commassie stained 10% SDS-PAGE of the fractions collected. Lane 1 on panel B shows the 
soluble fraction before loading the column (3µl of 60 ml); lane 2 the flow-through and lanes 3 to 9 and 
1 to 4 of panel C show the fractions collected (10µl of 2ml) of peak 2. peaks 1, 3 and 4 had no protein 
with the relevant weight (data not shown). Protein standards in kDa are shown in line M.  
 
The fractions of lanes 8 and 9 of figure 65B, which had a band running at the weight 
predicted for eIF4E were dialysed against  a buffer containing 20 mM MOPS, 0.25 mM DTT, 
0.1 mM EDTA, 50 mM NaF and 100 mM KCl, 3 times one hour at 4°C. Afterwards they were 
incubated with 100µl of m7GTP beads for 3 hours at 4°C. After incubation the beads were 
washed 2 times with the same buffer and the eIF4E was eluted with a new buffer (20 mM 
MOPS, 0.25 mM DTT, 0.1 mM EDTA, 50 mM NaF and 500 mM KCl). After washing and 
elution the protein was highly pure (figure 66, lane 4). 
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Figure 66: Commassie stained 12.5% SDS-PAGE of eIF4E eluted from m7GTP beads. Lane 1 
shows 2µl (of 60 µl) of m7GTP beads after elution; lane 2 the eIF4E fraction after incubation; lane 3 
the washing buffer and line 4 the eluate containing the purified eIF4E. 10µl of 1 ml were loaded in 
lanes 2 to 4. Protein standards in kDa are shown in line M.  
 
The protein was then concentrated from 8 ml to 250 µl and quantified (100µM). Figure 67 
shows the concentrated protein (A) and an immunoblot of the same sample performed with 
an anti-histidine probe (B). This concentration is rather low for NMR experiments. 
Additionally, as it needs to be complexed with eIF4GII 15N labelled at least at a ratio of 1:1, 
the protein will be too diluted to obtain reasonable measurements. For these reasons we 
need to purify higher and more concentrated amounts of eIF4E. Then this protein will be 
used with eIF4GII 15N labelled in NMR experiments. These experiments are not presented as 
they fall out of the time frame of this project. 
 
 
 
Figure 67: eIF4E after purification and concentration. A) Commassie stained 12.5% SDS-PAGE of 
the concentrated eIF4E.  Protein standards in kDa are shown in line M. 3µg of the sample was loaded. 
B) Immunoblot of 12.5% SDS-PAGE showing the sample of panel A blotted against an anti histidine 
probe (HisProbe™-HRP, Pierce) (1:10,000). 
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4.4  Screening for HRV2 and HRV14 2Apro binding partners 
4.4.1  Expression and purification of the protein complexes 
 HRV 2Apro bind and cleave several cellular proteins such as eIF4G and cytokeratin 8 
(Foeger et al., 2002). We wanted to identify further binding partners of HRV2 2Apro and 
HRV14 2Apro in the host cell by using a modified version of the method developed by Rigaut 
et al. (1999). The tandem affinity purification (TAP) method allows the purification of protein 
complexes under native conditions, without prior knowledge of their composition. The 
proteins isolated are then identified by mass spectroscopy (MS). This method is fast and can 
be used with a relatively small number of cells. The TAP tag consists of two proteins, protein 
A of Staphylococcus aureus (15.3 kDa) and a calmodulin binding peptide (CaBP, 3.0 kDa) 
which are separated by the cleavage sequence recognized by the Tobacco Etch Virus (TEV) 
protease. Figure 68 shows a schematic representation of the method.  
 
 
Figure 68: Overview of TAP procedure (adapted from Rigaut et al., 1999). 
 
We started by introducing the TAP tag (20.5 kDa) into the expression vector pET11d 
(Novagen) using the restriction sites SmaI and NcoI. The vector was digested with NcoI; the 
TAP tag was extracted from the pBluescript vector with the restriction enzymes SmaI and 
NcoI. The introduction of the TAP tag into the vector eliminated the NcoI site on the 3’ end of 
the insert; therefore the NcoI site on the 5’ end of the tag could be used for further cloning 
(figure 69).  
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Figure 69: Cloning strategy to introduce the TAP tag into pET11d. The tag was cut from the pBS 
(PBluescript) vector with NcoI and SmaI and introduced into pET11d digested with NcoI only. 
Consequently, the SmaI and the 3’ end NcoI restriction sites were eliminated.  
 
Once the vector pET11d-TAP was ready, the inactive forms of HRV2 2Apro (16.2 kDa) 
and HRV14 2Apro (16.0 kDa), in which the active cysteine had been substituted by an 
alanine, were introduced in frame with the TAP tag. The new vectors were named pET11d-
TAP-HRV2 2Apro C106A and pET11d-TAP-HRV14 2Apro C109A (figure 70). The expressed 
proteins with the TAP tag have a size of 36.7 kDa and 36.5 kDa respectively. 
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Figure 70: Cloning strategy to introduce the inactive forms of HRV2 and HRV14 2Apro into 
pET11d-TAP. A) pET11d-TAP-HRV2 2Apro C106A. B) pET11d-TAP-HRV14 2Apro C109A. The ORFs 
were amplified with the primers TIM1333 and TIM1332 (A) and TIM1331 and TIM1332 (B) and 
introduced into pET11d digested with NcoI. The TAP tag is C-terminal. 
 
The bacteria strain BL21(DES3)LysS was used to express the plasmids described 
above. We tested several expression conditions, such as temperature, IPTG concentration 
and time of incubation. Figure 71 shows a typical coomassie stained gel of samples collected 
after expression. The conditions of expression were 1 litre of bacterial culture incubated at 
30°C with 0.5 mM IPTG for 5 hours. The expression of the TAP tag only is evident (figure 
71A), whilst the expression of the inactive HRV2 and HRV14 2Apro is not visible (figure 71B 
and 71C). 
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Figure 71: Commassie stained 10% SDS-PAGE of the expression of: A) Tap tag, B) HRV2 2Apro-
TAP and C) HRV14 2Apro-TAP. Lane M shows the protein standards in kDa. T: total fraction; I: 
insoluble fraction; S: soluble fraction. The expression was carried out at 30°C with 0.5 mM IPTG for 5 
hours. The samples were mixed with 2x Laemmli sample buffer; the volume loaded was 4µl (0.4% of 
the sample total volume).  
 
We thought that the amount of expressed proteins was not high and probably they 
were not visible in the crude extract. Therefore, we decided to incubate the soluble fractions 
with IgG beads (Amersham Biosciences) for 1 hour at 4°C, in order to remove non-specific 
proteins and concentrate the tagged proteins. As can be observed in figure 72, the 
expressed 2Apro and TAP tag were easily identified on a coomassie stained gel. The bands 
observed at above 50 kDa and 25 kDa correspond to the heavy and light chains of IgG, 
respectively. 
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Figure 72: Commassie stained 10% SDS-PAGE of the soluble fractions from the expressions of 
TAP, HRV2 2Apro-TAP and HRV14 2Apro-TAP. A) TAP and HRV2 2Apro-TAP: lanes 1, 2, 4, 5 and 6 
show the soluble fractions after incubation with IgG beads; lanes 1 and 5 were expressed at 30°C with 
0.5 mM IPTG; lanes 2 and 6 were expressed at 30°C with 1mM IPTG; lane 4 was expressed at 37°C 
with 1mM IPTG; lanes 3 and 7 are the supernatants after incubation. B) HRV14 2Apro-TAP: lane 1 
shows the total fraction of the uninduced expression (30°C, 0.5 mM IPTG); lane 2 the total fraction of 
the expressed protein; lane 3 the soluble fraction of the expressed protein; lane 4 the soluble fraction 
after incubation with IgG beads and lane 5 shows the supernatant after incubation. The samples were 
mixed with 2x Laemmli sample buffer; the volume loaded was 4µl (0.16% of the sample total volume). 
The bands observed at above 50 kDa and 25 kDa correspond to the heavy and light chains of IgG, 
respectively. Lane M shows the protein standards in kDa. 
 
The samples bound to the IgG beads were further incubated with 50 mg of HeLa cells S10 
extracts (see section 3.5.2.2) so that any putative binding partners of HRV2 and HRV14 2A 
proteinases could bind them. Subsequently, the method described by Rigaut et al. (1999) 
was used to purify any complexes.  Figure 73 shows the result after purification and protein 
precipitation. The precipitation step was necessary to remove the detergent present in the 
buffer used to elute the complexes from the calmodulin beads (Ozols, 1990). The final pellet 
was ressuspend in 50 mM of ammonium hydrogencarbonate (NH4HCO3). 
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Figure 73: Silver stained 7 to 20% SDS-PAGE of TAP (A), HRV2 2Apro-TAP (B) and HRV14 2Apro-
TAP (C). Lane M shows the protein standards in kDa. Lanes 2, 4 and 6 were incubated with 50 mg of 
HeLa cells extracts; lanes 1, 3 and 5 were not incubated (negative controls). The arrows indicate 
proteins that are not present on the negative controls. The samples were mixed with 2x Laemmli 
sample buffer; the volume loaded was 5µl (2.5% of the sample total volume). 
 
Several proteins were present only in the samples incubated with HeLa extracts (indicated by 
the arrows in figure 73) and not in the negative controls. We decided therefore to send those 
samples to be analysed by mass spectroscopy. The results are shown in appendix A. 
 
 4.4.2  Analysis of the putative binding partners 
Table 14 shows some of the proteins that were co-purified with HRV2 2Apro-TAP and 
HRV14 2Apro-TAP. We selected these proteins due to their function in the cell and due to the 
fact that other proteins with similar functions are cleaved by picornaviral 2Apro (see 1.1.8.3.4). 
We focused on ribosomal proteins, translation and transcription factors, RNA binding 
proteins and proteins involved in cell structure.  
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Identified proteins function 
eIF4GI translation 
PABP translation 
eEF1α translation 
ß-actin cell structure and integrity 
hnRNP U RNA binding protein 
S17 Ribosomal protein 
RAP74 Transcription factor 
RBAF600 Interaction with 
retinoblastoma protein 
 
Table 14: Proteins purified with the TAP method and identified by mass spectroscopy. These 
proteins were selected for further investigation due to their function in the cell. 
 
One candidate, the retinoblastoma-associated factor 600 (RBAF600), was excluded 
after literature research revealed that this factor binds calmodulin (Nakatani et al., 2005). As 
we could not obtain antibodies against ribosomal protein S17, hnRNPU protein and 
eukaryotic translation elongation factor 1 alpha (eIF1 α), they were also excluded from future 
research. Finally, we considered the protein eIF4GI, binding to HRV2 2Apro, as a positive 
control for this method (Foeger et al., 2002) as well as the PABP, which is cleaved by CVB3 
2Apro (Kerekatte et al., 1999) and PV 3Cpro (Kuyumcu-Martinez et al., 2002). β-actin was 
chosen as putative HRV 2Apro binding partner.   
 We started the analysis of the putative interaction of β-actin with HRV2 and HRV14 
2Apro by performing GST pull downs to confirm its binding to 2Apro. Figure 74 shows  ̴1 µg of 
the expressed GST tag, HRV2 2Apro C106A - GST and HRV14 2Apro C109A - GST 
expressed in JM101 cells and bound to glutathione-sepharose beads.  
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Figure 74: Commassie stained 12.5% SDS-PAGE of GST tag (lane 1), HRV2 2Apro C106A – GST 
(lane2) and HRV14 2Apro C109A – GST (lane 3). 
 
These samples were incubated with 8 µl RRL overnight at 4°C, and after elution of 
the proteins from the beads with Laemmli sample buffer, we performed western blots against 
eIF4GI, PABP and β-actin. We chose RRL to perform the incubations because these extracts 
come from mammalian cells and  contain all the proteins that we decided to test (Pelham and 
Jackson, 1976). The results of the experiment are shown in figure 75. eIF4GI and PABP bind 
to HRV2 2Apro but not to HRV14 2Apro (figure 75A and B). However, as HRV14 2Apro is known 
to cleave eIF4GI and PABP (personal communication of Luiza Deszcz), the fact that the pull-
down experiments do not show an interaction between the HRV14 2Apro and these two 
proteins could indicate that the affinity of HRV14 2Apro for PABP and eIF4GI is low or that the 
binding is reversible, as it was observed for the interaction between Lbpro and eIF4GI (Foeger 
et al., 2002). β-actin does not bind neither HRV2 2Apro nor HRV14 2Apro (figure 75C). 
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Figure 75: GST pulldown of eIF4GI (6% SDS-PAGE) (A), PABP (12.5% SDS-PAGE) (B) and β-
actin (12.5% SDS-PAGE) (C). Glutathione-Sepharose beads coated with purified GST (lane 2) and 
with GST- HRV2 2Apro and GST- HRV14 2Apro (lanes 3 and 4, respectively). Lane 1 shows the input 
loading, corresponding to 2µl of RRL. The bound proteins were detected by immunoblotting using the 
antisera of eIF4GI (1:8000), PABP (1:1000) and β actin (1:1000). Protein standards in kDa are shown 
on the left side of the panel. 
 
Although β-actin does not bind HRV2 or HRV14 2Apro, we still wanted to see whether 
this protein is cleaved by the viral proteinases, as the interaction could be too weak to be 
observed with GST-pulldown experiments. Additionally, we also tested the eIF1α for 
cleavage as we were able to obtain an antibody against it (gift from Regina Cencic). To this 
end, we incubated 8µl of RRL (promega) and 50 mg of HeLa cell extracts with 100 ng of 
HRV2 and HRV14 2Apro at 30°C (overnight with the HeLa extracts and 2 hours with the 
RRLs) and performed a western blot against β-actin and the eIF1α. PAPB was used as 
control for the cleavage by HRV 2Apro (Luiza Deszcz, personal communication). Figure 76 
shows that HRV2 2Apro is not able to cleave either β-actin or eIF1α. HRV14 2Apro is also not 
able to cleave eIF1α under the conditions used.  
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Figure 76: Immunoblot of 12.5% SDS-PAGE of β actin, PABP and eIF1 α. 50 mg of HeLa cell 
extracts or 8 µl of RRL (Promega) were incubated with 100 ng of recombinant HRV2 and HRV14 2Apro 
at 30°C during 2 hours (RRL) or overnight (HeLa extracts).  A) α-PABP (1:1000); lane 1 shows RRLs 
without HRV2 2Apro; lane 2 RRLs incubated with HRV2 2Apro. B) anti β-actin (1:1000); lane 1 shows 
RRLs without HRV2 2Apro; lane 2 RRLs incubated with HRV2 2Apro.  C) α-eIF1α (1:2000); lane 1 
shows Hela cell extracts not incubated; lane 2 HeLa cell extracts incubated without proteinases; lane 3 
Hela cell extracts incubated with HRV2 2Apro and lane 4 RRLs incubated with HRV14 2Apro. 
 
 4.4.3  Alternative approach for expression and purification of the protein 
complexes 
 The results shown above were not satisfactory. Therefore, we decided to modify the 
method. Instead of over-expressing the HRV2 and HRV14 2Apro in bacteria, we decided to 
transiently transfect human cells with the same proteinases. We used the pMZI vector, 
developed by Zeghouf et al. (2003) which was given to us by J. K. Greenblatt. This vector 
contains an ecdysone promoter and the TAP tag. The ecdysone promoter allows the use of 
the Ecdysone-Inducible Mammalian Expression System (Invitrogen). In this system we use 
ponasterone A, an analogue of ecdysone, to induce the expression of the gene cloned 
downstream of the promoter. As mammalian cells are not responsive to ecdysone or 
analogs, the basal levels of transcription are very low (Ecdysone-Inducible Mammalian 
Expression System, version E, Invitrogen). 
The inactive forms of HRV2 2Apro and HRV14 2Apro were cloned into pMZI vector 
using the restriction enzymes NdeI and XhoI, in frame with the TAP tag which is located in 
the 3’ end of the construct (figure 77). The new vectors were named pMZI-HRV2 2Apro 
C106A and pMZI-HRV14 2Apro C109A. 
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Figure 77: Cloning strategy to introduce the inactive forms of HRV2 and HRV14 2Apro into pMZI. 
A) pMZI-HRV2 2Apro C106A. B) pMZI-HRV14 2Apro C109A. The ORFs were amplified with the primers 
TIM1474 and TIM1475 (A) and TIM1476 and TIM1477 (B) and introduced into pMZI digested with 
NdeI and XhoI. The TAP tag is C-terminal. 
 
 HEK 293T cells are highly transfectable (ATCC). Therefore we chose these cells for 
this set of experiments, in which the pMZI vectors were co-transfected with the vector 
pVgRXR from the Ecdysone-Inducible Mammalian Expression System (Invitrogen). The 
transfection was done using lipofectamin 2000 from Invitrogen, following the manufacturer 
instructions. The expression was induced using ponasterone A (Invitrogen) and cell extracts 
were prepared from several time points to observe the progress of the protein expression. 
Figure 78 shows the result of the first small scale transfection (6 well plate), in which the 
expressed HRV2 2Apro-TAP and HRV14 2Apro-TAP can be observed. For the protein 
detection, we used a polyclonal antibody against HRV2 2Apro which also detects the protein A 
domain of the TAP tag. Protein A binds to the Fc region of the antibody. 
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Figure 78: immunoblot of 12.5% SDS-PAGE showing the expression of HRV2 2Apro-TAP and 
HRV14 2Apro-TAP after a small scale transfection of HEK-293T cells. The proteins were detected 
by immunoblotting using the HRV2 2Apro antiserum (1:1000). Protein standards in kDa are shown in 
line M. Lane 10 shows a positive control for the immunoblot (HRV2 2Apro-TAP). The antiserum used is 
targeting the protein A, which is part of the TAP tag.  
 
After confirming that the transfection was successful, we performed large scale 
experiments using the protocol described by Anne-Claude Gingras (see section 3.5.3.5.2). 
However, the large scale experiments did not show any expression of 2Apro; only the TAP tag 
alone is expressed (figure 79).  
 
 
 
Figure 79: Immunoblot of 12.5% SDS-PAGE showing the expression of HRV2 2Apro-TAP and 
HRV14 2Apro-TAP after transfection of 2x106 HEK-293T cells and 48 hours expression. The 
proteins were detected by immunoblotting using the HRV2 2Apro antiserum (1:1000). Lane 1 shows the 
non transfected sample; lane 2 the TAP tag; lanes 3 and 4 show HRV2 2Apro-TAP and HRV14 2Apro-
TAP respectively. Protein standards in kDa are shown in line M. The antiserum used is targeting the 
protein A, which is part of the TAP tag. 
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As the TAP tag is visible on the western blots, a possible technical error could be excluded. 
Instead, we thought of the possibility of the HRV2 and HRV14 2Apro being toxic for the cells. 
For this reason we wanted to know how cells react to other viral proteins. Can HEK 293T 
cells overexpress other 2Apro or proteinases of other viruses? To this end, we cloned the 
inactive forms of HIV 1 proteinase (provided by Petra Schlick (Schlick, 2004)), CVB4 2Apro 
(constructed by Andreas Roetzer (Roetzer, 2004)) and FMDV Lbpro (constructed by Regina 
Cencic (Cencic, 2005)) into the pMZI vector using the restriction enzymes NdeI and XhoI 
(figure 80). The new vectors are pMZI-HIV1pro D25A D125A (encodes a protein product of 
42.5 kDa), pMZI-CBV4 2Apro C110A (encodes a protein product of 37.0 kDa) and pMZI-
FMDV Lbpro C51A (encodes a protein product of 40.3 kDa).  
 
 
Figure 80: Cloning strategy to introduce the inactive forms of HIV1 protease, CBV4 2Apro and 
FMDV Lbpro into pMZI. A) pMZI-HIV1pro D25A D125A (primers TIM1518 and TIM1519). B) pMZI-
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CBV4 2Apro C110A (primers TIM1520 and TIM1521). C) pMZI-FMDV Lbpro C51A (primers TIM1522 
and TIM1523). The ORFs were introduced into pMZI digested with NdeI and XhoI. The TAP tag is C-
terminal. 
 
These plasmids were transfected into HEK 293T cells. The protein complexes were purified 
via the same methods used for pMZI-HRV2 2Apro C106A and pMZI-HRV14 2Apro C109A. The 
expression was induced for 48 hours with different concentrations of ponasterone A. Only 
pMZI-FMDV Lbpro was successfully expressed (figure 81). 
 
 
 
Figure 81: immunoblot of 12.5% SDS-PAGE showing the expression pMZI-TAP (A),  HIV 1pro-
TAP (B), CBV4 2Apro-TAP (C) and FMDV Lbpro-TAP after a large scale transfection of HEK-293T 
cells and 48 hours expression (D). The proteins were detected by immunoblotting using the HRV2 
2Apro antiserum (1:1000). Lane 1 shows the non transfected sample; lanes 2 to 6 show the induction 
with different concentrations of ponasterone A. Lane 7 shows a positive control for the immunoblot 
(HRV2 2Apro-TAP). Protein standards in kDa are shown in line M. The antiserum used is targeting the 
protein A, which is part of the TAP tag. 
 
The eluted fractions of pMZI-FMDV Lbpro and pMZI from the calmodulin beads were 
quantified and loaded on a 7 to 20% SDS-PAGE for silver staining (figure 82) and sent for 
mass spectroscopy analysis. Lbpro cleaved of the protein A (first part of the TAP tag) has a 
molecular weight of 22.8 kDa and it was not observed on the gel. The band running at 37 
kDa (figure 82, lane 2) might be glyceraldehyde-3-phosphate dehydrogenase or annexin A2, 
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according wtih the results presented in tables 20 and 21 (appendix A). Unfortunately none of 
the 28 proteins identified appeard to be a promising candidate for a binding partner. Also, the 
one the protein that is known to bind Lbpro, the eIF4GI is missing. Possibly the amount of 
purified protein complexes was not sufficient for mass spectroscopy detection. 
 
 
 
Figure 82: Silver stained 7 to 20% SDS-PAGE of TAP FMDV Lbpro-TAP. After transfection and 
expression for 48 hours in HEK-293T cells, the cells were lysed and the supernatants were purified 
using the TAP tag protocol (see section 3.5.3.5.2). The volume loaded was 15µl (3.7% of the sample 
total volume). Protein standards in kDa are shown in line M.  
 
 The new strategy for the TAP tag protocol is closer to physiological conditions. 
Although the viral proteins are still over-expressed, the interaction with the cellular 
components occurs in biological conditions where the proteins are in native conditions and 
functional. This difference from first method is an improvement as it can help to minimize the 
number of false positives. However, it is necessary to determine whether over-expression of 
picornaviral proteinases in human cells, even in their inactive forms, is harmful for the cells. 
Of all the proteinases tested, only the FMDV Lbpro was successfully expressed, though the 
results from the TAP purification failed to show any promising binding partners. Therefore, 
further experiments must be done to optimise and scale-up the method. 
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5 Discussion 
 
HRV are responsible for about 50% of the common cold. Although common cold is not 
a severe infection it has a major economic impact. It is estimated that $40 billion are spent 
every year in the United States to treat common cold (Fendrick et al., 2003). Therefore, it is 
very important to study and understand these viruses. 
There has been constant research to find a vaccine against HRV. However the large 
number of HRV serotypes makes this task very difficult as one serotype is not neutralized by 
antibodies produced against other serotype. An alternative approach is to develop antiviral 
drugs against the non-structural proteins.  
Until recently, picornaviral 3Cpro and its precursor 3CD have been seen as the main 
potential drug targets. 3Cpro is the most well studied picornaviral proteinase as it performs the 
majority of the maturation cleavages on the polyprotein. Among the inhibitors developed 
against these proteins is the rupintrivir (formerly known as AG-7088), an irreversible inhibitor of 
rhino- and enteroviruses 3Cpro (Binford et al., 2005). Rupintrivir has been tested in clinical trials 
and the results showed that this inhibitor is able to moderate the severity of the symptoms and 
reduce the viral load during infection (Binford et al., 2007). Another inhibitor similar to rupintrivir 
is “compound 1” ((E)-(S)-4-((S)-2-(3-[(5-methyl-isoxazole-3-carbonyl)-amino]-2-oxo-2H-pyridin-
1-yl)-pent-4-ynoylamino)-5-((S)-2-oxo-pyrrolidin-3-yl) pent-2-enoic acid ethyl ester), which also 
demonstrated broad-spectrum activities against several HRV serotypes tested in vitro (Patick 
et al., 2005). These inhibitors interact with conserved residues of 3Cpro suggesting efficacy 
against a broad number of serotypes (Matthews et al., 1999). 
However, as mentioned in sections 1.1.8.3.1 and 4.1.2 HRV 2Apro of picornaviruses are 
potential targets for antiviral drugs. Yet, these proteins vary greatly among the different 
serotypes. In order to develop effective inhibitors, it is of great importance to understand the 
substrate specificity of the different rhinoviral 2Apro. 
The work in this thesis covered three aspects in order to characterize two rhinoviral 
2Apro, namely the investigation of the specificity of HRV2 and HRV14 2Apro during substrate 
recognition, the expression and purification of HRV14 2Apro and the cellular initiation factor 
eIF4GII for structural studies as well a the search for new cellular binding partners of 
picornaviral proteinases. 
 
5.1 Specificity of HRV 2A proteinases 
The first part of this work was centred on determining the substrate specificity of the 
2Apro of HRV2 and HRV14. These two proteins share only 40% amino acid residues. We 
showed that HRV2 and HRV14 2Apro have different kinetics when processing eIF4GI in vitro 
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(figure 16) and we wanted to know which residues are responsible for the differences 
observed.  
We found that HRV14 2Apro is not able to process the polyprotein when the cleavage 
sequence is that of eIF4GI. In contrast, HRV2 2Apro processes a polyprotein bearing the 
eIF4GI cleavage sequence at practically wild type levels. One caveat could be that it is 
necessary to determine the sequence cleavage in eIF4GI for HRV14 and other group B 
rhinoviruses to see whether the same site is used for cleavage. However, as eIF4GI is cleaved 
by CV and PV 2Apro at the same sequence as HRV2 2Apro (Lamphear et al., 1993; Zamora et 
al., 2002), the hypothesis that HRV14 2Apro can cleave eIF4GI at the same sequence seems 
plausible. Actually, our results showed that a single modification on the cleavage sequence of 
eIF4GI was sufficient to HRV14 2Apro recognize the cleavage site. This modification was made 
at P1 position in which we replaced the arginine by a tyrosine (the residue recognized by 
HRV14 2Apro in the polyprotein). We then introduced new mutations at P3 and P2’ sites which 
also show differences among the two proteinases. The results showed that these mutations 
did not produce any effect on the performance of the protease, enhancing the significance of 
the P1 site for substrate recognition by HRV14 2Apro.  
Considering that HRV B group rhinoviruses, amongst them HRV14 2Apro, are closer 
related to enteroviruses than to group A rhinoviruses (Laine et al., 2005), we wanted to see 
whether PV1 2Apro was also unable to recognize an arginine at P1 position. We would have 
expected a result similar to HRV14 2Apro as the wild type residue at P1 position in the 
polyprotein is a tyrosine for both HRV14 and PV (table 13). Additionally, the sequence identity 
is higher between HRV14 2Apro and PV1 2Apro than between HRV14 2Apro and HRV2 2Apro 
(figure 83). Surprisingly, the outcome of this experiment was only a slight delay on the activity 
of the 2Apro. This indicates that the 2Apro specificity lies mainly in the non-conserved regions of 
the protein. 
A 
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Figure 83: Analysis of HRV2, HRV14 and PV1 2Apro amino acid sequence. A and B) Sequence 
alignments between HRV14 2Apro and HRV2 2Apro (A) and HRV14 2Apro and PV1 2Apro (B). HRV 
14 2Apro shares 40% identity with HRV2 2Apro and 47% with PV1 2Apro. Conserved residues are 
represented in blue. The alignments were done with the clustalW2 program. C) Tree based on the 
amino acid identity of HRV2, HRV14 and PV1 2Apro, showing that HRV14 2Apro amino acid 
sequence is closer related to PV1 2Apro than to HRV2 2Apro. The tree was made using the program 
jalview. 
 
In order to understand why HRV14 2Apro behaves so differently from HRV2 2Apro, we 
performed site directed mutagenesis at several sites of the proteinase sequence. Our work 
was based in amino acid sequence comparisons, among several picornaviruses, and on the 
crystal structure of HRV2 2Apro (Petersen et al., 1999). At present, this is the only HRV 2Apro 
crystal structure solved. The NMR structure of CVB4 2Apro is also available (Baxter et al., 
2006); however, we did not consider it due to the low resolution of the region surrounding the 
catalytic triad. 
One region which seemed likely to be important was the substrate binding region of 
HRV14 (Gly85, Asn86 and Pro87), identified from the equivalent residues in HRV2 (Glu84, 
Ser83 and Glu84) (Petersen et al., 1999). Figure 84 shows the position of this region (black 
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rectangle). However, changes in this region had no effect on the HRV14 2Apro mutant bearing 
an arginine at P1. Furthermore, in the reciprocal experiment, when the residues from HRV14 
2Apro were introduced into HRV2 2Apro sequence (Glu84Pro and Glu82Gly), no influence on the 
recognition of substrate by the HRV2 2Apro was observed.  
 
 
 
Figure 84: The structure of HRV2 2Apro. Ribbon diagrams of the overall structure of HRV2 2Apro 
(Same as figure 23). The single α-helix is shown in green, the β-strands of the N-terminal and C-
terminal domains are shown in silver and deep blue, respectively. The three residues of the catalytic 
triad are shown as are residues C101 and E102. Residues 82 to 85 are marked with a black rectangle. 
The figure was generated using the program Molscript (Kraulis, 1991) and was a kindly prepared by 
Christina Mayer. 
 
Further analysis of HRV2 2Apro identified the Cys101 side chain (corresponding to 
Ala104 in HRV14 2Apro) as a important residue for substrate recognition. This residue 
protrudes into the S1 pocket, the site on the enzyme that recognizes the P1 substrate residue 
(figure 84). At the end of the pocket, the presence of Glu102 provides a negative charge which 
presumably assists in accepting the positive charge of the arginine at position P1 (Petersen et 
al., 1999). Further support for the importance of Cys101 and Glu102 was obtained from the 
structure of the Streptomyces griseus proteinase B (SGPB). This enzyme is the closest related 
serine protease to picornaviral 2Apro. Interestingly, the equivalent residues in this protease to 
the ones mentioned above are Ala192 and Glu192A (Bateman et al., 2000). Bateman et al. 
(2000) found that an inhibitor with tyrosine at the P1 position bound to SGPB 10 to 20 times 
stronger than another inhibitor with arginine at P1 position. These results support the role of 
Cys101 and thus of the equivalent Ala104 in the specificity of HRV14 2Apro. Additionally, the 
residue content at position 101 (for HRV2 and correspondent residue for other picornaviruses) 
is consistent with the amino acid content at the P1 position (see table 13). Based on these 
analyses, we decided to replace the Ala104 of HRV14 2Apro, containing the arginine at P1 
position, by a cysteine and by a serine.  We were expecting that the HRV14 2Apro would 
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accept the arginine at P1 position and perform the cleavage from VP1, like HRV2 2Apro, at 
least for the mutant containing a cysteine at position 104. However, the rate of self-processing 
was far from being restored to the wild type levels. Evidently, other residues are also involved 
in recognition of the P1 residue.  Thus, the structure of HRV14 2Apro is required before 
identification of such residues can be made, given the low level of identity between HRV2 and 
HRV14 2Apro. 
In PV1 2Apro, the residue at position 104 is alanine as for HRV14 2Apro; however, the 
residue corresponding to Glu102 is a serine. This could help explain why PV1 2Apro can accept 
an arginine at P1 position, in contrast with HRV14 2Apro. However, once again, the low level of 
similarity between the two proteins renders difficult the identification of other residues involved 
in determining specificity.  
We have shown that HRV2 2Apro and HRV14 2Apro differ significantly in the specificity at 
P1 position.  It will be interesting to investigate whether these differences are related with 
differences in pathogenicity of viruses from the two genetic groups. Furthermore, these 
differences have to be taken into account when designing inhibitors. Indeed, Deszcz et al. 
(2006) reported recently a specific inhibitor for 2Apro which is active against several HRV 2Apro 
and CVB4 2Apro in vitro (see sections 1.1.8.3.1 and 4.1.2). However, zVAM.fmk inhibits 
different 2Apro to different extents. HRV2 2Apro is inhibited in the intermolecular cleavage of 
eIF4GI and not during the self-processing whilst HRV14 2Apro is affected during the self-
processing and, to a lesser extent, in the intermolecular cleavage. The sensitivity of 2Apro to 
zVAM.fmk during the intermolecular cleavage varies from the nanomolar range for HRV2 2Apro 
to the micromolar range for HRV14 2Apro. CBV4 is inhibited at intermediate levels between 
HRV2 and HRV14 2Apro. We showed that PV1 2Apro is not inhibited at the intramolecular 
cleavage. In contrast, the intermolecular cleavage as well as viral replication are inhibited by 
zVAM.fmk (K. Kirkegaard, personal communication). These results are summarised in table 
15.  
 
zVAM.fmk effect in picornaviral 2Apro and caspases activity 
Protein Polyprotein cleavage 
(intramolecular) 
Cleavage of eIF4GI 
(intermolecular) 
HRV2 2Apro 
HRV14 2Apro 
PV1 2Apro 
CVB4 2Apro 
Pro-caspase 9 
++ 
+++ 
- 
? 
- 
+++ 
+ 
+++ 
+ 
- 
 
Table 15: Summary of the effect of zVAM.fmk on the inhibition of picornaviral 2Apro. 
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In conclusion, we have shown that HRV2 and HRV14 2Apro have different specificities 
at the P1 position in the polyprotein context. Furthermore, our results showed that the residue 
in position 101 of HRV2 2Apro (104 for HRV14 2Apro) is involved in the discrimination of the 
residues accepted by these proteinases at the P1 site. These results, together with the 
structure of HRV14 2Apro, will help to understand the mechanisms of HRV 2Apro and facilitate 
the discovery of new inhibitors. 
 
 5.2 Protein purification for crystallization and NMR 
experiments 
 Rhinoviral and enteroviral 2Apro cleavage mechanisms vary at a great extent. For 
instance, it was shown that PV 2Apro cleaves eIF4G in the same manner as HRV2 2Apro 
(Cencic, 2005) and not as HRV14 2Apro, although PV is closer related to group B HRVs 
(Laine et al., 2005). Additionally, the mechanisms used by 2Apro to cleave eIF4G are still a 
matter of controversy (see section 1.1.8.3.4). 
 To better understand HRV14 2Apro mechanisms, we set out to purify and crystallize 
HRV14 2Apro. In addition, we wanted to understand the interaction of this and other 
picornaviral proteinases, such as FMDV Lbpro, with the cellular protein eIF4G. For that we 
planned to obtain a fragment of eIF4GII, containing the binding site for eIF4E and the 
cleavage sites for FMDV Lbpro and HRV2 2Apro (residues 552 to 744) for crystallization and 
for NMR experiments. Although the structures of two fragments of eIF4GI are available 
(residues 393 to 490 (Gross et al., 2003) and residues 745 to 1003 (Marcotrigiano et al., 
2001), none of these fragments contain neither binding sites nor cleavage sites for 
picornaviral proteases. 
The purification of both proteins was successful, although the expression levels were 
low and the proteins were mainly insoluble. We obtained 1.2 mg of HRV14 2Apro at a 
concentration of 2.83 mg/ml; 1.5 mg of eIF4GII at a concentration of 2.4 mg/ml and 0.25 mg 
of 15N labelled eIF4GII at a concentration of 150 µM. However, it was not possible to set 
either protein for crystallization because they appeared unstructured after purification.  
We found HRV14 2Apro to be unstable at high concentrations under pH 9.0 in the 
buffers used throughout this work, remarkably different from HRV2 2Apro which is folded and 
active at pH 8.0. The buffer contents are mainly 50 mM Tris-HCl pH 9.0 and 50 mM NaCl. 
Perhaps a higher concentration of NaCl will help HRV14 2Apro to keep its structure during the 
purification process.  
The domain of eIF4GII purified was also unstructured, both in the samples prepared 
for crystallization and in the labelled sample prepared for NMR studies. However, this 
observation was not surprising as it has been shown that the binding of eIF4E induces 
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changes in the conformation of eIF4GI (Gross et al., 2003; Hershey et al., 1999). We believe 
that eIF4E and picornaviral proteinases such as FMDV Lbpro can also introduce modifications 
in the structure of eIF4GII. Therefore, we performed a second NMR experiment in which a 
four fold excess of inactive FMDV Lbpro was added to the 15N labelled eIF4GII. Unfortunately, 
the results showed that eIF4GII was, once again, unstructured. One of the reasons could 
have been the rather low concentration of eIF4GII upon addition of FMDV Lbpro. However, we 
believe that the complex with eIF4E is of primary importance, as the formation of the 
complex eIF4GII-eIF4E seems to acquire a structure that is better recognized by picornaviral 
2Apro (Haghighat et al., 1996). To this end, we expressed and purified eIF4E to a level of 
purity and concentration sufficient to perform preliminary NMR experiments. Unfortunately, 
these experiments fall out of the time frame of this thesis. Nevertheless, we believe that the 
addition of an excess of non labelled eIF4E to 15N labelled eIF4GII will form a stable and well 
structured complex and we will be able to solve the structure of this important domain. 
However, the expression of eIF4GII probably needs to be done in eukaryotic cells, as our 
results showed that only the fragment of eIF4GII expressed in Sf9 cells was putatively 
recognized by the HRV14 3Cpro (see section 4.3.1). These results indicate that eIF4GII only 
acquires a correctly folding state when expressed in a eukaryotic system, perhaps due to 
post-translation modifications. 
 
5.3 Screening of HRV2 and HRV14 2Apro binding partners 
 Picornaviral 2Apro bind and cleave several cellular proteins. Rhinovirus and 
enterovirus 2Apro cleave eIF4G and PABP. HRV14 2Apro cleaves cytokeratin 8. PV 2Apro 
cleave TATA-box binding protein (TBP) and two nuclear pore complex (NPC) proteins, 
Nup153 and Nup62. CV 2Apro cleave dystrophin causing cardiomyopathy (Badorff et al., 
2000; Badorff et al., 1999; Foeger et al., 2002; Kerekatte et al., 1999; Park et al., 2008; 
Seipelt et al., 2000; Yalamanchili et al., 1997a).  
Despite this long list we wanted to find out whether other and yet undetected partners 
in the host cell for HRV2 and HRV14 2Apro exist. To that end, we chose the TAP method 
developed by Rigaut et al. (1999). We used a different approach in that the 2Apro were over 
expressed in E. coli and after sonication and binding to IgG beads they were incubated with 
HeLa extracts.  
Two proteins that are known to bind HRV2 2Apro were found, eIF4GI and PABP 
((Foeger et al., 2002) and Luiza Deszcz, personal communication). We considered the 
interaction of these proteins with the 2Apro as positive controls for the method. However, 
cytokeratin 8 was not found. One of the reasons for this result could have been that the 
interaction of cytokeratin 8 with HRV14 2Apro is very weak or that the expression levels of this 
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protein is below the limit of sensitivity of the detection method used. The amount of total 
protein extract was very high and proteins that are highly expressed can mask other proteins 
that have very low expression levels.  
We selected some proteins co-purified with the HRV2 and HRV14 2Apro and identified 
by mass spectroscopy analysis to use in further experiments in order to confirm their 
interaction with 2Apro. The criteria for the choice were the role of the proteins in the cell. For 
instance, the identified proteins should be involved in transcription, translation or be part of 
the cytoskeleton. A literature search excluded some of the candidates such as 
retinoblastoma-associated factor 600 (RBAF600), which binds to calmodulin beads (Nakatani 
et al., 2005). Our interest in this protein was based on the known interaction of other viral 
proteins with retinoblastoma, namely simian virus 40 (SV40) (Moens et al., 2007). Some of 
the proteins selected like ribosomal protein S17 or hnRNPU could not be investigated due to 
lack of antibodies. It will be of interest to acquire antibodies and perform pull-down 
experiments to confirm whether there is an interaction with HRV2 and HRV14 2Apro.  
In the end, three of the selected proteins were tested for interaction with HRV2 and 
HRV14 2Apro. β-actin and PABP were tested for binding and cleavage. The translation factor 
eEF1α was tested for cleavage. The results showed that PABP binds and is cleaved by 
HRV2 2Apro, confirming the results of Luiza Deszcz (data not shown). In contrast, β-actin 
does not bind neither is cleaved by HRV2 and HRV14 2Apro. Finally, the eEF1α is not 
cleaved by any of the two proteases in vitro; therefore we did not perform the binding 
experiments. The outcome of this work suggests that the method used was not optimal; 
perhaps the amount of cell extract used for incubation was too high, which raised such an 
elevated number of false positives.  
To achieve conditions closer to physiological levels we used the vector (pMZI) for 
human cells transfection which contains the TAP tag, developed by Zeghouf et al. (2004). 
We introduced the inactive forms of HRV2 and HRV14 2Apro in this vector and transfected 
transiently human HEK 293T cells with the two constructs. We did not success in expressing 
the viral proteases in large scale experiments; only cells transfected with the empty vector 
expressed the TAP tag. We hypothesised that HRV2 and HRV14 2Apro can be toxic for the 
cells, even the inactive form, and maybe the expression would have been blocked. 
Therefore, we decided to clone the inactive forms of HIV 1 protease, CVB4 2Apro and FMDV 
Lbpro in the pMZI vector and tried to express them. Only FMDV Lbpro was successfully 
expressed; however, the results from the mass spectroscopy analysis did not reveal any 
potential Lbpro binding partner. For the other proteins, it is possible that they are toxic for the 
cells. 
In conclusion, the TAP method is a useful tool for identification of protein-protein 
interactions. The modifications that we introduced in the method only worked partially. We 
                                                                                                                                             5. Discussion 
 125
were able to confirm two interactions of cellular proteins with 2Apro; however we failed in 
identifying new binding partners for these proteinases. Further optimization of the method is 
necessary, namely find the optimal expression conditions in the HEK 293T cells or even try 
the expression of 2Apro-TAP tag in yeast by creating stable clones expressing the inactive 
viral proteins, as described in the original method (Rigaut et al., 1999). 
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6 Appendixes 
 
6.1 Appendix A 
Mass spectroscopy results for the TAP experiments 
 
HRV14-2Apro C109A negative control 
 
Table 16: HRV14-2Apro C109A negative control. Search against the mammalian subset of the NCBI 
nr database. 
 
 
 
 
 
 
 
 
protein Mass kDa score 
gi|223036 
troponin C-like protein 
16696 889 
gi|109327   
myosin-light-chain kinase (EC 
2.7.1.117), skeletal muscle - 
rabbit 
65997 635 
gi|162648   
albumin [Bos taurus] 
71244 494 
gi|106586   
Ig kappa chain V-III (KAU cold 
agglutinin) - human 
23037 170 
gi|27806751  
alpha-2-HS-glycoprotein [Bos 
taurus] 
39193 105 
gi|33700   
immunoglobulin lambda light 
chain [Homo sapiens] 
25519 72 
gi|29649713    
protease serine 1 [Homo 
sapiens] 
9218 64 
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HRV14-2Apro C109A positive 
 
protein Mass kDa score 
gi|4506787 
IQ motif containing GTPase 
activating protein 1 [Homo sapiens] 
189761 1610 
gi|12667788 
myosin, heavy polypeptide 9, non-
muscle [Homo sapiens] 
227646 1591 
gi|223036  
troponin C-like protein 
16696 1553 
gi|18088719 
Tubulin, beta polypeptide [Homo 
sapiens] 
50096 1342 
gi|15277503 
ACTB protein [Homo sapiens] 
40536 1039 
gi|42476013  
NHL repeat containing 2 [Homo 
sapiens] 
80249 760 
gi|2119266 
tubulin alpha-1 chain - human 
50804 705 
gi|5729877|ref|NP_006588.1|  heat 
shock 70kDa protein 8 isoform 
  
gi|14993776  
skeletal myosin light chain kinase 
[Homo sapiens] 
65214 539 
gi|16507237    
heat shock 70kDa protein 5 
(glucose-regulated protein, 78kDa) 
[Homo sapiens] 
72402 386 
gi|162648 
albumin [Bos taurus] 
71244 374 
gi|17986258 
smooth muscle and non-muscle 
myosin alkali light chain isoform 1 
[Homo sapiens] 
17090 323 
gi|19070472  
retinoblastoma-associated factor 
600 [Homo sapiens] 
580607 308 
gi|5123454|ref|NP_005336.2|  heat 
shock 70kDa protein 1A [Homo 
sapiens] 
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protein Mass kDa score 
gi|57209936 
melanoma antigen, family D, 2 
[Homo sapiens] 
55932 266 
gi|4506693   
ribosomal protein S17 [Homo 
sapiens] 
15597 256 
gi|266992  
Splicing factor, arginine/serine-rich 2 
(Splicing factor SC35) (SC-35) 
(Splicing component, 35 kDa) 
25560 245 
gi|14141163 
heterogeneous nuclear 
ribonucleoprotein U isoform a 
[Homo sapiens] 
91164 225 
gi|189998   
M2-type pyruvate kinase 
58447 201 
gi|5032069  
splicing factor 3b, subunit 4 [Homo 
sapiens] 
44414 179 
gi|16741043 
MRCL3 protein [Homo sapiens] 
19839 174 
gi|54696696  
annexin A1 [Homo sapiens] 
38918 173 
gi|7706310   
LUC7-like 2 [Homo sapiens] 
48104 169 
gi|48734733 
Eukaryotic translation elongation 
factor 1 alpha 1 [Homo sapiens] 
50438 161 
gi|42490910  
Ribosomal protein L13 [Homo 
sapiens] 
24308 127 
gi|538581  
polyadenylate-binding protein - 
human 
70508 126 
gi|54696638  
heat shock 27kDa protein 1 [Homo 
sapiens] 
22826 125 
gi|45219787  
Ribosomal protein S3a [Homo 
sapiens] 
30184 120 
gi|106529   
Ig kappa chain C region (allotype 
Inv(1,2)) - human (fragment) 
11161 109 
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protein Mass kDa score 
gi|12803339 
PAI-RBP1 protein [Homo sapiens] 
44291 100 
gi|4506455  
reticulocalbin 1 precursor [Homo 
sapiens] 
38866 99 
gi|62897725|dbj|BAD96802.1|  
ribosomal protein L19 variant [Homo   
  
gi|2521983|dbj|BAA22652.1|  
alpha2-HS glycoprotein [Homo 
sapiens] 
  
gi|33150766 
heparin-binding protein HBp15 
[Homo sapiens] 
14866 86 
gi|19343694  
MAP7 protein [Homo sapiens] 
84146 81 
gi|61369330|gb|AAX43318.1|  
nuclease sensitive element binding 
  
gi|7657532|ref|NP_055439.1|  S100 
calcium-binding protein A6 
  
gi|56205102  
single stranded DNA binding protein 
3 [Homo sapiens] 
28692 69 
gi|16924231 
ribosomal protein S19 [Homo 
sapiens] 
17271 66 
gi|51471019  
PREDICTED: similar to 60S 
ribosomal protein L29 (Cell surface 
heparin binding protein HIP) [Homo 
sapiens]17146 
 59 
 
Table 17: HRV14-2Apro C109A positive. Search against the mammalian subset of the NCBI nr 
database. The highlighted proteins were considered relevant for this work. 
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HRV2-2Apro C106A negative control 
 
protein Mass kDa score 
gi|7766868   
Chain B, 2a Cysteine Proteinase From 
Human Rhinovirus 2 
16596 2954 
gi|54306511 
CTAP-tag [Cloning vector pUAST-
CTAP] 
20524 1229 
gi|50507914 
yellow cameleon 2.60 [synthetic 
construct] 
73565 1031 
gi|38491478    
GroEL [Escherichia coli] 
57434 719 
gi|208991   
protein A signal fusion protein 
27046 454 
gi|71665    
calmodulin - electric eel 
16799 432 
gi|223036  
troponin C-like protein 
16696 408 
gi|26246446 
Trigger factor [Escherichia coli 
CFT073] 
48221 250 
>gi|16131182|ref|NP_417762.1| 30S 
ribosomal subunit protein S5 
[Escherichia coli K12] 
  
gi|229552  
albumin [Bos taurus] 
68083 147 
gi|16974825   
Chain A, Solution Structure Of 
Calcium-Calmodulin N-Terminal 
Domain 
8483 135 
gi|106529  
Ig kappa chain C region (allotype 
Inv(1,2)) - human (fragment) 
11161 130 
gi|12516297  
galactitol-specific enzyme IIA of 
phosphotransferase system 
[Escherichia coli O157:H7] 
17011 99 
gi|29649713  
protease serine 1 [Homo sapiens] 
9218 93 
gi|25013638 
NIa-Pro protein [Tobacco etch virus] 
27738 82 
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protein Mass kDa score 
gi|261553   
GTP cyclohydrolase I (N-terminal) 
[Escherichia coli, Peptide Partial, 50 
aa, segment 1 of 2] 
5544 73 
gi|4506773  
S100 calcium-binding protein A9 
[Homo sapiens] 
13291 68 
gi|457116 
S20 protein 
9763 61 
>gi|16131199|ref|NP_417779.1| 50S 
ribosomal subunit protein L3 
[Escherichia coli K12] 
  
gi|226334  
myosin L kinase 
36258 1854 
 
Table 18: HRV2-2Apro C106A negative control. Search against all entries in the NCBI nr database. 
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HRV2-2Apro C106A positive  
 
protein Mass kDa score 
gi|7766868   
Chain B, 2a Cysteine 
Proteinase From Human 
Rhinovirus 2 
16596 18034 
gi|38490010 
polyprotein [Human rhinovirus 
30] 
53303 5710 
gi|4506787   
IQ motif containing GTPase 
activating protein 1 [Homo 
sapiens] 
189761 5026 
gi|109327  
myosin-light-chain kinase (EC 
2.7.1.117), skeletal muscle - 
rabbit 
65997 2317 
gi|54306511  
CTAP-tag [Cloning vector 
pUAST-CTAP] 
20524 2020 
gi|50507914   
yellow cameleon 2.60 [synthetic 
construct] 
73565 1490 
gi|56205916 
retinoblastoma-associated 
factor 600 (RBAF600) [Homo 
sapiens] 
580547 1294 
gi|4506693  
ribosomal protein S17 [Homo 
sapiens] 
15597 1238 
gi|4885109  
calmodulin 3 [Homo sapiens] 
17152 1059 
gi|4586876   
huntingtin [Homo sapiens] 
351557 1025 
gi|24111820   
trigger factor [Shigella flexneri 
2a str. 301] 
48163 1015 
gi|14250401   
actin, beta [Homo sapiens] 
41321 956 
gi|18088719  
Tubulin, beta polypeptide [Homo 
sapiens] 
50096 741 
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protein Mass kDa score 
gi|2119266    
tubulin alpha-1 chain - human 
50804 700 
gi|48734733   
Eukaryotic translation 
elongation factor 1 alpha 1 
[Homo sapiens] 
50438 624 
gi|31645     
glyceraldehyde-3-phosphate 
dehydrogenase [Homo sapiens] 
36202 544 
gi|693933    
2-phosphopyruvate-hydratase 
alpha-enolase; carbonate 
dehydratase [Homo sapiens] 
47421 518 
gi|20072478  
PAI-RBP1 protein [Homo 
sapiens] 
44995 505 
gi|30583577   
vesicle amine transport protein 
1 homolog (T californica) [Homo 
sapiens] 
42122 493 
gi|189998   
M2-type pyruvate kinase 
58447 416 
>gi|5729877|ref|NP_006588.1| 
heat shock 70kDa protein 8 
isoform 1 [Homo sapiens] 
  
gi|12667788   
myosin, heavy polypeptide 9, 
non-muscle [Homo sapiens] 
227646 362 
gi|52783777    
Phosphoglycerate kinase 1 
44973 355 
gi|17986258    
smooth muscle and non-muscle 
myosin alkali light chain isoform 
1 [Homo sapiens] 
17090 354 
gi|32358       
hnRNP U protein [Homo 
sapiens] 
89631 342 
gi|4507895  
vimentin [Homo sapiens] 
53710 296 
gi|32454741 
serine (or cysteine) proteinase 
inhibitor, clade H, member 1 
precursor [Homo sapiens] 
46525 289 
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protein Mass kDa score 
gi|16507237    
heat shock 70kDa protein 5 
(glucose-regulated protein, 
78kDa) [Homo sapiens] 
72402 288 
gi|27676004    
similar to ribosomal protein L9 
[Rattus norvegicus] 
21994 281 
gi|10863927   
peptidylprolyl isomerase A 
isoform 1 [Homo sapiens] 
18098 280 
gi|54696696   
annexin A1 [Homo sapiens] 
38918 265 
gi|57036493 
PREDICTED: similar to 
ribosomal protein S19 [Canis 
familiaris] 
16051 243 
gi|18645167  
Annexin A2, isoform 2 [Homo 
sapiens] 
38780 237 
gi|15559443  
Hypothetical protein BC014089 
[Homo sapiens] 
14669 236 
gi|3309539   
liprin-beta1 [Homo sapiens] 
113632 229 
gi|28614  
aldolase A [Homo sapiens] 
39706 227 
gi|56972440   
Ribosomal protein L3 [Homo 
sapiens] 
46365 224 
gi|38201623    
eukaryotic translation 
initiation factor 4 gamma, 1 
isoform 1 [Homo sapiens] 
176094 223 
gi|999893     
Chain B, Triosephosphate 
Isomerase (Tim) (E.C.5.3.1.1) 
Complexed With 2-
Phosphoglycolic Acid 
36807 211 
gi|57209936     
melanoma antigen, family D, 2 
[Homo sapiens] 
55932 200 
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protein Mass kDa score 
gi|2773160     
neuronal tissue-enriched acidic 
protein [Homo sapiens] 
22941 183 
gi|6016838|dbj|BAA85184.1| 14-
3-3gamma [Homo sapiens] 
  
gi|33187679    
hypothetical protein [Homo 
sapiens] 
14682 177 
gi|185945  
immunoglobulin kappa chain 
constant region [Homo sapiens] 
11773 166 
gi|35871 
RAP74 [Homo sapiens] 
58276 161 
gi|5031857   
lactate dehydrogenase A [Homo 
sapiens] 
36950 154 
gi|107082  
microtubule-associated protein 
4 - human 
121618 153 
gi|180985 
CpG island protein 
39022 149 
gi|19343933      
PPP3CA protein [Homo 
sapiens] 
58306 148 
gi|4092054       
GTP binding protein [Homo 
sapiens] 
24668 93 
gi|16418383 
transcriptional repressor NAC1 
[Homo sapiens] 
57906 90 
gi|460317       
chaperonin 
58598 79 
gi|55959887    
peroxiredoxin 1 [Homo sapiens] 
19135 78 
gi|54695918  
flap structure-specific 
endonuclease 1 [Homo sapiens] 
42908 76 
gi|13569488  
OSBP related protein 11 [Homo 
sapiens] 
35076 75 
gi|55859705  
tropomyosin 2 (beta) [Homo 
sapiens] 
37010 74 
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protein Mass kDa score 
gi|55749406  
transcription elongation factor A 
(SII)-like 1 [Homo sapiens] 
18686 68 
gi|27802691   
caspase 9, apoptosis-related 
cysteine protease [Homo 
sapiens] 
47035 66 
 
Table 19: HRV2-2Apro C106A positive. Search against the mammalian subset of the NCBI nr 
database. The highlighted proteins were considered relevant for this work. 
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Lbpro negative control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 20: Lbpro negative control. Search against the mammalian subset of the NCBI nr database. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
protein Mass kDa score 
gi|825635   
calmodulin [Homo sapiens] 
17152 4097 
gi|16974825 
Chain A, Solution Structure Of 
Calcium-Calmodulin N-Terminal 
Domain 
8483 2405 
gi|29649713 
protease serine 1 [Homo 
sapiens] 
9218 66 
gi|38051823   
Plasminogen [Homo sapiens] 
93263 59 
gi|14993776   
skeletal myosin light chain 
kinase [Homo sapiens] 
65214 55 
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Lbpro  positive 
 
protein Mass kDa score 
gi|825635 
calmodulin [Homo sapiens] 
17152 7812 
gi|4506773 
S100 calcium-binding protein A9 
[Homo sapiens] 
13291 372 
gi|18490211  
Unknown (protein for 
MGC:23888) [Homo sapiens] 
26503 239 
gi|21614544                           
S100 calcium-binding protein A8 
[Homo sapiens] 
10885 233 
gi|14043538  
Unknown (protein for 
IMAGE:4110141) [Homo 
sapiens] 
27865 199 
gi|16554039  
unnamed protein product [Homo 
sapiens] 
65755 179 
gi|4885111    
calmodulin-like 3 [Homo 
sapiens] 
16937 173 
gi|31645   
glyceraldehyde-3-phosphate 
dehydrogenase [Homo sapiens] 
36202 160 
gi|8393159  
calmodulin-like skin protein 
[Homo sapiens] 
15911 144 
gi|29649713   
protease serine 1 [Homo 
sapiens] 
9218 111 
gi|38348366   
suprabasin [Homo sapiens] 
25377 100 
gi|62122917 
filaggrin 2 [Homo sapiens] 
249296 94 
gi|3891470    
Chain A, Crystal Structure Of 
Human Galectin-7 In Complex 
With Galactosamine 
14992 91 
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protein Mass kDa score 
gi|6912286    
caspase 14 precursor [Homo 
sapiens] 
27947 87 
gi|18645167 
Annexin A2 [Homo sapiens] 
38780 71 
gi|62897625     
beta actin variant [Homo 
sapiens] 
42080 67 
gi|5803225  
tyrosine 3/tryptophan 5 -
monooxygenase activation 
protein, epsilon polypeptide 
[Homo sapiens] 
29326 65 
gi|4506671 
ribosomal protein P2 [Homo 
sapiens] 
11658 64 
gi|38051823   
Plasminogen [Homo sapiens] 
93263 63 
gi|4885375 
histone cluster 1, H1c [Homo 
sapiens] 
21352 60 
gi|38014625   
RPL8 protein [Homo sapiens] 
23114 60 
gi|338695   
beta-tubulin 
50240 56 
gi|229532   
ubiquitin 
8446 55 
gi|5729877   
heat shock 70kDa protein 8 
isoform 1 [Homo sapiens] 
71082 51 
gi|4503113    
cystatin M precursor [Homo 
sapiens] 
16785 45 
gi|494296   
Chain B, Cathepsin D 
(E.C.3.4.23.5) 
26457 43 
gi|60097902  
filaggrin [Homo sapiens] 
435036 39 
gi|178995    
arginase (EC 3.5.3.1) 
34884 38 
 
Table 21: Lbpro  positive. Search against the mammalian subset of the NCBI nr database. 
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6.2 Appendix B 
DNA and protein markers 
 
Figure 85: DNA marker.  λ-DNA (Promega) digested with the restriction enzyme HindIII. 1µg/well was 
loaded. 
 
 
 
 
Figure 86: Biorad prestained protein marker. Catalog number 161-0373. 5µl of marker were 
loaded. 
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Figure 87: [14C] Methylated proteins (Amersham Biosciences). Catalog number CFA-626. 5µl of 
marker were loaded. 
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6.3 Appendix C 
Amino acids abbreviations 
 
Amino acid Three letters 
abbreviation 
One letter 
abbreviation  
Alanine Ala 
 
A 
Cysteine Cys 
 
C 
Aspartate Asp 
 
D 
Glutamate Glu 
 
E 
Phenylalanine Phe 
 
F 
Glycine Gly 
 
G 
Histidine His 
 
H 
Isoleucine Ile 
 
I 
Lysine Lys 
 
K 
Leucine Leu 
 
L 
Methionine Met 
 
M 
Asparagine Asn 
 
N 
Proline Pro 
 
P 
Glutamine Gln 
 
Q 
Arginine Arg 
 
R 
Serine Ser 
 
S 
Threonine Thr 
 
T 
Valine Val 
 
V 
Tryptophan Trp 
 
W 
Tyrosine Tyr 
 
Y 
 
 Table 22: List and abbreviations of the 20 amino acids. 
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6.4 Appendix D 
List of figures 
 
Figure 1: Phylogenetic tree of the VP4 region of 26 HRV strains collected from nasopharyngeal 
aspirates. 
 
Figure 2: Structure of picornaviruses. 
 
Figure 3: Schematic representation of the predicted stem-loop structures in the (A) poliovirus, (B) 
encephalomyocarditis virus, and (C) hepatitis A virus 5’ UTR of the viral RNAs. 
 
Figure 4:  Overview of the picornavirus replication cycle. 
 
Figure 5: Surface potential of the receptor binding site of several HRVs. 
 
Figure 6: Cryo-EM (cryo electron microscopy) image reconstruction of HRV14 complexed with a 
soluble fragment of ICAM-1. 
 
Figure 7: Primary cleavages of picornavirus polyprotein. 
 
Figure 8: 5’ cap-dependent versus IRES-dependent translation initiation. 
 
Figure 9: The structure of FMDV Lbpro. 
 
Figure 10: The structure of PV 3Cpro. 
 
Figure 11: The structure of HRV2 2Apro. 
 
Figure 12: Diagram of translation initiation in eukaryotes. 
 
Figure 13: Schematic drawing of eIF4GI. 
 
Figure 14: Schematic representation of the initiation translation complex. 
 
Figure 15: Fluorography of a 17.5% SDS-PAGE showing an in vitro translation experiment. 
 
Figure 16: Immunoblot of 6% SDS-PAGE of the samples from figure 16 showing cleavage of eIF4GI 
by A) HRV2 VP1-2Apro and B) HRV14 VP1-2Apro. 
 
Figure 17: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV2 and HRV14 VP1-
2Apro bearing the eIF4GI cleavage site. 
 
Figure 18: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 VP1-2Apro bearing 
the eIF4GI cleavage site in which the P1 residue arginine was substituted by tyrosine. 
 
Figure 19: Fluorography of a 17.5% SDS-PAGE showing processing of HRV14 VP1-2Apro containing 
several substitutions at the cleavage site. 
 
Figure 20: Sequence alignment between HRV14 2Apro and PV1 2Apro. 
 
Figure 21: Fluorography of a 17.5% SDS-PAGE showing the processing of PV1 VP1-2Apro wild type 
(A) and a mutant containing an arginine at P1 site (B). 
 
Figure 22: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 and HRV2 VP1-
2Apro bearing several mutations on the 2Apro sequence. 
 
Figure 23: The structure of HRV2 2Apro. 
                                                                                                                                            6. Appendixes 
 144
 
Figure 24: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV14 VP1-2Apro 
containing an arginine at the P1 site and a mutation in position 104. 
 
Figure 25: Fluorography of a 17.5% SDS-PAGE showing the processing of HRV2 VP1-2Apro 
containing a mutation in position 101. 
 
Figure 26: 17.5% SDS-PAGE showing the inhibition of self-processing of HRV2 and HRV14 2Apro by 
zVAM.fmk. 
 
Figure 27: Cloning strategy to introduce the inactive form of HRV14 2Apro carrying a His tag into 
pGEX-6P-1. 
 
Figure 28: Coomassie stained SDS-PAGE (10% (A) and 15% (B) polyacrylamide) of the expression 
of HRV14 2Apro-GST-His (A) and the protein after incubation with PreScission proteinase (Amersham) 
(B). 
 
Figure 29: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 ml 
(Amersham). B) Coomassie stained 15% SDS-PAGE of the fractions collected. 
 
Figure 30: Coomassie stained 12.5% SDS-PAGE of the expression of HRV14 2Apro-GST-His (A) and 
the protein after incubation with PreScission protease (Amersham) (B). 
 
Figure 31: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 ml 
(Amersham). B) Coomassie stained 12.5% SDS-PAGE of the fractions collected. 
 
Figure 32: A) Chromatogram of gel filtration performed on a superdex 26/60 column. B) Coomassie 
stained 12.5% SDS-PAGE of the fractions collected. 
 
Figure 33: Coomassie stained 12.5% SDS-PAGE of the concentrated HRV14 2Apro-His.  
  
Figure 34: Determination of the melting temperature of a protein. 
 
Figure 35: Graphic showing the melting temperature curve of HRV14 2Apro-His. 
 
Figure 36: Cloning strategy to introduce the inactive form of HRV14 2Apro carrying a His tag into 
pET11d. 
 
Figure 37: Coomassie stained 12.5% SDS-PAGE of the expression HRV14 2Apro-His. 
 
Figure 38: A) Chromatogram of HRV14 2Apro-His purification performed on a HisTrap column 1 ml 
(Amersham). B) Coomassie stained 12.5% SDS-PAGE of the fractions collected. C) Coomassie 
stained 12.5% SDS-PAGE of the concentrated (pool of lanes 9 to 13 of panel B) HRV14 2Apro-His. 
 
Figure 39: A) Cromatogram of gel filtration performed on a superdex 26/60 column. B) and C) 
Coomassie stained 12.5% SDS-PAGE of the fractions collected. 
 
Figure 40: Scheme for the pGEX-6P1-eIF4GII-(aa 445-744)-FLAG vector provided by A. Gradi. 
 
Figure 41: Coomassie stained 10% SDS-PAGE of the expression eIF4GII-GST aminoacids 445 to 
744. 
 
Figure 42: Coomassie stained 10% SDS-PAGE of eIF4GII aminoacids 445 to 744 after cleavage from 
the GST-tag. 
 
Figure 43: A) Chromatogram of gel filtration of the sample from figure 43, after being concentrated to 
2 ml, performed on a superdex 26/60 column. B) Coomassie stained 10% SDS-PAGE of the fractions 
corresponding to peak 1 and 2 respectively. 
 
Figure 44: Coomassie stained 10% SDS-PAGE of the pooled and concentrated fractions of eIF4GII. 
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Figure 45: Cloning strategy to introduce the GST tag and eIF4GII residues 445 to 744 into the 
pFastBac vector (Invitrogen). 
 
Figure 46: immunoblot of 12.5% SDS-PAGE showing the expression of eIF4GII-GST. 
 
Figure 47: Coomassie stained 10% SDS-PAGE of eIF4GII after incubation with PreScission protease 
(Amersham). 
 
Figure 48: fragment of eIF4GII (residues 445 to 744) cloned in pGEX-6P1 (Amersham). 
 
Figure 49: Cloning strategy to introduce the fragment corresponding to the residues 552 to 744 of 
eIF4GII into pGEX-6P-1. 
 
Figure 50: Coomassie stained 10% SDS-PAGE of the expression eIF4GII-GST-His aminoacids 552 
to 744 (A) and the protein after incubation with PreScission protease (Amersham) (B). 
 
Figure 51: Cloning strategy to introduce the fragment corresponding to the residues 552 to 744 of 
eIF4GII carrying a His tag into pET11d. 
 
Figure 52: Coomassie stained 12.5% SDS-PAGE of the expression eIF4GII-GST aminoacids 552 to 
744.   
 
Figure 53: A) Chromatogram of eIF4GII-His aminoacid 552 to 744 performed on a HisTrap column 1 
ml (Amersham). B) Commassie stained 10% SDS-PAGE of the fractions collected. 
 
Figure 54: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions of 
eIF4GII.   
 
Figure 55: A) Chromatogram of gel filtration performed on a superdex 26/60 column. B) Commassie 
stained 10% SDS-PAGE of the fractions collected. 
 
Figure 56: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions 13 to 16 
of eIF4GII of figure 56B.   
 
Figure 57: Melting temperature curve of eIF4GII-His amino acids 552 to 744. 
 
Figure 58: Superimposition of 1H-15N-HSQC of 15NLbproC51A and 1H-15N-HSQC of 15N/13C LbproC51A. 
 
Figure 59: A) Chromatogram of eIF4GII-His aminoacid 552 to 744 performed on a HisTrap column 1 
ml (Amersham). B) and C) Commassie stained 10% SDS-PAGE of the fractions collected. 
 
Figure 60: Commassie stained 12.5% SDS-PAGE of the pooled and concentrated fractions of 
eIF4GII.   
 
Figure 61: Superimposition of 15N-eIF4GII (red) and 15N-eIF4GII plus FMDV Lb (blue). 
 
Figure 62: Commassie stained 12.5% SDS-PAGE of the expression eIF4EΔ27.   
 
Figure 63: Scheme for the ppro ExHTA-meIF4E vector provided by Regina Cencic. 
 
Figure 64: Commassie stained 12.5% SDS-PAGE of the expression eIF4E. 
 
Figure 65: A) Chromatogram of eIF4E performed on a MonoQ 10/10 column (Amersham). B) and C) 
Commassie stained 10% SDS-PAGE of the fractions collected. 
 
Figure 66: Commassie stained 12.5% SDS-PAGE of eIF4E eluted from m7GTP beads. 
 
Figure 67: eIF4E after purification and concentration. 
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Figure 68: Overview of TAP procedure (adapted from Rigaut et al., 1999). 
 
Figure 69: Cloning strategy to introduce the TAP tag into pET11d. 
 
Figure 70: Cloning strategy to introduce the inactive forms of HRV2 and HRV14 2Apro into pET11d-
TAP. 
 
Figure 71: Commassie stained 10% SDS-PAGE of the expression of: A) Tap tag, B) HRV2 2Apro-TAP 
and C) HRV14 2Apro-TAP. 
 
Figure 72: Commassie stained 10% SDS-PAGE of the soluble fractions from the expressions of TAP, 
HRV2 2Apro-TAP and HRV14 2Apro-TAP. 
 
Figure 73: Silver stained 7 to 20% SDS-PAGE of TAP (A), HRV2 2Apro-TAP (B) and HRV14 2Apro-
TAP (C). 
 
Figure 74: Commassie stained 12.5% SDS-PAGE of GST tag (lane 1), HRV2 2Apro C106A – GST 
(lane2) and HRV14 2Apro C109A – GST (lane 3). 
 
Figure 75: GST pulldown of eIF4GI (6% SDS-PAGE) (A), PABP (12.5% SDS-PAGE) (B) and β-actin 
(12.5% SDS-PAGE) (C). 
 
Figure 76: Immunoblot of 12.5% SDS-PAGE of β actin, PABP and eIF1 α. 
 
Figure 77: Cloning strategy to introduce the inactive forms of HRV2 and HRV14 2Apro into pMZI. 
 
Figure 78: immunoblot of 12.5% SDS-PAGE showing the expression of HRV2 2Apro-TAP and HRV14 
2Apro-TAP after a small scale transfection of HEK-293T cells. 
 
Figure 79: Immunoblot of 12.5% SDS-PAGE showing the expression of HRV2 2Apro-TAP and HRV14 
2Apro-TAP after transfection of 2x106 HEK-293T cells and 48 hours expression. 
 
Figure 80: Cloning strategy to introduce the inactive forms of HIV1 protease, CBV4 2Apro and FMDV 
Lbpro into pMZI. 
 
Figure 81: immunoblot of 12.5% SDS-PAGE showing the expression pMZI-TAP (A),  HIV 1pro-TAP 
(B), CBV4 2Apro-TAP (C) and FMDV Lbpro-TAP after a large scale transfection of HEK-293T cells and 
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Figure 83: Analysis of HRV2, HRV14 and PV1 2Apro amino acid sequence. A and B) Sequence 
alignments between HRV14 2Apro and HRV2 2Apro (A) and HRV14 2Apro and PV1 2Apro (B). C) Tree 
based on the amino acid identity of HRV2, HRV14 and PV1 2Apro, showing that HRV14 2Apro amino 
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Figure 84: The structure of HRV2 2Apro. Ribbon diagrams of the overall structure of HRV2 2Apro 
(Same as figure 24). 
 
Figure 85: DNA marker (Promega).   
 
Figure 86: Biorad prestained protein marker. 
 
Figure 87: [14C] Methylated proteins (Amersham Biosciences). 
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